Heteroaromatic ring compound as well as preparation method and application thereof

CN119095844APending Publication Date: 2024-12-06SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380037220.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-30
Filing Date
2023-06-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

It is difficult to develop KRAS G12D PROTAC molecules with novel structure and good biological activity using existing technology to treat cancers caused by the aggregation and overactivation of KRAS G12D protein.

Method used

Provides a PROTAC molecule with a moiety that binds to the KRAS G12D protein and a high-affinity VHL ligand capable of recruiting E3 ubiquitin ligase, leading to ubiquitination and degradation of the KRAS G12D protein.

Benefits of technology

This molecule can be used to treat and prevent cancers caused by the KRAS G12D protein. By targeting the KRAS G12D protein for degradation, it can effectively inhibit its overactivation and provide a new method of treating cancers related to KRAS mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095844A_ABST
    Figure CN119095844A_ABST
Patent Text Reader

Abstract

The invention relates to a heteroaromatic ring compound as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula (I) or pharmaceutically acceptable salt, stereoisomer, tautomer, polymorphic substance, solvate, N-oxide, isotope labeled compound, metabolite or prodrug thereof, and a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt, the stereoisomer, the tautomer, the polymorphic substance, the solvate, the N-oxide, the isotope labeled compound, the metabolite or the prodrug thereof. The invention also relates to a preparation method of the compound and application of the compound in preparation of drugs for preventing or treating KRAS G12D-mediated related diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Heteroaromatic ring compound, preparation method and use thereof Technical Field

[0001] The present invention belongs to the field of medicine, and in particular relates to a class of heteroaromatic ring compounds, a preparation method thereof and uses thereof. Background Art

[0002] RAS is a guanine nucleotide-binding protein with GTPase activity that anchors to the inner side of the cell membrane. RAS proteins can transition between an inactive, GDP-bound state and an active, GTP-bound state, influencing downstream signaling pathways such as Raf, PI3K, and RalGDS, regulating protein synthesis, gene transcription, cell growth, differentiation, apoptosis, and migration.

[0003] RAS mutations lead to persistent activation of downstream signaling pathways, promoting tumor development and progression. Across all tumor types, RAS mutations primarily occur in KRAS (85%), with the most frequent mutation occurring at position 12 of KRAS, glycine to aspartic acid (G12D), at 34.2%. In KRAS-mutated tumor cells, KRAS GTPase activity decreases, remaining persistently active. KRAS mutations are closely associated with the development of lung, pancreatic, and colorectal cancers.

[0004] The development of small molecule inhibitors of KRAS G12D is still in the clinical validation stage. WO2020173935 discloses a class of RAS inhibitors that utilize the principle of molecular glue to induce KRAS G12D to form dimers, thereby blocking the interaction between KRAS and downstream proteins. In addition, companies represented by Mirati, TAIHO, and Jacobs have published multiple patents for KRAS G12D inhibitors (WO2021041671, WO2021107160, WO2022061251, WO2022105857, etc.).

[0005] Proteolysis-Targeting Chimeras (PROTAC) are bifunctional molecules whose structure consists of three parts: (1) a part that binds to the target protein substrate; (2) a part that binds to the E3 ubiquitin ligase; and (3) a chain connecting the first two parts. PROTAC can recognize the target protein and E3 ubiquitin ligase respectively, shorten the distance between the target protein and the E3 ubiquitin ligase, and induce the ubiquitination process and induce the degradation of the target protein by inducing the recruitment of the E3 ubiquitin ligase to the surface of the target protein. PROTAC molecules have the advantages of a wide range of pharmacological activities, high target selectivity, can be used for the degradation of difficult-to-drug target proteins, strong degradation efficiency, and can maintain catalytic degradation at low concentrations.

[0006] There is an urgent need in this field to develop KRAS G12D PROTAC molecules with novel structures and good biological activity.

[0007] SUMMARY OF THE INVENTION

[0008] The present invention provides compounds that can be used as degraders and / or inhibitors targeting the KRAS G12D protein. The compounds of the present invention are PROTACs, one end of which can bind to the target protein, while the high-affinity VHL ligand at the other end can recruit the target protein to the E3 ubiquitin ligase, leading to ubiquitination and subsequent degradation of the KRAS G12D protein. The compounds of the present invention can be used to treat and / or prevent cancers or conditions caused by aggregation and / or overactivation of the target protein.

[0009] In one aspect, the present invention provides a compound or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of Formula (I):

[0010] in:

[0011] is a single bond or a double bond;

[0012] When X 1 With X 2 between When it is a single bond, X 1 Selected from C(R 7 )2 and C(O); and X 2 Selected from N and CR 7 ;

[0013] When X 1 With X 2 between When it is a double bond, X 1 Selected from CR 8 and N; and X 2 is C;

[0014] When X 3 With X 4 between When it is a single bond, X 3 and X 4 Each independently selected from C(R 7 )2 and O;

[0015] When X 3 With X 4 between When it is a double bond, X 3 and X 4 Each independently selected from CR 8 and N;

[0016] Ring A is C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, the cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0017] Ring B is a 3-12 membered nitrogen-containing heterocyclic group;

[0018] L is selected from C 1-3 Alkylene and -C 1-2 Alkylene-OC 1-2 Alkylene-;

[0019] L 1 Selected from O, S and NR 9 ;

[0020] L 2 is a covalent bond, or is selected from C 1-6 Alkylene and halogenated C 1-6 alkylene;

[0021] L 3 is a covalent bond, or is selected from C 1-6 Alkylene and halogenated C 1-6 alkylene;

[0022] L 4 is a covalent bond, or is selected from O, NR 10 、C 1-6 Alkylene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -C 1-6 Alkylene-NR 10 -、-C 1-6 Alkylene-OC 1-6 Alkylene-, C 3-6 Cycloalkyl and 3-10 membered heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups;

[0023] L 5 Selected from -C(=O)-NR 11 -、-C 1-6 Alkylene-C(=O)-NR 11 -、-NR 11 -C(=O)-, -C 1-6 Alkylene-NR 11 -C(=O)- and 5-10 membered heteroaryl, said heteroaryl being optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6Alkyl, C 1-6 Substitution of haloalkyl groups;

[0024] Each R 1 are independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 1-6 alkyl halide;

[0025] R 2 Selected from C 6-10 Aryl and 5-10 membered heteroaryl, said aryl or heteroaryl being optionally substituted by one or more R 12 replace;

[0026] R 3 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 3-6 Cycloalkyl;

[0027] R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-6 Alkylene -OH and C 3-6 Cycloalkyl;

[0028] R 5 is selected from halogen, phenyl and 5-6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0029] Each R 6 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 haloalkyl; or

[0030] R 5 and adjacent R 6 and the carbon atoms to which they are connected together form a benzene ring, which is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0031] Each R 7 independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 haloalkyl; or two R on the same carbon atom 7 The carbon atoms they are connected to form carbonyl groups, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group;

[0032] Each R8 independently selected from hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl and -OC 3-6 Cycloalkyl;

[0033] R 9 Selected from hydrogen and C 1-6 alkyl;

[0034] R 10 Selected from hydrogen and C 1-6 alkyl;

[0035] R 11 Selected from hydrogen and C 1-6 alkyl;

[0036] When present, each R 12 Each independently selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups;

[0037] m is selected from 0, 1, 2, 3 and 4;

[0038] n is selected from 0, 1, 2, 3 and 4.

[0039] On the other hand, the present invention provides a pharmaceutical composition comprising a prophylactically and / or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, and one or more pharmaceutically acceptable carriers.

[0040] In another aspect, the present invention provides a kit comprising a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention.

[0041] On the other hand, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention, which targets KRAS G12D protein and is used to degrade KRAS G12D protein.

[0042] On the other hand, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention, for use in preventing and / or treating KRAS G12D-mediated related diseases.

[0043] On the other hand, the present invention provides use of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention in the preparation of a medicament for preventing and / or treating KRAS G12D-mediated related diseases.

[0044] On the other hand, the present invention provides a method for preventing and / or treating KRAS G12D-mediated related diseases, which comprises administering to an individual in need thereof a preventive and / or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention.

[0045] In another aspect, the present invention provides methods of preparing the compounds of the present invention.

[0046] Detailed Description of the Invention

[0047] definition

[0048] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to technology used herein are intended to refer to technology commonly understood in the art, including variations of technology or substitutions of equivalent technology that would be apparent to those skilled in the art. While it is believed that the following terms are well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.

[0049] As used herein, the terms "comprises," "comprising," "having," "containing," or "involving," and variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps.

[0050] As used herein, the term "alkyl" is defined as a straight-chain or branched saturated aliphatic hydrocarbon group. For example, as used herein, the term "C 1-6 "Alkyl" refers to a straight or branched chain group having 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl), which is optionally substituted by one or more (such as 1, 2 or 3) suitable substituents such as halogen.

[0051] As used herein, the term "alkylene" refers to a divalent saturated aliphatic hydrocarbon group derived from the corresponding "alkyl" by removing one hydrogen atom. For example, as used herein, the term "C 1-6 "Alkylene" refers to an alkylene group having 1 to 6 carbon atoms, for example methylene (-CH2-), ethylene (-CH2CH2-), isopropylene (-CH(CH3)CH2-), which is optionally substituted by one or more (such as 1, 2 or 3) suitable substituents such as halogen.

[0052] As used herein, the term "alkenyl" refers to a straight or branched aliphatic hydrocarbon group having one or more carbon-carbon double bonds. 2-6 The term "alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms and one, two or three (preferably one) carbon-carbon double bonds (such as vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl or 4-methyl-3-pentenyl, etc.), which is optionally substituted by one or more (such as 1, 2 or 3) suitable substituents such as halogen.

[0053] As used herein, the term "alkynyl" refers to a straight or branched aliphatic hydrocarbon group having one or more carbon-carbon triple bonds. 2-6 The term "alkynyl" refers to an alkynyl group having 2 to 6 carbon atoms and one, two or three (preferably one) carbon-carbon triple bonds (such as ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl or 5-hexynyl, etc.), which is optionally substituted by one or more (such as 1, 2 or 3) suitable substituents such as halogen.

[0054] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (e.g., a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or cyclononyl, or a bicyclic ring, including spirocyclic, fused or bridged systems such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, decahydronaphthyl, etc.), which is optionally substituted with one or more (such as 1 to 3) suitable substituents. For example, the term "C 3-6 "Cycloalkyl" refers to a saturated or partially unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring having 3 to 6 ring carbon atoms (for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), which is optionally substituted by one or more (such as 1, 2 or 3) suitable substituents, for example methyl substituted cyclopropyl.

[0055] As used herein, the term "cycloalkylene" refers to a divalent group derived from a corresponding "cycloalkyl" by removing a hydrogen atom.

[0056] As used herein, the term "halo" or "halogen" group is defined to include fluorine, chlorine, bromine, or iodine.

[0057] As used herein, the term "haloalkyl" refers to an alkyl group substituted by one or more (such as 1, 2 or 3) the same or different halogen atoms. For example, the term "C 1-6 "Haloalkyl" refers to a haloalkyl group having 1 to 6 carbon atoms, for example, -CF3, -C2F5, -CHF2, -CH2F, -CH2CF3, -CH2Cl or -CH2CH2CF3.

[0058] As used herein, the term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic group (including bridged, fused or spirocyclic rings), for example, having 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms and one or more (e.g., 1, 2, 3 or 4) independently selected from N, O or S(O) in the ring. t (wherein t is 0, 1 or 2) a heteroatom, such as a 3-12 membered heterocyclyl, a 3-7 membered heterocyclyl, a 3-6 membered heterocyclyl, a 5-6 membered heterocyclyl, etc. Representative examples of heterocyclyl include, but are not limited to, oxiranyl, aziridinyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyrrolidinyl, hexahydro-1H-pyrroline, pyrrolidonyl, imidazolidinyl, pyrazolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl or piperazinyl.

[0059] As used herein, the term "nitrogen-containing heterocyclic group" refers to a group containing at least one nitrogen heteroatom, optionally containing one or more (e.g., 1, 2, 3 or 4) nitrogen-containing heterocyclic groups selected from O or S(O) t (wherein t is 0, 1 or 2), which may include a nitrogen-containing monocyclic heterocyclic group or a polycyclic heterocyclic group (e.g., a nitrogen-containing bridged heterocyclic group, a nitrogen-containing bis-heterocyclic group, a nitrogen-containing spiro heterocyclic group).

[0060] As used herein, the term "heterocyclylene" refers to a divalent group obtained by removing a hydrogen atom from a corresponding "heterocyclyl".

[0061] As used herein, the term "aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated π electron system. For example, the term "C 6-10 Aryl" or "C 6-10 "Aromatic ring" refers to an aromatic group containing 6 to 10 carbon atoms, such as phenyl (ring) or naphthyl (ring). The aryl group is optionally substituted by one or more (such as 1, 2 or 3) suitable substituents (for example, halogen, -OH, -CN, -NO2 or C 1-6 alkyl, etc.) substituted.

[0062] As used herein, the term "heteroaryl" or "heteroaromatic ring" refers to a monocyclic, bicyclic or tricyclic aromatic ring system containing at least one heteroatom selected from N, O and S, for example having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular containing 1, 2, 3, 4, 5, 6, 9 or 10 carbon atoms, and in each case may be benzo-fused. For example, the heteroaryl or heteroaromatic ring can be selected from thienyl (ring), furanyl (ring), pyrrolyl (ring), oxazolyl (ring), thiazolyl (ring), imidazolyl (ring), pyrazolyl (ring), isoxazolyl (ring), isothiazolyl (ring), oxadiazolyl (ring), triazolyl (ring), thiadiazolyl (ring) and the like, and benzo derivatives thereof; or pyridyl (ring), pyridazinyl (ring), pyrimidinyl (ring), pyrazinyl (ring), triazinyl (ring) and the like, and benzo derivatives thereof.

[0063] As used herein, the term "heteroarylene" refers to a divalent group derived from a corresponding "heteroaryl" by removing a hydrogen atom.

[0064] As used herein, the term "methylsulfinyl" refers to a CH3S(=O)- group.

[0065] As used herein, the term "methylsulfonyl" refers to a CH3S(=O)2- group.

[0066] As used herein, the term "boronic acid" refers to a -B(OH)2 group.

[0067] As used herein, the term "boronic acid ester group" refers to an ester group formed by a boronic acid group and an alcohol, for example, a boronic acid group and pinacol form a boronic acid pinacol ester group.

[0068] The term "substituted" means that one or more (e.g., 1, 2, 3, or 4) hydrogen atoms on the designated atom are replaced with a group selected from the indicated group, provided that the designated atom's normal valence in the present context is not exceeded and that the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0069] If a substituent is described as being "optionally substituted with," the substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the substituents listed, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be replaced, individually and / or collectively, with independently selected substituents or unsubstituted. If a nitrogen of a substituent is described as being optionally substituted with one or more of the substituents listed, one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be replaced with an independently selected substituent or unsubstituted.

[0070] If a substituent is described as being "independently selected" from a group of groups, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.

[0071] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10, where reasonable.

[0072] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.

[0073] When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such substituent may be bonded to any ring atom in the substitutable ring.

[0074] The present invention also includes all pharmaceutically acceptable isotopically labeled compounds which are identical to the compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of suitable isotopes for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., 2 H. 3 H, deuterium D, tritium T); carbon isotopes (such as 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 37 Cl); isotopes of fluorine (e.g.18 F); isotopes of iodine (such as 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (such as 32 P); and sulfur isotopes (e.g. 35 S). Certain isotopically labeled compounds of the invention (e.g., those incorporating radioactive isotopes) are useful in drug and / or substrate tissue distribution studies (e.g., assays). The radioactive isotope tritium (i.e., 3 H) and carbon-14 (i.e. 14 C) are particularly useful for this purpose because they are easy to incorporate and easy to detect. 11 C. 18 F. 15 O and 13 N) substitution can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds of the present invention can be prepared by methods analogous to those described in the accompanying schemes and / or examples and preparations by using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent is isotopically substituted, for example, D2O, acetone-d6 or DMSO-d6.

[0075] The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In compounds with one or more (e.g., 1, 2, 3, or 4) asymmetric centers, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers can be produced. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is understood that the scope of this application encompasses all such isomers or mixtures thereof in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%).

[0076] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.

[0077] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, solvates, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.

[0078] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof. Suitable acid addition salts are formed from acids that form pharmaceutically acceptable salts. Suitable base addition salts are formed from bases that form pharmaceutically acceptable salts. For a review of suitable salts, see Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds of the present invention are known to those skilled in the art.

[0079] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.

[0080] Those skilled in the art will appreciate that not all nitrogen-containing heterocycles are capable of forming N-oxides, as nitrogen requires an available lone pair of electrons to oxidize to an oxide; those skilled in the art will recognize nitrogen-containing heterocycles that are capable of forming N-oxides. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides. Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art and include oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic acid and meta-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxirane such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; and GWH Cheeseman and ESGWerstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.

[0081] Also included within the scope of the present invention are metabolites of the compounds of the invention, i.e., substances formed in vivo upon administration of the compounds of the invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the invention, including compounds produced by contacting a compound of the invention with a mammal for a period of time sufficient to produce a metabolic product thereof.

[0082] The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity, and when administered to the body or thereon, can be converted into the compounds of the present invention having the desired activity by, for example, hydrolytic cleavage. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compounds in vivo. Further information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems," Volume 14, ACS Symposium Series (T. Higuchi and V. Stella) and "Bioreversible Carriers in Drug Design," Pergamon Press, 1987 (E.B. Roche, ed., American Pharmaceutical Association). The prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in "Design of Prodrugs," H. Bundgaard (Elsevier, 1985)).

[0083] The present invention also encompasses compounds of the present invention that contain protecting groups. During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved using conventional protecting groups, for example, those described in Protective Groups in Organic Chemistry, ed. JFW McOmie, Plenum Press, 1973; and TW Greene & P.GM Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.

[0084] The term "about" means within ±10%, preferably within ±5%, and more preferably within ±2% of the stated numerical value.

[0085] Compound

[0086] The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof:

[0087] in Ring A, Ring B, X 1 、X 2 、X 3 、X 4 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 ,L,L 1 , L 2 , L 3 , L 4 , L 5 , m and n are as defined above.

[0088] In some embodiments of the present invention, in the compound of formula (I):

[0089] is a single bond or a double bond;

[0090] When X 1 With X 2 between When it is a single bond, X 1 Selected from C(R 7 )2 and C(O); and X 2 Selected from N and CR 7 ;

[0091] When X 1 With X 2 between When it is a double bond, X 1 Selected from CR 8 and N; and X 2 is C;

[0092] When X 3 With X 4 between When it is a single bond, X 3 and X 4 Each independently selected from C(R 7 )2 and O;

[0093] When X 3 With X 4 between When it is a double bond, X 3 and X 4 Each independently selected from CR8 and N;

[0094] Ring A is C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0095] Ring B is a 3-12 membered nitrogen-containing heterocyclic group;

[0096] L is selected from C 1-3 Alkylene and -C 1-2 Alkylene-OC 1-2 Alkylene-;

[0097] L 1 Selected from O, S and NR 9 ;

[0098] L 2 is a covalent bond, or is selected from C 1-6 Alkylene and halogenated C 1-6 alkylene;

[0099] L 3 is a covalent bond, or is selected from C 1-6 Alkylene and halogenated C 1-6 alkylene;

[0100] L 4 is a covalent bond, or is selected from O, NR 10 、C 1-6 Alkylene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -C 1-6 Alkylene-NR 10 -、-C 1-6 Alkylene-OC 1-6 Alkylene-, C 3-6 Cycloalkyl and 3-10 membered heterocyclic group, wherein the cycloalkyl and heterocyclic group are each optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups;

[0101] L 5 Selected from -C(=O)-NR 11 -、-C 1-6 Alkylene-C(=O)-NR 11 -、-NR 11 -C(=O)-, -C 1-6 Alkylene-NR 11-C(=O)- and 5-10 membered heteroaryl, said heteroaryl being optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups;

[0102] Each R 1 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 1-6 alkyl halide;

[0103] R 2 Selected from C 6-10 Aryl and 5-10 membered heteroaryl, each of which is optionally substituted by one or more R 12 replace;

[0104] R 3 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 3-6 Cycloalkyl;

[0105] R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-6 Alkylene -OH and C 3-6 Cycloalkyl;

[0106] R 5 selected from halogen, phenyl and 5-6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0107] Each R 6 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 haloalkyl; or

[0108] R 5 and adjacent R 6 and the carbon atoms to which they are connected together form a benzene ring, which is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0109] Each R 7 independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 haloalkyl; or two R on the same carbon atom 7 The carbon atoms they are connected to form carbonyl groups, C3-6 Cycloalkyl or 3-6 membered heterocyclic group;

[0110] Each R 8 independently selected from hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl and -OC 3-6 Cycloalkyl;

[0111] R 9 Selected from hydrogen and C 1-6 alkyl;

[0112] R 10 Selected from hydrogen and C 1-6 alkyl;

[0113] R 11 Selected from hydrogen and C 1-6 alkyl;

[0114] When present, each R 12 Each independently selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl or heteroaryl are each optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups;

[0115] m is selected from 0, 1, 2, 3 and 4;

[0116] n is selected from 0, 1, 2, 3 and 4.

[0117] In some embodiments of the present invention, in the compound of formula (I):

[0118] R 2 Selected from C 6-10 Aryl and 5-10 membered heteroaryl, said aryl or heteroaryl being optionally substituted by one or more R 12 replace;

[0119] When present, each R 12 Each independently selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups;

[0120] R 5 is selected from halogen, phenyl and 5-6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;

[0121] Each R 6 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;

[0122] Ring A, Ring B, X 1 、X 2 、X 3 、X 4 、R 1 、R 3 、R 4 ,L,L 1 , L 2 , L 3 , L 4 , L 5 , m and n are as defined above.

[0123] In some embodiments of the present invention, in the compound of formula (I):

[0124] R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 3-6 Cycloalkyl.

[0125] In some embodiments of the present invention, in the compound of formula (I):

[0126] Each R 6 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0127] In some embodiments of the present invention, in the compound of formula (I):

[0128] R 2 Selected from C 6-10 Aryl and 5-10 membered heteroaryl, said aryl or heteroaryl being optionally substituted by one or more R 12 replace;

[0129] When present, each R 12 Each independently selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 The substituents of the haloalkyl group are substituted.

[0130] In some embodiments of the present invention, in the compound of formula (I):

[0131] R 5 is selected from phenyl and 5-6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0132] In some embodiments of the present invention, the compound of formula (I) has a structure as shown in formula (IA), (IB), (IC) or (ID):

[0133] Among them, ring A, ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 , L 1 , L 2 , L 3 , L 4 , L 5 and n are as defined above.

[0134] In some embodiments of compounds of Formula (I), Formula (IB), (IC), and (ID), each R 8 are independently selected from hydrogen and halogen. Preferably, R8 is hydrogen, fluorine or chlorine.

[0135] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 2 is optionally replaced by 1-3 R 12 substituted naphthyl, benzothiazolyl and benzopyrazolyl, and R 12 are each independently selected from halogen, C 1-6 Alkyl, C 2-6 Preferably, in some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC) and (ID), R 2 is optionally replaced by 1-3 R 12 substituted naphthyl, benzothiazolyl and benzopyrazolyl, and R 12 Each is independently selected from F, Cl, Br, I, methyl, ethyl, isopropyl, ethynyl, amino and hydroxy. Preferably, R 2 is optionally replaced by 1-3 R 12 substituted naphthyl, benzothiazolyl and benzopyrazolyl, and R 12 Each is independently selected from F, Cl, ethyl, ethynyl, amino and hydroxyl. Preferably, R 2 Selected from

[0136] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 2 is optionally replaced by 1-3 R 12 substituted naphthyl, and R 12 Each is independently selected from F, Cl, Br, I, methyl, ethyl, isopropyl, ethynyl and hydroxyl. Preferably, R 2 is optionally replaced by 1-3 R 12 substituted naphthyl, and R 12 Each is independently selected from F, Cl, ethyl, ethynyl and hydroxyl. Preferably, R 2 Selected from

[0137] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 2 is optionally replaced by 1-3 R 12 Substituted benzothiazolyl, and R 12 are each independently selected from F, Cl, methyl and amino. Preferably, R 2 is optionally replaced by 1 or 2 R 12 Substituted benzothiazolyl, and R 12 are each independently selected from F and amino. Preferably, R2 for

[0138] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 2 is optionally replaced by 1-3 R 12 Substituted benzopyrazolyl, and R 12 are each independently selected from F, Cl and methyl. Preferably, R 2 is optionally replaced by 1 or 2 R 12 Substituted benzopyrazolyl, and R 12 are each independently selected from F and methyl. Preferably, R 2 for

[0139] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 1 It is -O-.

[0140] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 2 C 1-6 Preferably, L 2 C 1-3 Alkylene.

[0141] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 3 C 1-6 Preferably, L 3 C 1-3 Alkylene.

[0142] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), Ring A is C 3-6 Preferably, ring A is cyclopropyl or cyclobutyl.

[0143] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 2 C 1-3 Alkylene, L 3 C 1-3 Alkylene, Ring A is C 3-6 Cycloalkyl; preferably, L 2 -CH2-, L 3 is -CH2-, and ring A is cyclopropyl or cyclobutyl.

[0144] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC) and (ID), Ring B is selected from a 3-8 membered nitrogen-containing monoheterocyclyl, a 5-12 membered nitrogen-containing bridged heterocyclyl, a 6-12 membered nitrogen-containing heterocyclyl and a 7-12 membered nitrogen-containing spiro heterocyclyl. Preferably, Ring B is selected from a 4-6 membered nitrogen-containing monoheterocyclyl, a 7-9 membered nitrogen-containing bridged heterocyclyl, a 6-8 membered nitrogen-containing heterocyclyl and a 7-11 membered nitrogen-containing spiro heterocyclyl.

[0145] Preferably, ring B is selected from

[0146] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), Ring B is selected from

[0147] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 4 is a covalent bond, or is selected from O, C 1-6 Alkylene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O- and -C 1-6 Alkylene-OC 1-6 Alkylene-.

[0148] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 4 Selected from C 1-6 Alkylene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O- and -C 1-6 Alkylene-OC 1-6 Alkylene-; preferably, L 4 Selected from -CH2-, -CH2-CH2-, -O-CH2-, -CH2-O- and -CH2-O-CH2-.

[0149] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 4 It is a covalent bond.

[0150] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 5 is selected from -C(=O)-NH- and 5-10 membered heteroaryl. 5 Selected from -C(=O)-NH-,

[0151] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), L 5 Selected from -C(=O)-NH- and 5-membered heteroaryl.

[0152] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 3 Selected from C 1-6 Alkyl and C 3-6 Preferably, R 3 is tert-butyl or cyclohexyl.

[0153] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 4 Selected from hydrogen, C 1-6 Alkyl and -C 1-6 Preferably, R 4 It is hydrogen, -CH2OH or methyl.

[0154] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 5 is selected from halogen, phenyl and 5-6 membered heteroaryl, wherein the phenyl or heteroaryl is each optionally substituted by one or more selected from halogen and C 1-6 Preferably, R 5 is selected from fluorine, chlorine, phenyl optionally substituted by one or two halogens, or 5-membered heteroaryl optionally substituted by one or two methyl or ethyl groups. 5 is selected from chlorine, phenyl optionally substituted by fluorine or chlorine, or thiazolyl or pyrazolyl optionally substituted by methyl or ethyl. 5 Selected from chlorine,

[0155] In some embodiments of compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), each R 6 independently selected from hydrogen, halogen and C 1-6 Preferably, each R 6 are independently selected from hydrogen, fluorine, chlorine and methoxy.

[0156] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 5 and adjacent R 6 and the carbon atoms to which they are attached together form a benzene ring optionally substituted by one or more halogens. 5 and adjacent R 6and the carbon atoms to which they are attached together form a benzene ring optionally substituted by fluorine or chlorine.

[0157] In some embodiments of the compound of Formula (I), Formula (IA), (IB), (IC), and (ID), n is 0 or 1.

[0158] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 3 C 1-6 Alkyl or C 3-6 Cycloalkyl, R 4 For hydrogen, -C 1-6 Alkylene -OH or C 1-6 Alkyl, R 5 is fluorine, chlorine, phenyl optionally substituted by one or two halogens, or a 5-membered heteroaryl optionally substituted by one or two methyl or ethyl groups, R 6 is hydrogen, fluorine, chlorine or methoxy, and n is 0 or 1.

[0159] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 3 C 1-6 Alkyl, R 4 For hydrogen, -C 1-6 Alkylene -OH or C 1-6 Alkyl, R 5 is a 5-membered heteroaryl group optionally substituted by one or two methyl or ethyl groups, R 6 is hydrogen, and n is 0 or 1.

[0160] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 3 C 1-6 Alkyl or C 3-6 Cycloalkyl, R 4 is hydrogen or C 1-6 Alkyl, R 5 is fluorine, chlorine, phenyl optionally substituted by one or two halogens, or a 5-membered heteroaryl optionally substituted by one or two methyls, R 6 is hydrogen, fluorine, chlorine or methoxy, and n is 0 or 1.

[0161] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 3 C 1-6 Alkyl, R 4 is hydrogen or C 1-6 Alkyl, R 5 is a 5-membered heteroaryl group optionally substituted by one or two methyl groups, R 6 is hydrogen, and n is 0 or 1.

[0162] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), R 5 and adjacent R 6 and the carbon atoms to which they are attached together form a benzene ring optionally substituted by one or two halogens.

[0163] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), the fragment Selected from Preferably selected from

[0164] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), the fragment Selected from Preferably selected from

[0165] In some embodiments of the compounds of Formula (I), Formula (IA), (IB), (IC), and (ID), the fragment Selected from Preferably selected from

[0166] In a particularly preferred embodiment, the compound of formula (I) is selected from:

[0167] Preparation method

[0168] When L 5 -C(=O)-NR11 -, the compound of formula (IB) of the present invention can be prepared by the method shown in the following route 1:

[0169] Route 1

[0170] in

[0171] Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 and n is as defined above;

[0172] LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group;

[0173] PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl;

[0174] The method comprises the following steps:

[0175] 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3;

[0176] 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5;

[0177] 3) Compound IB-5 is reacted with 3b The reagent of the group is reacted to obtain compound IB-6;

[0178] 4) reacting compound IB-6 with compound IB-7 to obtain compound IB-8;

[0179] 5) coupling reaction of compound IB-8 with compound IB-9 to obtain compound IB-10;

[0180] 6) subjecting compound IB-10 to a hydrolysis reaction to obtain compound IB-11;

[0181] 7) reacting compound IB-11 with compound IB-12 to obtain compound IB-13; and

[0182] 8) Compound IB-13 is subjected to a deprotection reaction to obtain compound IB.

[0183] The reaction in step (1) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base. The organic solvent may be selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The organic base may be selected from N,N-diisopropylethylamine and triethylamine, preferably N,N-diisopropylethylamine. The reaction is preferably carried out at a temperature of -50°C to 80°C for 2-24 hours.

[0184] The reaction in step (2) is preferably carried out in a suitable organic solvent and in the presence of a suitable base. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylformamide. The base may be selected from N,N-diisopropylethylamine, triethylamine, potassium carbonate, cesium carbonate, and any combination thereof, preferably a combination of triethylamine and cesium carbonate. The reaction is preferably carried out at a temperature of 20°C to 100°C for 2 to 48 hours.

[0185] The reaction of step (3) is preferably carried out in a suitable organic solvent and in a suitable solvent containing -LG 3b The reagent containing -LG 3b The reagent for the group can be selected from methanesulfonyl chloride, p-toluenesulfonyl chloride, or trifluoromethanesulfonic anhydride, preferably methanesulfonyl chloride. The base can be selected from N,N-diisopropylethylamine or triethylamine, preferably triethylamine. The organic solvent can be selected from tetrahydrofuran, dichloromethane, toluene, 1,2-dichloroethane, and any combination thereof, preferably dichloromethane. The reaction is preferably carried out at a temperature of 0-40°C for 2-16 hours.

[0186] The reaction of step (4) is preferably carried out in a suitable organic solvent and in the presence of an inorganic base and an inorganic salt. The inorganic base can be selected from potassium carbonate or cesium carbonate, preferably potassium carbonate. The inorganic salt can be selected from potassium iodide or sodium iodide, preferably potassium iodide. The organic solvent can be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane and any combination thereof, preferably N,N-dimethylacetamide. The reaction is preferably carried out at a temperature of 25-80°C for 2-16 hours.

[0187] The coupling reaction of the above-mentioned step (5) is preferably carried out in a suitable solvent and in the presence of a metal catalyst and a base. The metal catalyst can be a palladium metal catalyst, such as tris (dibenzylideneacetone) dipalladium, [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium, methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II), tetrakistriphenylphosphine palladium and palladium acetate, preferably methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II). The base can be an organic base or an inorganic base, for example, selected from sodium tert-butoxide, potassium carbonate, potassium phosphate, cesium carbonate and sodium carbonate, preferably cesium carbonate or potassium phosphate. The solvent may be selected from N,N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably a combination of 1,4-dioxane and water. The reaction is preferably carried out at a temperature of 50-120° C. for 2-16 hours.

[0188] The hydrolysis reaction in step (6) is preferably carried out in a suitable solvent in the presence of an inorganic base. The inorganic base may be selected from sodium hydroxide, potassium hydroxide, or lithium hydroxide, preferably lithium hydroxide. The solvent may be selected from acetonitrile, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, water, and any combination thereof, preferably a combination of methanol and water. The reaction is preferably carried out at a temperature of 0-80° C. for 2-16 hours.

[0189] The reaction of step (7) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base and a condensing agent. The organic solvent may be selected from dichloromethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, and any combination thereof, preferably N,N-dimethylformamide. The organic base may be selected from N,N-diisopropylethylamine, triethylamine, 1,8-diazacyclo[5,4,0]undec-7-ene, preferably N,N-diisopropylethylamine. The condensing agent can be selected from 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxy-7-azabenzotriazole, dicyclohexylcarbodiimide, and any combination thereof, preferably 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate. The reaction is preferably carried out at a temperature of 0-60°C for 1-12 hours.

[0190] The deprotection reaction in step (8) is preferably carried out in a suitable organic solvent and in the presence of a suitable deprotection agent. The organic solvent may be selected from ethyl acetate, toluene, acetonitrile, 1,4-dioxane, dichloromethane, and any combination thereof, preferably dichloromethane. The deprotection agent may be selected from hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, aluminum chloride, and trimethylsilyl iodide, preferably trifluoroacetic acid. The reaction is preferably carried out at a temperature of 0-80° C. for 1-12 hours.

[0191] The present invention provides a second method for preparing a compound of formula (IB), comprising the following steps:

[0192] Route 2

[0193] in

[0194] Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 , L 1 , L 2 , L 3 , L 4 , L 5 and n is as defined above;

[0195] LG b LG 1b LG 2b LG 3b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group;

[0196] PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl;

[0197] The method comprises the following steps:

[0198] 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3;

[0199] 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5;

[0200] 3) coupling reaction of compound IB-5 with compound IB-9 to obtain compound IB-6a;

[0201] 4) Compound IB-6a is reacted with 3b The reaction is carried out with a reagent of the group to obtain compound IB-7a;

[0202] 5) reacting compound IB-7a with compound IB-8a to obtain compound IB-13; and

[0203] 6) Compound IB-13 is subjected to a deprotection reaction to obtain Compound IB.

[0204] The reaction in step (1) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base. The organic solvent may be selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The organic base may be selected from N,N-diisopropylethylamine and triethylamine, preferably N,N-diisopropylethylamine. The reaction is preferably carried out at a temperature of -50°C to 80°C for 2-24 hours.

[0205] The reaction in step (2) is preferably carried out in a suitable organic solvent and in the presence of a suitable base. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylformamide. The base may be selected from N,N-diisopropylethylamine, triethylamine, potassium carbonate, cesium carbonate, and any combination thereof, preferably a combination of triethylamine and cesium carbonate. The reaction is preferably carried out at a temperature of 20°C to 100°C for 2 to 48 hours.

[0206] The coupling reaction of the above-mentioned step (3) is preferably carried out in a suitable solvent and in the presence of a metal catalyst and a base. The metal catalyst can be a palladium metal catalyst, such as tris (dibenzylideneacetone) dipalladium, [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium, methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II), tetrakistriphenylphosphine palladium and palladium acetate, preferably methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II). The base can be an organic base or an inorganic base, for example, selected from sodium tert-butoxide, potassium carbonate, potassium phosphate, cesium carbonate and sodium carbonate, preferably cesium carbonate or potassium phosphate. The solvent may be selected from N,N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably a combination of 1,4-dioxane and water. The reaction is preferably carried out at a temperature of 50-120° C. for 2-16 hours.

[0207] The reaction of step (4) is preferably carried out in a suitable organic solvent and in a suitable solvent containing -LG3b The reagent containing -LG 3b The reagent for the group can be selected from methanesulfonyl chloride, p-toluenesulfonyl chloride, or trifluoromethanesulfonic anhydride, preferably methanesulfonyl chloride. The base can be selected from N,N-diisopropylethylamine or triethylamine, preferably triethylamine. The organic solvent can be selected from tetrahydrofuran, dichloromethane, toluene, 1,2-dichloroethane, and any combination thereof, preferably dichloromethane. The reaction is preferably carried out at a temperature of 0-40°C for 2-16 hours.

[0208] The reaction of step (5) is preferably carried out in a suitable organic solvent and in the presence of an inorganic base and an inorganic salt. The inorganic base may be selected from potassium carbonate or cesium carbonate, preferably potassium carbonate. The inorganic salt may be selected from potassium iodide or sodium iodide, preferably potassium iodide. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The reaction is preferably carried out at a temperature of 25-80°C for 2-16 hours.

[0209] The deprotection reaction in step (6) is preferably carried out in a suitable organic solvent and in the presence of a suitable deprotection agent. The organic solvent may be selected from ethyl acetate, toluene, acetonitrile, 1,4-dioxane, dichloromethane, and any combination thereof, preferably dichloromethane. The deprotection agent may be selected from hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, aluminum chloride, and trimethylsilyl iodide, preferably trifluoroacetic acid. The reaction is preferably carried out at a temperature of 0-80° C. for 1-12 hours.

[0210] The present invention provides a third method for preparing a compound of formula (IB), comprising the following steps:

[0211] Route 3

[0212] in

[0213] Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 , L 5 and n is as defined above;

[0214] LG b LG 1b LG2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group;

[0215] PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl;

[0216] The method comprises the following steps:

[0217] 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3;

[0218] 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5;

[0219] 3) coupling reaction of compound IB-5 with compound IB-9 to obtain compound IB-6a;

[0220] 4) Compound IB-6a is reacted with 3b The reaction is carried out with a reagent of the group to obtain compound IB-7a;

[0221] 5) reacting compound IB-7a with compound IB-8b to obtain compound IB-9b;

[0222] 6) subjecting compound IB-9b to a hydrolysis reaction to obtain compound IB-10b;

[0223] 7) reacting compound IB-10b with compound IB-11b to obtain compound IB-13; and

[0224] 8) Compound IB-13 is subjected to a deprotection reaction to obtain compound IB.

[0225] The reaction in step (1) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base. The organic solvent may be selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The organic base may be selected from N,N-diisopropylethylamine and triethylamine, preferably N,N-diisopropylethylamine. The reaction is preferably carried out at a temperature of -50°C to 80°C for 2-24 hours.

[0226] The reaction in step (2) is preferably carried out in a suitable organic solvent and in the presence of a suitable base. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylformamide. The base may be selected from N,N-diisopropylethylamine, triethylamine, potassium carbonate, cesium carbonate, and any combination thereof, preferably a combination of triethylamine and cesium carbonate. The reaction is preferably carried out at a temperature of 20°C to 100°C for 2 to 48 hours.

[0227] The coupling reaction of the above-mentioned step (3) is preferably carried out in a suitable solvent and in the presence of a metal catalyst and a base. The metal catalyst can be a palladium metal catalyst, such as tris (dibenzylideneacetone) dipalladium, [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium, methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II), tetrakistriphenylphosphine palladium and palladium acetate, preferably methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II). The base can be an organic base or an inorganic base, for example, selected from sodium tert-butoxide, potassium carbonate, potassium phosphate, cesium carbonate and sodium carbonate, preferably cesium carbonate or potassium phosphate. The solvent may be selected from N,N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably a combination of 1,4-dioxane and water. The reaction is preferably carried out at a temperature of 50-120° C. for 2-16 hours.

[0228] The reaction of step (4) is preferably carried out in a suitable organic solvent and in a suitable solvent containing -LG 3b The reagent containing -LG 3b The reagent for the group can be selected from methanesulfonyl chloride, p-toluenesulfonyl chloride, or trifluoromethanesulfonic anhydride, preferably methanesulfonyl chloride. The base can be selected from N,N-diisopropylethylamine or triethylamine, preferably triethylamine. The organic solvent can be selected from tetrahydrofuran, dichloromethane, toluene, 1,2-dichloroethane, and any combination thereof, preferably dichloromethane. The reaction is preferably carried out at a temperature of 0-40°C for 2-16 hours.

[0229] The reaction of step (5) is preferably carried out in a suitable organic solvent and in the presence of an inorganic base and an inorganic salt. The inorganic base may be selected from potassium carbonate or cesium carbonate, preferably potassium carbonate. The inorganic salt may be selected from potassium iodide or sodium iodide, preferably potassium iodide. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The reaction is preferably carried out at a temperature of 25-80°C for 2-16 hours.

[0230] The hydrolysis reaction in step (6) is preferably carried out in a suitable solvent in the presence of an inorganic base. The inorganic base may be selected from sodium hydroxide, potassium hydroxide, or lithium hydroxide, preferably lithium hydroxide. The solvent may be selected from acetonitrile, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, water, and any combination thereof, preferably a combination of methanol and water. The reaction is preferably carried out at a temperature of 0-80° C. for 2-16 hours.

[0231] The reaction of step (7) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base and a condensing agent. The organic solvent may be selected from dichloromethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, and any combination thereof, preferably N,N-dimethylformamide. The organic base may be selected from N,N-diisopropylethylamine, triethylamine, 1,8-diazacyclo[5,4,0]undec-7-ene, preferably N,N-diisopropylethylamine. The condensing agent can be selected from 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxy-7-azabenzotriazole, dicyclohexylcarbodiimide, and any combination thereof, preferably 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate. The reaction is preferably carried out at a temperature of 0-60°C for 1-12 hours.

[0232] The deprotection reaction in step (8) is preferably carried out in a suitable organic solvent and in the presence of a suitable deprotection agent. The organic solvent may be selected from ethyl acetate, toluene, acetonitrile, 1,4-dioxane, dichloromethane, and any combination thereof, preferably dichloromethane. The deprotection agent may be selected from hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, aluminum chloride, and trimethylsilyl iodide, preferably trifluoroacetic acid. The reaction is preferably carried out at a temperature of 0-80° C. for 1-12 hours.

[0233] When L 5 -C(=O)-NR 11 -, the compound of formula (IC) of the present invention can be prepared by the method shown in the following route 4:

[0234] Route 4

[0235] in

[0236] Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R11 , L 1 , L 2 , L 3 , L 4 and n is as defined above;

[0237] LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group;

[0238] PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl;

[0239] The method comprises the following steps:

[0240] 1) reacting compound IC-1 with compound IC-2 to obtain compound IC-3;

[0241] 2) reacting compound IC-3 with compound IC-4 to obtain compound IC-5;

[0242] 3) Compound IC-5 is reacted with -LG 3b The reagent of the group is reacted to obtain compound IC-6;

[0243] 4) reacting compound IC-6 with compound IC-7 to obtain compound IC-8;

[0244] 5) coupling reaction of compound IC-8 with compound IC-9 to obtain compound IC-10;

[0245] 6) subjecting compound IC-10 to a hydrolysis reaction to obtain compound IC-11;

[0246] 7) reacting compound IC-11 with compound IC-12 to obtain compound IC-13; and

[0247] 8) Compound IC-13 is subjected to a deprotection reaction to obtain Compound IC.

[0248] The reaction in step (1) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base. The organic solvent may be selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The organic base may be selected from N,N-diisopropylethylamine and triethylamine, preferably N,N-diisopropylethylamine. The reaction is preferably carried out at a temperature of -50°C to 80°C for 2-24 hours.

[0249] The reaction in step (2) is preferably carried out in a suitable organic solvent and in the presence of a suitable base. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylformamide. The base may be selected from N,N-diisopropylethylamine, triethylamine, potassium carbonate, cesium carbonate, and any combination thereof, preferably a combination of triethylamine and cesium carbonate. The reaction is preferably carried out at a temperature of 20°C to 100°C for 2 to 48 hours.

[0250] The reaction of step (3) is preferably carried out in a suitable organic solvent and in a suitable solvent containing -LG 3b The reagent containing -LG 3b The reagent for the group can be selected from methanesulfonyl chloride, p-toluenesulfonyl chloride, or trifluoromethanesulfonic anhydride, preferably methanesulfonyl chloride. The base can be selected from N,N-diisopropylethylamine or triethylamine, preferably triethylamine. The organic solvent can be selected from tetrahydrofuran, dichloromethane, toluene, 1,2-dichloroethane, and any combination thereof, preferably dichloromethane. The reaction is preferably carried out at a temperature of 0-40°C for 2-16 hours.

[0251] The reaction of step (4) is preferably carried out in a suitable organic solvent and in the presence of an inorganic base and an inorganic salt. The inorganic base can be selected from potassium carbonate or cesium carbonate, preferably potassium carbonate. The inorganic salt can be selected from potassium iodide or sodium iodide, preferably potassium iodide. The organic solvent can be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane and any combination thereof, preferably N,N-dimethylacetamide. The reaction is preferably carried out at a temperature of 25-80°C for 2-16 hours.

[0252] The coupling reaction of the above-mentioned step (5) is preferably carried out in a suitable solvent and in the presence of a metal catalyst and a base. The metal catalyst can be a palladium metal catalyst, such as tris (dibenzylideneacetone) dipalladium, [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium, methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II), tetrakistriphenylphosphine palladium and palladium acetate, preferably methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II). The base can be an organic base or an inorganic base, for example, selected from sodium tert-butoxide, potassium carbonate, potassium phosphate, cesium carbonate and sodium carbonate, preferably cesium carbonate or potassium phosphate. The solvent may be selected from N,N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably a combination of 1,4-dioxane and water. The reaction is preferably carried out at a temperature of 50-120° C. for 2-16 hours.

[0253] The hydrolysis reaction in step (6) is preferably carried out in a suitable solvent in the presence of an inorganic base. The inorganic base may be selected from sodium hydroxide, potassium hydroxide, or lithium hydroxide, preferably lithium hydroxide. The solvent may be selected from acetonitrile, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, water, and any combination thereof, preferably a combination of methanol and water. The reaction is preferably carried out at a temperature of 0-80° C. for 2-16 hours.

[0254] The reaction of step (7) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base and a condensing agent. The organic solvent may be selected from dichloromethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, and any combination thereof, preferably N,N-dimethylformamide. The organic base may be selected from N,N-diisopropylethylamine, triethylamine, 1,8-diazacyclo[5,4,0]undec-7-ene, preferably N,N-diisopropylethylamine. The condensing agent can be selected from 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxy-7-azabenzotriazole, dicyclohexylcarbodiimide, and any combination thereof, preferably 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate. The reaction is preferably carried out at a temperature of 0-60°C for 1-12 hours.

[0255] The deprotection reaction in step (8) is preferably carried out in a suitable organic solvent and in the presence of a suitable deprotection agent. The organic solvent may be selected from ethyl acetate, toluene, acetonitrile, 1,4-dioxane, dichloromethane, and any combination thereof, preferably dichloromethane. The deprotection agent may be selected from hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, aluminum chloride, and trimethylsilyl iodide, preferably trifluoroacetic acid. The reaction is preferably carried out at a temperature of 0-80° C. for 1-12 hours.

[0256] When L 5 -C(=O)-NR 11 -, the compound of formula (ID) of the present invention can be prepared by the method shown in the following route 5, which comprises the following steps:

[0257] Route 5

[0258] in

[0259] Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 and n is as defined above;

[0260] LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group;

[0261] PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl;

[0262] The method comprises the following steps:

[0263] 1) reacting compound IB-1 with compound ID-2 to obtain compound ID-3;

[0264] 2) reacting compound ID-3 with compound ID-4 to obtain compound ID-5;

[0265] 3) coupling reaction of compound ID-5 with compound IB-9 to obtain compound ID-6;

[0266] 4) Compound ID-6 is reacted with 3b The reaction was carried out with a reagent of the group to obtain compound ID-7;

[0267] 5) reacting compound ID-7 with compound IB-7 to obtain compound ID-8;

[0268] 6) subjecting compound ID-8 to a hydrolysis reaction to obtain compound ID-9;

[0269] 7) reacting compound ID-9 with compound IB-12 to obtain compound ID-10; and

[0270] 8) Compound ID-10 was subjected to a deprotection reaction to obtain Compound ID.

[0271] The reaction in step (1) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base. The organic solvent may be selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The organic base may be selected from N,N-diisopropylethylamine and triethylamine, preferably N,N-diisopropylethylamine. The reaction is preferably carried out at a temperature of -50°C to 80°C for 2-24 hours.

[0272] The reaction in step (2) is preferably carried out in a suitable organic solvent and in the presence of a suitable base. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylformamide. The base may be selected from N,N-diisopropylethylamine, triethylamine, potassium carbonate, cesium carbonate, and any combination thereof, preferably a combination of triethylamine and cesium carbonate. The reaction is preferably carried out at a temperature of 20°C to 100°C for 2 to 48 hours.

[0273] The coupling reaction of the above-mentioned step (3) is preferably carried out in a suitable solvent and in the presence of a metal catalyst and a base. The metal catalyst can be a palladium metal catalyst, such as tris (dibenzylideneacetone) dipalladium, [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium, methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II), tetrakistriphenylphosphine palladium and palladium acetate, preferably methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II). The base can be an organic base or an inorganic base, for example, selected from sodium tert-butoxide, potassium carbonate, potassium phosphate, cesium carbonate and sodium carbonate, preferably cesium carbonate or potassium phosphate. The solvent may be selected from N,N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably a combination of 1,4-dioxane and water. The reaction is preferably carried out at a temperature of 50-120° C. for 2-16 hours.

[0274] The reaction of step (4) is preferably carried out in a suitable organic solvent and in a suitable solvent containing -LG 3b The reagent containing -LG 3b The reagent for the group can be selected from methanesulfonyl chloride, p-toluenesulfonyl chloride, or trifluoromethanesulfonic anhydride, preferably methanesulfonyl chloride. The base can be selected from N,N-diisopropylethylamine or triethylamine, preferably triethylamine. The organic solvent can be selected from tetrahydrofuran, dichloromethane, toluene, 1,2-dichloroethane, and any combination thereof, preferably dichloromethane. The reaction is preferably carried out at a temperature of 0-40°C for 2-16 hours.

[0275] The reaction of step (5) is preferably carried out in a suitable organic solvent and in the presence of an inorganic base and an inorganic salt. The inorganic base may be selected from potassium carbonate or cesium carbonate, preferably potassium carbonate. The inorganic salt may be selected from potassium iodide or sodium iodide, preferably potassium iodide. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The reaction is preferably carried out at a temperature of 25-80°C for 2-16 hours.

[0276] The hydrolysis reaction in step (6) is preferably carried out in a suitable solvent in the presence of an inorganic base. The inorganic base may be selected from sodium hydroxide, potassium hydroxide, or lithium hydroxide, preferably lithium hydroxide. The solvent may be selected from acetonitrile, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, water, and any combination thereof, preferably a combination of methanol and water. The reaction is preferably carried out at a temperature of 0-80° C. for 2-16 hours.

[0277] The reaction of step (7) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base and a condensing agent. The organic solvent may be selected from dichloromethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, and any combination thereof, preferably N,N-dimethylformamide. The organic base may be selected from N,N-diisopropylethylamine, triethylamine, 1,8-diazacyclo[5,4,0]undec-7-ene, preferably N,N-diisopropylethylamine. The condensing agent can be selected from 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxy-7-azabenzotriazole, dicyclohexylcarbodiimide, and any combination thereof, preferably 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate. The reaction is preferably carried out at a temperature of 0-60°C for 1-12 hours.

[0278] The deprotection reaction in step (8) is preferably carried out in a suitable organic solvent and in the presence of a suitable deprotection agent. The organic solvent may be selected from ethyl acetate, toluene, acetonitrile, 1,4-dioxane, dichloromethane, and any combination thereof, preferably dichloromethane. The deprotection agent may be selected from hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, aluminum chloride, and trimethylsilyl iodide, preferably trifluoroacetic acid. The reaction is preferably carried out at a temperature of 0-80° C. for 1-12 hours.

[0279] The present invention provides a fourth method for preparing a compound of formula (IB), comprising the following steps:

[0280] Route 6

[0281] in

[0282] Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 , L 1 , L 2 , L 3 , L 4 , L 5 and n is as defined above;

[0283] LG b LG 1b LG 2b and LG 5beach independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group;

[0284] PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl;

[0285] The method comprises the following steps:

[0286] 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3;

[0287] 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5;

[0288] 3) coupling reaction of compound IB-5 with compound IB-9 to obtain compound IB-6a;

[0289] 4) subjecting compound IB-6a to an oxidation reaction to obtain compound IB-7c;

[0290] 5) reacting compound IB-7c with compound IB-8a to obtain compound IB-13; and

[0291] 6) Compound IB-13 is subjected to a deprotection reaction to obtain Compound IB.

[0292] The reaction in step (1) is preferably carried out in a suitable organic solvent and in the presence of a suitable organic base. The organic solvent may be selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylacetamide. The organic base may be selected from N,N-diisopropylethylamine and triethylamine, preferably N,N-diisopropylethylamine. The reaction is preferably carried out at a temperature of -50°C to 80°C for 2-24 hours.

[0293] The reaction in step (2) is preferably carried out in a suitable organic solvent and in the presence of a suitable base. The organic solvent may be selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, tetrahydrofuran, 1,4-dioxane, and any combination thereof, preferably N,N-dimethylformamide. The base may be selected from N,N-diisopropylethylamine, triethylamine, potassium carbonate, cesium carbonate, and any combination thereof, preferably a combination of triethylamine and cesium carbonate. The reaction is preferably carried out at a temperature of 20°C to 100°C for 2 to 48 hours.

[0294] The coupling reaction of the above-mentioned step (3) is preferably carried out in a suitable solvent and in the presence of a metal catalyst and a base. The metal catalyst can be a palladium metal catalyst, such as tris (dibenzylideneacetone) dipalladium, [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium, methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II), tetrakistriphenylphosphine palladium and palladium acetate, preferably methanesulfonic acid [n-butyldi (1-adamantyl) phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II). The base can be an organic base or an inorganic base, for example, selected from sodium tert-butoxide, potassium carbonate, potassium phosphate, cesium carbonate and sodium carbonate, preferably cesium carbonate or potassium phosphate. The solvent may be selected from N,N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably a combination of 1,4-dioxane and water. The reaction is preferably carried out at a temperature of 50-120° C. for 2-16 hours.

[0295] The reaction in step (4) is preferably carried out in a suitable organic solvent and in the presence of a suitable oxidizing agent. The organic solvent may be selected from dichloromethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, and any combination thereof, preferably dichloromethane. The oxidizing agent may be selected from Dess-Martin periodinane, 2-iodoxybenzoic acid, pyridinium dichromate, and pyridinium chlorochromate, preferably pyridinium chlorochromate. The reaction is preferably carried out at a temperature of 0-60° C. for 1-16 hours.

[0296] The reaction in step (5) is preferably carried out in a suitable organic solvent and in the presence of a suitable reducing agent. The organic solvent may be selected from dichloromethane, tetrahydrofuran, acetonitrile, methanol, isopropanol, and any combination thereof, preferably tetrahydrofuran. The reducing agent may be selected from sodium borohydride, sodium cyanoborohydride, sodium triacetylborohydride, and 2-methylpyridine borane, preferably sodium cyanoborohydride. The reaction is preferably carried out at a temperature of 0-90° C. for 1-12 hours.

[0297] The deprotection reaction in step (6) is preferably carried out in a suitable organic solvent and in the presence of a suitable deprotection agent. The organic solvent may be selected from ethyl acetate, toluene, acetonitrile, 1,4-dioxane, dichloromethane, and any combination thereof, preferably dichloromethane. The deprotection agent may be selected from hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, aluminum chloride, and trimethylsilyl iodide, preferably trifluoroacetic acid. The reaction is preferably carried out at a temperature of 0-80° C. for 1-12 hours.

[0298] Pharmaceutical compositions and kits

[0299] Another object of the present invention is to provide a pharmaceutical composition comprising a preventively and / or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, and one or more pharmaceutically acceptable carriers.

[0300] Another object of the present invention is to provide a drug kit comprising a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention, and optionally packaging and / or instructions.

[0301] In the present invention, "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with the therapeutic agent and is suitable for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic response or other problems or complications corresponding to a reasonable benefit / risk ratio within the scope of reasonable medical judgment.

[0302] Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions or pharmaceutical formulations of this invention include, but are not limited to, sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.

[0303] The pharmaceutical composition may be in the form of a solid preparation, a semisolid preparation, a liquid preparation, or a gaseous preparation. Examples of solid preparations include tablets, capsules, powders, granules, or suppositories, and examples of liquid preparations include solutions, suspensions, or injections. The composition may also be in the form of liposomes, microspheres, or other dosage forms.

[0304] The pharmaceutical compositions of the present invention can act systemically and / or locally. For this purpose, they can be administered by suitable routes, for example, by injection (such as intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection, including instillation) or transdermal administration; or by oral, buccal, nasal, transmucosal, topical, in the form of ophthalmic preparations or by inhalation.

[0305] The content or dosage of the compound of the present invention in the pharmaceutical composition may be about 0.001 mg to about 1000 mg, suitably 0.01-800 mg, preferably 0.05-500 mg, more preferably 0.1-350 mg, particularly preferably 0.5-100 mg.

[0306] In some embodiments, the present invention provides a method for preparing a pharmaceutical composition of the present invention, comprising combining a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof with one or more pharmaceutically acceptable carriers.

[0307] Treatment methods and uses

[0308] Another object of the present invention is to provide a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention, for use in preventing and / or treating KRAS G12D-mediated related diseases.

[0309] Another object of the present invention is to provide use of the compound of the present invention or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug, or the pharmaceutical composition of the present invention in the preparation of a medicament for preventing and / or treating KRAS G12D-mediated related diseases.

[0310] Another object of the present invention is to provide a method for preventing and / or treating KRAS G12D-mediated related diseases, which comprises administering to an individual in need thereof a preventively or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, or a pharmaceutical composition of the present invention.

[0311] According to some embodiments of the present invention, the KRAS G12D-mediated related disease is a tumor or cancer.

[0312] As used herein, the term "effective amount" refers to an amount sufficient to achieve the desired prophylactic or therapeutic effect, for example, to achieve relief of one or more symptoms associated with the disease being treated.

[0313] The dosage regimen can be adjusted to provide the optimal desired response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It is to be noted that dosage values ​​can vary with the type and severity of the condition to be alleviated and can include single or multiple doses. It is to be further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition.

[0314] The amount of the compound of the present invention administered will depend on the severity of the individual, disease or the patient's condition, the speed of administration, the disposal of the compound and the judgment of the prescribing physician for treatment. Generally speaking, effective dose is about 0.0001 to about 50mg per kg body weight per day, for example, about 0.01 to about 10mg / kg / day (single or divided administration). For 70kg people, this will add up to about 0.007mg / day to about 3500mg / day, for example, about 0.7mg / day to about 700mg / day. In some cases, it can be enough to be not higher than the dosage level of the lower limit of the aforementioned range, and in other cases, it is still possible to adopt a larger dose in the case of not causing any harmful side effects, provided that the larger dose is first divided into several smaller doses to be administered throughout the day.

[0315] The term "prevention" as used herein includes inhibition and delay of the onset of a disease, and includes not only prevention before the development of a disease but also prevention of recurrence of a disease after treatment.

[0316] The terms "treat," "treat," "treat," or "treating" as used herein means to reverse, alleviate, or eliminate the progression of the disorder or condition to which such terms apply, or one or more symptoms of such disorder or condition.

[0317] As used herein, "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from diseases (e.g., the diseases described herein) (referred to as patients) or normal individuals. "Non-human animals" herein include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.). Example

[0318] The embodiments of the present invention are described in detail below with reference to the examples. However, those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention.

[0319] In the examples, if the specific conditions are not specified, all experiments were carried out under conventional conditions or those recommended by the manufacturer. All reagents or instruments used, if the manufacturer is not specified, are commercially available conventional products.

[0320] The structure of the compound was determined by nuclear magnetic resonance ( 1 H NMR) and / or mass spectrometry (MS).

[0321] 1H NMR measurements were performed on a JEOL Eclipse 400 nuclear magnetometer. The solvents used were deuterated methanol (CD3OD), deuterated chloroform (CDCl3), or hexadeuterated dimethyl sulfoxide (DMSO-d6). The internal standard was tetramethylsilane (TMS). Chemical shifts (δ) were given in parts per million (ppm).

[0322] The MS measuring instrument is an Agilent (ESI) mass spectrometer, manufactured by Agilent, model: Agilent 6120B.

[0323] The preparative HPLC conditions were as follows:

[0324] Instrument model: Agilent 1260; chromatographic column: Waters SunFire Prep C18 OBD (19 mm × 150 mm × 5.0 μm); column temperature: 25°C; flow rate: 20.0 mL / min; detection wavelength: 214 nm; elution gradient: (0 min: 10% A, 90% B; 16.0 min: 90% A, 10% B); mobile phase A: acetonitrile; mobile phase B: 0.05% formic acid in water.

[0325] Aluminum plates (20×20 cm) produced by Merck were used for thin layer chromatography silica gel plates (TLC), and the specifications used for thin layer chromatography separation and purification were GF 254 (1 mm) produced in Yantai.

[0326] The reaction is monitored by thin layer chromatography (TLC) or LC-MS; the developing solvent systems used include: dichloromethane and methanol system, n-hexane and ethyl acetate system, and petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound or by adding triethylamine.

[0327] Column chromatography generally uses 200-300 mesh silica gel as a carrier. Eluent systems include: dichloromethane and methanol systems, and petroleum ether and ethyl acetate systems. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine can also be added for adjustment.

[0328] Unless otherwise specified, the reaction temperature was room temperature (20°C-35°C).

[0329] The reagents used in the examples were purchased from Acros Organics, Aldrich Chemical Company, Teber Chemical and other companies.

[0330] The meanings of the abbreviations used in this document are shown in the following table.

[0331] Preparation of intermediates:

[0332] Intermediate Preparation Example 1: Preparation of ethyl 2-(piperidin-4-ylmethoxy)acetate

[0333] Step 1: Preparation of tert-butyl 4-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

[0334] Dissolve tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (4.0 g, 18.6 mmol) in dichloromethane (40 mL). Add dimerized rhodium acetate (419.2 mg, 0.9 mmol). Ethyl diazoacetate (3.2 g, 28.1 mmol) was added dropwise to the reaction mixture at 0°C. The atmosphere was purged with nitrogen three times, then warmed to room temperature and allowed to react for 16 hours. The reaction mixture was poured into water (40 mL) and extracted twice with dichloromethane (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 9, volume ratio) to obtain the title compound (2.6 g, yield: 46.4%).

[0335] MS m / z(ESI):302.0[M+H] + .

[0336] Step 2: Preparation of ethyl 2-(piperidin-4-ylmethoxy)acetate

[0337] tert-Butyl 4-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (2.6 g, 8.6 mmol) was added to a 4M solution of hydrogen chloride in ethyl acetate (30 mL) and reacted at 20°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the hydrochloride salt of the title compound (1.9 g, yield: 95.0%).

[0338] MS m / z(ESI):202.0[M+H] + .

[0339] Intermediate Preparation Example 2: Preparation of ethyl 2-(piperidin-4-oxy)acetate

[0340] Step 1: Preparation of tert-butyl 4-(2-ethoxy-2-oxoethoxy)piperidine-1-carboxylate

[0341] Dissolve tert-butyl 4-hydroxypiperidine-1-carboxylate (4.0 g, 19.9 mmol) in dichloromethane (40 mL). Add dimerized rhodium acetate (442 mg, 1.0 mmol). Ethyl diazoacetate (3.4 g, 29.85 mmol) was added dropwise to the reaction mixture at 0°C. The atmosphere was purged with nitrogen three times, then warmed to room temperature and allowed to react for 16 hours. The reaction mixture was poured into water (40 mL) and extracted twice with dichloromethane (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 9, volume ratio) to obtain the title compound (2.2 g, yield: 38.4%).

[0342] MS m / z(ESI):288.2[M+H] + .

[0343] Step 2: Preparation of ethyl 2-(piperidin-4-oxy)acetate

[0344] tert-Butyl 4-(2-ethoxy-2-oxoethoxy)piperidine-1-carboxylate (2.2 g, 7.6 mmol) was added to a 4 M solution of hydrogen chloride in ethyl acetate (30 mL) and reacted at 20°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the title compound (1.4 g, yield: 97.2%).

[0345] MS m / z(ESI):188.1[M+H] + .

[0346] Intermediate Preparation Example 3: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0347] Step 1: Preparation of ethyl 4-amino-6-chloro-5-fluoropyridine-3-carboxylate

[0348] 2-Chloro-3-fluoro-5-iodopyridin-4-amine (3.60 g, 13.08 mmol), triethylamine (1.99 g, 19.62 mmol), and Pd(dppf)Cl2 (478.59 mg, 654.07 μmol) were added sequentially to anhydrous ethanol (100 mL). The reaction system was stirred at 80°C overnight under a carbon monoxide atmosphere. The system was cooled to room temperature, the solvent was evaporated, and the product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to obtain the title compound (2.5 g, yield: 83.05%).

[0349] MS m / z(ESI):219.0[M+H] + .

[0350] Step 2: Preparation of ethyl 6-chloro-5-fluoro-4-[(2,2,2-trichloroacetyl)carbamoylamino]pyridine-3-carboxylate

[0351] Ethyl 4-amino-6-chloro-5-fluoropyridine-3-carboxylate (2.5 g, 10.99 mmol) was added to anhydrous tetrahydrofuran (50 mL), and 2,2,2-trichloroacetyl isocyanate (3.14 g, 16.49 mmol) was slowly added. The mixture was stirred at 25°C for 15 minutes. The tetrahydrofuran was removed by rotary evaporation under reduced pressure, and the crude product was added to methyl tert-butyl ether. The mixture was stirred thoroughly for 5 minutes, filtered, and the filter cake was dried to obtain the title compound (4.3 g, yield: 91.29%).

[0352] MS m / z(ESI):405.9[M+H] + .

[0353] Step 3: Preparation of 7-chloro-8-fluoro-pyrido[4,3-d]pyrimidine-2,4-diol

[0354] Ethyl 6-chloro-5-fluoro-4-[(2,2,2-trichloroacetyl)carbamoylamino]pyridine-3-carboxylate (4.30 g, 10.04 mmol) was added to anhydrous methanol (50 mL), and ammonia / methanol (10 mL) was added dropwise. The mixture was stirred at 25°C for 1.5 hours. The methanol was removed by rotary evaporation under reduced pressure, and the crude product was added to methyl tert-butyl ether. The mixture was stirred thoroughly for 10 minutes, filtered, and the filter cake was collected to obtain the title compound (2.7 g, yield: 96.99%).

[0355] MS m / z(ESI):216.0[M+H] + .

[0356] Step 4: Preparation of 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine

[0357] To phosphorus oxychloride (35 mL) cooled in an ice-salt bath, N,N-diisopropylethylamine (5.8 g, 45.1 mmol) was added dropwise, followed by the slow addition of 7-chloro-8-fluoro-pyrido[4,3-d]pyrimidine-2,4-diol (2.5 g, 9.0 mmol). After addition, the reaction system was stirred at 100°C for 1.5 hours. The system was cooled to room temperature, and most of the phosphorus oxychloride was removed by rotary evaporation under reduced pressure. Chloroform (40 mL) was added and the remaining phosphorus oxychloride was removed by azeotropic rotary evaporation under reduced pressure to obtain the title compound (2.56 g, yield: 98.5%), which was used directly in the next step.

[0358] MS m / z(ESI):251.9[M+H] + .

[0359] Step 5: Preparation of tert-butyl 3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0360] 2,4,7-Trichloro-8-fluoropyrido[4,3-d]pyrimidine (2.56 g, 8.9 mmol) was added to dichloromethane (30 mL) and the temperature was lowered to -40°C. At this temperature, tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (2.07 g, 9.75 mmol) was added, followed by the slow dropwise addition of N,N-diisopropylethylamine (3.44 g, 26.65 mmol). The mixture was stirred at this temperature for 10 minutes. Sodium bicarbonate solution (20 mL) was added, and the mixture was extracted three times with ethyl acetate (25 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and then purified by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, volume ratio) to obtain the title compound (3.5 g, yield: 80.5%).

[0361] MS m / z(ESI):428.2[M+H] + .

[0362] Step 6: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0363] Tert-butyl 3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.5 g, 8.18 mmol), 1,1-cyclopropane dimethanol (2.51 g, 24.54 mmol), triethylamine (0.83 g, 8.18 mmol), and cesium carbonate (8.0 g, 24.54 mmol) were added sequentially to DMF (40 mL). The system was stirred at 25°C for 20 hours. The reaction solution was added dropwise to water to precipitate a solid, which was filtered and the filter cake dried to obtain the title compound (3.5 g, yield: 86.6%).

[0364] MS m / z(ESI):494.2[M+H] + .

[0365] Step 7: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0366] Tert-butyl 3-(7-chloro-8-fluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (400.0 mg, 0.81 mmol) and triethylamine (409.67 mg, 4.05 mmol) were dissolved in dichloromethane (6 mL). The mixture was cooled to 0°C in an ice bath. Methanesulfonyl chloride (139.18 mg, 1.21 mmol) was added, and the mixture was stirred at 20°C for 6 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 2, volume ratio) to obtain the title compound (450 mg, yield: 97.1%).

[0367] MS m / z(ESI):572.2[M+H] + .

[0368] Intermediate Preparation Example 4: Preparation of 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0369] Step 1: Preparation of 2-(8-ethynyl-7-fluoro-3-((methoxymethyl)oxy)-1-naphthyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0370] Dissolve ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (5.0 g, 9.75 mmol) in DMF (50 mL), add cesium fluoride (7.4 g, 48.78 mmol), and react at room temperature for 4 hours. Pour the reaction solution into water (400 mL), filter the precipitated solid, and dry the filter cake to obtain the title compound (3.4 g, 97.7% yield).

[0371] MS m / z(ESI):357.2[M+H] + .

[0372] Step 2: Preparation of 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0373] 2-(8-Ethynyl-7-fluoro-3-((methoxymethyl)oxy)-1-naphthyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.4 g, 9.55 mmol) was dissolved in a mixed solvent of tetrahydrofuran (30 mL) and methanol (15 mL). Platinum dioxide (217.9 mg, 0.96 mmol) was added, and the atmosphere was replaced with hydrogen three times. The reaction was continued at 20°C for 14 hours. The mixture was filtered and concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1, volume ratio) to obtain the title compound (2.6 g, yield: 75.6%).

[0374] MS m / z(ESI):361.2[M+H] + .

[0375] Intermediate Preparation Example 5: Preparation of ethyl (7-azaspiro[3.5]non-2-yloxy)acetate

[0376] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 7-tert-butoxycarbonyl-7-azaspiro[3.5]-2-nonanol to obtain the title compound (500 mg, yield: 45.3%).

[0377] MS m / z(ESI):228.1[M+H] + .

[0378] Intermediate Preparation Example 6: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide

[0379] Step 1: Preparation of tert-butyl (2S,4R)-4-hydroxy-2-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidine-1-carboxylate

[0380] (2S,4R)-1-(tert-Butyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (1 g, 6.36 mmol) was dissolved in N,N-dimethylformamide (14.33 mL), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (3.14 mg, 8.27 mmol) was added. The temperature was lowered to 0°C, and N,N-diisopropylethylamine (2.47 g, 19.08 mmol) and 2-(aminomethyl)naphthalene (1.62 g, 7.00 mmol) were added. The mixture was stirred at this temperature for 30 minutes, and then reacted at room temperature for 16 hours. The reaction solution was poured into water (40 mL) and extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 9, volume ratio) to give the title compound (2.4 g, yield: 98.3%).

[0381] MS m / z(ESI):371.2[M+H] + .

[0382] Step 2: Preparation of (2S,4R)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide

[0383] Dissolve tert-butyl (2S,4R)-4-hydroxy-2-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidine-1-carboxylate (631.58 mg, 1.70 mmol) in dichloromethane (5 mL). Add 4M hydrogen chloride in 1,4-dioxane (4 mL) and react at room temperature for 2 hours. The reaction mixture was concentrated to obtain the title compound (475 mg, yield: 95.6%).

[0384] MS m / z(ESI):271.2[M+H] + .

[0385] Step 3: Preparation of tert-butyl (S)-1-((2S,4R)-4-hydroxy-2-((naphthalene-2-ylmethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutane-2-yl)carbamate

[0386] (S)-2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (300 mg, 1.30 mmol) was dissolved in N,N-dimethylformamide (6 mL), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (641.15 mg, 1.69 mmol) was added. The temperature was lowered to 0°C, and N,N-diisopropylethylamine (502.91 mg, 3.89 mmol) and (2S,4R)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide hydrochloride (437.72 mg, 1.43 mmol) were added. The mixture was stirred at this temperature for 30 minutes, and then reacted at room temperature for 7 hours. The reaction solution was poured into water (20 mL), and a beige solid product precipitated. The filter cake was filtered to obtain the title compound (217 mg, yield: 34.6%).

[0387] MS m / z(ESI):484.3[M+H] + .

[0388] Step 4: Preparation of (2S,4R)-1-(S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide

[0389] Dissolve tert-butyl (S)-1-((2S,4R)-4-hydroxy-2-((naphthalene-2-ylmethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (217 mg, 0.448 mmol) in dichloromethane (6 mL). Add 4M hydrogen chloride in 1,4-dioxane (2 mL) and react at room temperature for 2 hours. The reaction mixture was concentrated to obtain the title compound (150 mg, yield: 87.2%).

[0390] MS m / z(ESI):384.3[M+H] + .

[0391] Intermediate Preparation Example 7: Preparation of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide

[0392] Step 1: Preparation of tert-butyl N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]carbamate

[0393] Dissolve tert-butyl N-[(1S)-1-(4-bromophenyl)ethyl]carbamate (2.0 g, 6.60 mmol) and (2-fluorophenyl)boronic acid (1.12 g, 7.91 mmol) in 1,4-dioxane (20 mL) and water (2 mL). Add potassium carbonate (1.84 g, 13.19 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (243.74 mg, 329.79 μmol). Replace the atmosphere with nitrogen three times, heat to 90°C, and stir for 2 hours. The reaction mixture is concentrated, and the residue is purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to obtain the title compound (1.8 g, yield: 86.5%).

[0394] MS m / z(ESI):316.1[M+H] + .

[0395] Step 2: Preparation of (1S)-1-[4-(2-fluorophenyl)phenyl]ethan-1-amine

[0396] Tert-butyl N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]carbamate (1.8 g, 5.7 mmol) was added to dichloromethane (5 mL) and a 4M solution of hydrogen chloride in 1,4-dioxane (5 mL). The mixture was reacted at 20°C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the title compound (1.3 g, 90.6% yield).

[0397] MS m / z(ESI):216.1[M+H] + .

[0398] Step 3: Preparation of tert-butyl (2S,4R)-2-{[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]carbamoyl}-4-hydroxypyrrolidine-1-carboxylate

[0399] (1S)-1-[4-(2-fluorophenyl)phenyl]ethan-1-amine (1.3 g, 5.16 mmol) and (2S,4R)-1-[(tert-butoxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid (1.2 g, 5.18 mmol) were dissolved in DMF (10 mL). N,N-diisopropylethylamine (1.84 g, 14.15 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.61 g, 6.79 mmol) were added. The mixture was stirred at 25°C for 3 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to obtain the title compound (1.88 g, yield: 85.1%).

[0400] MS m / z(ESI):429.2[M+H] + .

[0401] Step 4: Preparation of (2S,4R)-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide

[0402] Tert-butyl (2S,4R)-2-{[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]carbamoyl}-4-hydroxypyrrolidine-1-carboxylate (1.88 g, 4.39 mmol) was added to 1,4-dioxane (5 mL) and a 4M solution of hydrogen chloride in 1,4-dioxane (5 mL) and reacted at 20°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the hydrochloride salt of the title compound (1.24 g, yield: 77.5%).

[0403] MS m / z(ESI):329.2[M+H] + .

[0404] Step 5: Preparation of tert-butyl N-[(2S)-1-[(2S,4R)-2-{[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]carbamoyl}-4-hydroxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate

[0405] (2S,4R)-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (1.24 g, 3.78 mmol) and N-tert-butyloxycarbonyl-L-tert-leucine (0.87 g, 3.78 mmol) were dissolved in DMF (10 mL). N,N-diisopropylethylamine (1.2 g, 9.45 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.72 g, 4.54 mmol) were added. The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, volume ratio) to obtain the title compound (1.5 g, yield: 73.2%).

[0406] MS m / z(ESI):542.3[M+H] + .

[0407] Step 6: Preparation of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutyryl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide

[0408] Tert-butyl N-[(2S)-1-[(2S,4R)-2-{[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]carbamoyl}-4-hydroxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (1.24 g, 3.79 mmol) was added to 1,4-dioxane (5 mL) and a 4M solution of hydrogen chloride in 1,4-dioxane (5 mL) and reacted at 20°C for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain the hydrochloride salt of the title compound (1.3 g, yield: 72.2%).

[0409] MS m / z(ESI):442.2[M+H] + .

[0410] Intermediate Preparation Example 8: Preparation of ethyl 3-(piperazin-1-yl)propionate

[0411] Step 1: Preparation of 4-(3-ethoxy-3-oxopropyl)piperazine-1-carboxylic acid benzyl ester

[0412] Benzyl piperazine-1-carboxylate (1.0 g, 4.54 mmol) was dissolved in methanol (10 mL), and ethyl acrylate (2.27 g, 22.7 mmol) and triethylamine (0.92 g, 9.08 mmol) were added. The mixture was allowed to react at room temperature for 16 hours. The reaction mixture was concentrated, and water (40 mL) was added to the concentrate. The mixture was extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (1.2 g, yield: 82.5%).

[0413] MS m / z(ESI):321.2[M+H] + .

[0414] Step 2: Preparation of ethyl 3-(piperazin-1-yl)propionate

[0415] Benzyl 4-(3-ethoxy-3-oxopropyl)piperazine-1-carboxylate (1.2 g, 3.75 mmol) was dissolved in methanol (30 mL), and 10% palladium on carbon (120 mg) was added. The atmosphere was replaced with hydrogen three times, and the reaction was continued at 20°C for 6 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound (0.5 g, yield: 71.4%).

[0416] MS m / z(ESI):187.1[M+H] + .

[0417] Intermediate Preparation Example 9: Preparation of (2-((tert-Butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)boronic acid

[0418] Step 1: Preparation of N-((2-bromo-5-fluorophenyl)carbamoylthioate)benzamide

[0419] Dissolve 2-bromo-5-fluoroaniline (4.0 g, 21.1 mmol) in tetrahydrofuran (30 mL). Add dropwise a solution of benzoyl isothiocyanate (2.27 g, 22.7 mmol) in tetrahydrofuran (10 mL) under an ice bath. Allow to react at room temperature for 0.5 hour. Add the reaction solution dropwise to water (400 mL). The precipitated solid was filtered and the filter cake dried to obtain the title compound (6.0 g, yield: 82.5%).

[0420] MS m / z(ESI):353.1[M+H] + .

[0421] Step 2: Preparation of 1-(2-bromo-5-fluorophenyl)thiourea

[0422] N-((2-bromo-5-fluorophenyl)carbamoylthioate)benzamide (6.0 g, 16.99 mmol) was dissolved in tetrahydrofuran (60 mL) and water (10 mL). Sodium hydroxide (1.36 g, 33.98 mmol) was added and the mixture was allowed to react at 60°C for 16 hours. The reaction mixture was concentrated, and water (40 mL) was added to the concentrate. The mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1, volume ratio) to obtain the title compound (3.5 g, yield: 82.7%).

[0423] MS m / z(ESI):249.1[M+H] + .

[0424] Step 3: Preparation of 4-bromo-7-fluorobenzo[d]thiazol-2-amine

[0425] 1-(2-Bromo-5-fluorophenyl)thiourea (1.0 g, 4.02 mmol) was dissolved in chloroform (10 mL). Bromine (707 mg, 4.42 mmol) was added dropwise at 0°C. The mixture was reacted at 0°C for 0.5 hours and then at 70°C for 12 hours. The reaction solution was diluted with dichloromethane (50 mL), and the organic phase was washed with saturated sodium sulfite solution (20 mL). The organic phase was separated and washed with sodium bicarbonate solution (20 mL). The organic phase was separated and washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the title compound (0.81 g, yield: 81.7%).

[0426] MS m / z(ESI):247.1[M+H] + .

[0427] Step 4: Preparation of tert-butyl (4-bromo-7-fluorobenzo[d]thiazol-2-yl)carbamate

[0428] Dissolve 4-bromo-7-fluorobenzo[d]thiazol-2-amine (0.81 g, 3.28 mmol) in dichloromethane (10 mL). Add 4-dimethylaminopyridine (40 mg, 0.33 mmol), triethylamine (730 mg, 7.22 mmol), and di-tert-butyl dicarbonate (1.79 g, 8.2 mmol) at 0°C. React at 20°C for 12 hours. Dilute the reaction solution with dichloromethane (50 mL), wash the organic phase with sodium bicarbonate solution (20 mL), separate the layers, wash the organic phase with saturated brine (20 mL), dry it over anhydrous sodium sulfate, and concentrate under reduced pressure. The residue is purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1, volume ratio) to obtain the title compound (0.79 g, yield: 69.4%).

[0429] MS m / z(ESI):347.1[M+H] + .

[0430] Step 5: Preparation of (2-((tert-Butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)boronic acid

[0431] Dissolve tert-butyl (4-bromo-7-fluorobenzo[d]thiazol-2-yl)carbamate (0.79 g, 2.28 mmol) in tetrahydrofuran (10 mL). Add sodium hydride (197 mg, 4.92 mmol) at -10°C and stir for 0.5 hour. Cool the system to -70°C and add n-butyllithium (2.17 mL, 3.88 mmol) dropwise. Stir for 0.2 hour at the same temperature. Add triisopropyl borate (1.29 g, 6.84 mmol) and react at -70°C for 0.5 hour. Quench the reaction with saturated ammonium chloride solution (20 mL) and extract three times with ethyl acetate (20 mL). Separate the layers and wash the organic phase with saturated brine (20 mL). Dry the organic phase over anhydrous sodium sulfate and concentrate under reduced pressure. The residue was purified by slurrying (eluent: petroleum ether / ethyl acetate = 10 / 1, volume ratio) to give the title compound (0.79 g, yield: 69.4%).

[0432] MS m / z(ESI):313.0[M+H] + .

[0433] Intermediate Preparation Example 10: Preparation of (2S,4R)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0434] Step 1: Preparation of tert-butyl (2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carboxylate

[0435] (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine hydrochloride (1.0 g, 3.92 mmol) and (2S,4R)-1-[(tert-butoxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid (998 mg, 4.31 mmol) were dissolved in DMF (10 mL). N,N-diisopropylethylamine (1.52 g, 11.76 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.94 g, 5.10 mmol) were added. The mixture was stirred at 25°C for 3 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, volume ratio) to obtain the title compound (1.23 g, yield: 62.3%).

[0436] MS m / z(ESI):432.2[M+H] + .

[0437] Step 2: Preparation of (2S,4R)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0438] Tert-butyl (2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carboxylate (1.23 g, 2.85 mmol) was added to 1,4-dioxane (5 mL) and a 4M solution of hydrogen chloride in 1,4-dioxane (5 mL). The mixture was reacted at 20°C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the hydrochloride salt of the title compound (1.05 g, 100% yield).

[0439] MS m / z(ESI):332.2[M+H] + .

[0440] Intermediate Preparation Example 11: Preparation of (S)-3,3-dimethyl-2-(4-(piperidin-4-ylmethyl)-1H-1,2,3-triazol-1-yl)butanoic acid methyl ester

[0441] Step 1: Preparation of (S)-3,3-dimethyl-2-azidobutyric acid methyl ester

[0442] Dissolve L-tert-leucine methyl ester hydrochloride (1.5 g, 8.26 mmol) in methanol (15 mL), add copper sulfate pentahydrate (206 mg, 0.826 mmol), potassium carbonate (4.57 g, 33.04 mmol), and 1H-imidazole-1-sulfonyl azide hydrochloride (2.25 g, 10.74 mmol). After nitrogen substitution three times, the mixture was allowed to react at room temperature for 16 hours. The reaction solution was concentrated, and water (40 mL) was added to the residue. The mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title compound (1.2 g, yield: 85.7%).

[0443] MS m / z(ESI):176.1[M+H] + .

[0444] Step 2: Preparation of tert-butyl (S)-4-((1-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperidine-1-carboxylate

[0445] Methyl (S)-3,3-dimethyl-2-triazidobutanoate (1.2 g, 6.8 mmol) and tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (1.52 g, 6.8 mmol) were dissolved in dimethyl sulfoxide (10 mL) and water (2 mL). Sodium ascorbate (2.02 g, 10.2 mmol) and copper sulfate pentahydrate (3.4 g, 13.6 mmol) were added and reacted at 20°C for 2 hours. Water (30 mL) was added to the reaction solution, which was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1, volume ratio) to obtain the title compound (1.96 g, yield: 72.9%).

[0446] MS m / z(ESI):395.2[M+H] + .

[0447] Step 3: Preparation of (S)-3,3-dimethyl-2-(4-(piperidin-4-ylmethyl)-1H-1,2,3-triazol-1-yl)butanoic acid methyl ester

[0448] (S)-tert-Butyl 4-((1-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperidine-1-carboxylate (1.96 g, 4.96 mmol) was added to 1,4-dioxane (10 mL) and a 4M solution of hydrogen chloride in 1,4-dioxane (20 mL). The mixture was reacted at 20°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the title compound (1.41 g, 94% yield).

[0449] MS m / z(ESI):295.2[M+H] + .

[0450] Intermediate Preparation Example 12: Preparation of tert-butyl 4-(prop-2-yn-1-oxy)piperidine-1-carboxylate

[0451] Dissolve tert-butyl 4-hydroxypiperidine-1-carboxylate (1.0 g, 4.98 mmol) in tetrahydrofuran (10 mL). Cool the system to 0°C and add sodium hydride (299 mg, 7.46 mmol) in portions. The mixture is allowed to react at 0°C for 0.5 hours. 3-Bromopropyne (711 mg, 5.98 mmol) is then added and allowed to react at room temperature for 16 hours. The reaction solution is concentrated, and water (20 mL) is added to the concentrate. The mixture is extracted twice with ethyl acetate (20 mL). The organic phase is washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 6 / 1, volume ratio) to obtain the title compound (0.95 g, yield: 79.5%).

[0452] MS m / z(ESI):240.1[M+H] + .

[0453] Intermediate Preparation Example 13: Preparation of (S)-3,3-dimethyl-2-(4-((piperidin-4-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoic acid methyl ester

[0454] Using the synthetic route in Intermediate Preparation Example 11, the second-step reaction raw material 4-(prop-2-yn-1-yl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 4-(prop-2-yn-1-oxy)piperidine-1-carboxylic acid tert-butyl ester to obtain the title compound (700 mg, yield: 65.5%).

[0455] MS m / z(ESI):311.2[M+H] + .

[0456] Intermediate Preparation Example 14: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0457] Step 1: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0458] Tert-butyl 3-(7-chloro-8-fluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (5.0 g, 10.1 mmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl ) Triisopropylsilane (6.25 g, 12.2 mmol) was dissolved in 1,4-dioxane (50 mL) and water (5 mL). Potassium phosphate (4.28 g, 20.2 mmol) and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (736 mg, 1.01 mmol) were added. The atmosphere was purged with nitrogen three times, and the temperature was raised to 100°C with stirring for 3.5 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / dichloromethane = 1 / 4, volume ratio) to obtain the title compound (8.5 g, yield: 99.5%).

[0459] MS m / z(ESI):844.4[M+H] + .

[0460] Step 2: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0461] Dissolve tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8.5 g, 10.1 mmol) and triethylamine (3.07 g, 30.3 mmol) in dichloromethane (100 mL). Cool to 0°C in an ice bath. Add methylsulfonyl chloride (1.74 g, 15.15 mmol) and stir at 20°C for 4 hours. Wash the reaction solution with water (100 mL), dry the organic phase, and concentrate to obtain 8.5 g of the title compound (yield: 91.5%).

[0462] MS m / z(ESI):922.4[M+H] + .

[0463] Intermediate Preparation Example 15: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((methylsulfonyl)oxy)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0464] Using the synthetic route in Intermediate Preparation Example 14, the first step reaction raw material ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)naphthalene-1-yl)ethynyl)triisopropylsilane was replaced with 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalene-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane) to obtain the title compound (7.7 g, yield: 88.3%).

[0465] MS m / z(ESI):770.3[M+H] + .

[0466] Intermediate Preparation Example 16: Preparation of tert-butyl 3-(7-bromo-6-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0467] The synthetic route in Intermediate Preparation 3 was used to replace the raw material of the fifth step, 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine, with 7-bromo-2,4,6-trichloro-8-fluoroquinazoline to obtain the title compound (0.95 g, yield: 80.1%).

[0468] MS m / z(ESI):649.1[M+H] + .

[0469] Intermediate Preparation Example 17: Preparation of tert-butyl 3-(7-bromo-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0470] The synthetic route in Intermediate Preparation 3 was adopted to replace the raw material of the fifth step, 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine, with 7-bromo-2,4-dichloro-8-fluoroquinazoline to obtain the title compound (0.6 g, yield: 82.4%).

[0471] MS m / z(ESI):615.1[M+H]+ .

[0472] Intermediate Preparation Example 18: Preparation of tert-butyl 3-(7-bromo-6-chloro-2-((1-((4-(2-ethoxy-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0473] Tert-butyl 3-(7-bromo-6-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (600 mg, 923 μmol) and ethyl 2-(piperidin-4-ylmethoxy)acetate (168.7 mg, 1.38 mmol) were dissolved in DMF (6 mL), potassium carbonate (383 mg, 2.77 mmol) and potassium iodide (153 mg, 923 μmol) were added, and the mixture was reacted at 55° C. for 4 hours. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (425 mg, yield: 62.1%).

[0474] MS m / z(ESI):740.2[M+H] + .

[0475] Intermediate Preparation Example 19: Preparation of tert-butyl 3-(7-bromo-2-((1-((4-(2-ethoxy-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0476] The synthetic route in intermediate preparation 18 was adopted to replace the reaction raw material 3-(7-bromo-6-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester with 3-(7-bromo-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester to give the title compound (0.4 g, yield: 70.6%).

[0477] MS m / z(ESI):706.3[M+H] + .

[0478] Intermediate Preparation Example 20: Preparation of (2S,4R)-1-((2S)-2-amino-3,3-dimethylbutanoyl)-N-((S)-1-(4-chlorophenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0479] The synthetic route in Intermediate Example 6 was used to replace the first step reaction raw material 2-(aminomethyl)naphthalene with (S)-1-(4-chlorophenyl)ethylamine to obtain the title compound (400 mg, yield: 73.74%).

[0480] MS m / z(ESI):382.1[M+H] + .

[0481] Intermediate Preparation Example 21: Preparation of ethyl 2-(2-azaspiro(3.5)non-7-yl)acetate

[0482] Step 1: Preparation of tert-butyl 7-(2-ethoxy-2-oxoethylidene)-2-azaspiro[3.5]nonane-2-carboxylate

[0483] Triethyl phosphoacetate (1.03 g, 4.60 mmol) was dissolved in tetrahydrofuran (15 mL), the atmosphere was replaced with nitrogen three times, and the temperature was lowered to -15°C. Lithium bis(trimethylsilyl)amide (1 M, 4.76 mL) was added dropwise to the reaction mixture. After stirring for 30 minutes, a solution of tert-butyl oxo-2-azaspiro[3.5]nonane-2-carboxylate (1.0 g, 4.18 mmol) in tetrahydrofuran was added dropwise to the reaction mixture. The reaction was stirred at -15°C for 5 hours. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 9, volume ratio) to obtain the title compound (800 mg, yield: 62.0%).

[0484] MS m / z(ESI):310.1[M+H] + .

[0485] Step 2: Preparation of tert-butyl 7-(2-ethoxy-2-oxoethyl)-2-azaspiro[3.5]nonane-2-carboxylate

[0486] Dissolve tert-butyl 7-(2-ethoxy-2-oxoethylidene)-2-azaspiro[3.5]nonane-2-carboxylate (420 mg, 1.36 mmol) in methanol (10 mL), add 10% palladium / carbon (164.86 mg, 135.75 μmol), replace the atmosphere with hydrogen three times, and stir at 25°C for 16 hours. The reaction mixture was filtered, and the filtrate was concentrated to obtain the title compound (400 mg, yield: 94.6%).

[0487] MS m / z(ESI):312.1[M+H] + .

[0488] Step 3: Preparation of ethyl 2-(2-azaspiro(3.5)non-7-yl)acetate

[0489] Dissolve tert-butyl 7-(2-ethoxy-2-oxoethyl)-2-azaspiro[3.5]nonane-2-carboxylate (400 mg, 1.28 mmol) in dichloromethane (5 mL). Add a solution of hydrogen chloride in 1,4-dioxane (4 mL) and react at room temperature for 2 hours. The reaction mixture was concentrated to obtain the title compound (250 mg, yield: 92.1%).

[0490] MS m / z(ESI):212.1[M+H] + .

[0491] Intermediate Preparation Example 22: Preparation of ethyl 2-(9-azabicyclo(3.3.1)nonan-3-oxy)acetate

[0492] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester

[0493] The residue was replaced with tert-butyl 3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate to give the title compound (300 mg, yield: 83.8%).

[0494] MS m / z(ESI):228.1[M+H] + .

[0495] Intermediate Preparation Example 23: Preparation of ethyl 3-(piperidin-4-yl)propionate

[0496] Dissolve tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate (450 mg, 1.58 mmol) in dichloromethane (5 mL). Add a solution of hydrogen chloride in 1,4-dioxane (4 mL) and react at room temperature for 2 hours. Concentrate the reaction mixture to obtain the title compound (340 mg, yield: 97.2%).

[0497] MS m / z(ESI):186.1[M+H] + .

[0498] Intermediate Preparation Example 24: Preparation of ethyl (3-azaspiro[5.5]undec-9-yloxy)acetate

[0499] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 9-hydroxy-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester to obtain the title compound (460 mg, yield: 63.3%).

[0500] MS m / z(ESI):256.1[M+H] + .

[0501] Intermediate Preparation Example 25: Preparation of ethyl 2-((2-azaspiro[3.5]non-7-yl)oxy)acetate

[0502] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester to obtain the title compound (540 mg, yield: 56.3%).

[0503] MS m / z(ESI):228.1[M+H] + .

[0504] Intermediate Preparation Example 26: Preparation of ethyl 2-((2-azaspiro[3.5]non-7-yl)methoxy)acetate

[0505] Step 1: Preparation of tert-butyl 7-(methoxymethylene)-2-azaspiro[3.5]nonane-2-carboxylate

[0506] To methoxymethyltriphenylphosphine chloride (1.9 g, 6.27 mmol) in tetrahydrofuran (10 mL) was added lithium bis(trimethylsilyl)amide (2.1 g, 12.54 mmol) dropwise at -78°C. The resulting red solution was then stirred at -78°C for 0.5 hours. Tert-butyl 7-oxo-2-azaspiro[3.5]nonane-2-carboxylate (1 g, 4.18 mmol) in tetrahydrofuran was added, and the mixture was slowly warmed to room temperature and stirred for 16 hours. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 4, volume ratio) to give the title compound (560 mg, yield: 50.1%).

[0507] MS m / z(ESI):268.2[M+H] + .

[0508] Step 2: Preparation of tert-butyl 7-formyl-2-azaspiro[3.5]nonane-2-carboxylate

[0509] Dissolve tert-butyl 7-(methoxymethylene)-2-azaspiro[3.5]nonane-2-carboxylate (1.2 g, 4.44 mmol) in acetonitrile (10 mL) and water (5 mL). Add trifluoroacetic acid (0.2 mL) and react at room temperature for 2 hours. The residue is purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 4, volume ratio) to obtain the title compound (1.13 g, yield: 87.9%).

[0510] MS m / z(ESI):254.2[M+H] + .

[0511] Step 3: Preparation of tert-butyl 7-(hydroxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate

[0512] Dissolve tert-butyl 7-formyl-2-azaspiro[3.5]nonane-2-carboxylate (1.05 g, 4.07 mmol) in methanol (10 mL) and stir until clear. Add sodium borohydride (237 mg, 6.1 mmol) portionwise at room temperature, replace the atmosphere with nitrogen, and stir for 2 hours. Adjust the pH of the reaction mixture to neutral with 4 M hydrogen chloride in ethyl acetate, and concentrate the reaction mixture to obtain the title compound (1 g, yield: 96.3%).

[0513] MS m / z(ESI):256.2[M+H] + .

[0514] Step 4: Preparation of tert-butyl 7-((2-ethoxy-2-oxoethoxy)methyl)-2-azaspiro[3.5]nonane-2-carboxylate

[0515] Dissolve tert-butyl 7-(hydroxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate (1.0 g, 3.9 mmol) in dichloromethane (40 mL). Add dimerized rhodium acetate (173 mg, 391.6 μmol). Ethyl diazoacetate (1.34 g, 11.75 mmol) was added dropwise to the reaction mixture at 0°C. The atmosphere was purged with nitrogen three times, then the mixture was warmed to room temperature and allowed to react for 16 hours. The reaction mixture was poured into water (20 mL) and extracted twice with dichloromethane (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 9, volume ratio) to obtain the title compound (0.9 g, yield: 68.0%).

[0516] MS m / z(ESI):342.2[M+H] + .

[0517] Step 5: Preparation of ethyl 2-((2-azaspiro[3.5]non-7-yl)methoxy)acetate

[0518] Tert-butyl 7-((2-ethoxy-2-oxoethoxy)methyl)-2-azaspiro[3.5]nonane-2-carboxylate (0.9 g, 2.6 mmol) was added to a 4M solution of hydrogen chloride in ethyl acetate (10 mL) and reacted at 20°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the title compound (660 mg, yield: 90.1%).

[0519] MS m / z(ESI):242.1[M+H] + .

[0520] Intermediate Preparation Example 27: Preparation of ethyl 2-((2-azaspiro[3.3]hept-6-yl)methoxy)acetate

[0521] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester to obtain the title compound (240 mg, yield: 62.3%).

[0522] MS m / z(ESI):214.1[M+H] + .

[0523] Intermediate Preparation Example 28: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0524] Step 1: Preparation of (R)-N-(4-bromo-2-fluorobenzylidene)-2-methylpropane-2-sulfenamide

[0525] 4-Bromo-2-fluorobenzaldehyde (2 g, 9.85 mmol) and (R)-2-methylpropane-2-sulfenamide (1.79 g, 14.78 mmol) were dissolved in 1,2-dichloroethane, and copper sulfate pentahydrate (3.69 g, 14.78 mmol) was added. The mixture was reacted at 60°C for 18 hours. The mixture was filtered through celite, washed with dichloromethane, and concentrated in vacuo to obtain the title compound (2.9 g, yield: 96.1%).

[0526] MS m / z(ESI):306.1[M+H] + .

[0527] Step 2: Preparation of (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfenamide

[0528] (R)-N-(4-bromo-2-fluorobenzylidene)-2-methylpropane-2-sulfenamide (2.9 g, 9.47 mmol) was added to dichloromethane (10 mL), and methylmagnesium bromide (5.65 g, 47.36 mmol) was slowly added dropwise at 0°C. The mixture was then reacted at 25°C for 1 hour. A saturated aqueous solution of ammonium chloride was slowly added dropwise to the reaction solution, followed by extraction twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to obtain the title compound (1.1 g, yield: 36.1%).

[0529] MS m / z(ESI):322.1[M+H] + .

[0530] Step 3: Preparation of (R)-N-((S)-1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfenamide

[0531] (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfenamide (1.1 g, 3.41 mmol) was dissolved in 1,4-dioxane (10 mL), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (1.73 g, 6.83 mmol) was added. Potassium acetate (1.01 g, 10.24 mmol) was then added, and the atmosphere was replaced with nitrogen three times. 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (244.4 mg, 341.36 μmol) was added, and the mixture was stirred at 95°C for 12 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1, volume ratio) to give the title compound (1.15 g, yield: 91.2%).

[0532] MS m / z(ESI):355.2[M+H] + .

[0533] Step 4: Preparation of (R)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-2-methylpropane-2-sulfenamide

[0534] (S)-N-((S)-1-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfenamide (1.15 g, 3.11 mmol) and 5-bromo-4-methylthiazole (1.11 g, 6.23 mmol) were dissolved in 1,4-dioxane (10 mL) and water (1 mL). Potassium phosphate (1.98 g, 9.34 mmol) and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (225.76 mg, 311.40 μmol) were added. After nitrogen was replaced three times, the mixture was microwaved at 110°C for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 3, volume ratio) to obtain the title compound (1.0 g, yield: 94.3%).

[0535] MS m / z(ESI):341.1[M+H] + .

[0536] Step 5: Preparation of (S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine

[0537] (S)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-2-methylpropane-2-sulfenamide (1 g, 2.94 mmol) was dissolved in a 4 M solution of hydrogen chloride in dioxane (2 mL) and methanol (5 mL) and stirred at 25°C for 1 hour. The mixture was filtered directly to obtain the title compound (550 mg, yield: 79.2%).

[0538] MS m / z(ESI):237.1[M+H] + .

[0539] Step 6: Preparation of tert-butyl (2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate

[0540] (2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (538.2 mg, 2.33 mmol) was dissolved in dichloromethane (10 mL). 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.06 g, 2.79 mmol) was added, followed by N,N-diisopropylethylamine (750.6 mg, 5.8 mmol) and (S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine (550 mg, 2.33 mmol). The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was poured into water (40 mL) and extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (800 mg, yield: 76.4%).

[0541] MS m / z(ESI):450.1[M+H] + .

[0542] Step 7: Preparation of (2S,4R)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0543] Dissolve tert-butyl (2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (800 mg, 1.78 mmol) in dichloromethane (5 mL). Add 4M hydrogen chloride in 1,4-dioxane (4 mL) and react at room temperature for 2 hours. The reaction mixture was concentrated to obtain the title compound (610 mg, yield: 98.1%).

[0544] MS m / z(ESI):350.2[M+H] + .

[0545] Step 8: Preparation of tert-butyl ((S)-1-((2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate

[0546] (2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (403.7 mg, 1.75 mmol) was dissolved in dichloromethane (10 mL), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (796 mg, 2.09 mmol) was added. N,N-diisopropylethylamine (563 mg, 4.36 mmol) and (2S,4R)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (610 mg, 1.75 mmol) were added. The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was poured into water (20 mL) and extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (940 mg, yield: 95.7%).

[0547] MS m / z(ESI):563.3[M+H] + .

[0548] Step 9: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0549] Tert-butyl ((S)-1-((2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (940 mg, 1.67 mmol) was dissolved in dichloromethane (10 mL). A 4M solution of hydrogen chloride in 1,4-dioxane (5 mL) was added, and the mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated to obtain the title compound (740 mg, yield: 95.7%).

[0550] MS m / z(ESI):463.3[M+H]+ .

[0551] Intermediate Preparation Example 29: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((6-chloronaphthalen-2-yl)methyl)-4-hydroxypyrrolidine-2-carboxamide

[0552] Step 1: Preparation of 6-chloro-2-naphthamide

[0553] Dissolve 6-chloro-2-naphthoic acid (800 mg, 3.87 mmol) in N,N-dimethylformamide (10 mL), add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.21 g, 5.81 mmol), then add N,N-diisopropylethylamine (1.50 g, 11.62 mmol) and ammonium chloride (1.04 g, 19.36 mmol), and allow to react at room temperature for 12 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (640 mg, yield: 80.3%).

[0554] MS m / z(ESI):206.1[M+H] + .

[0555] Step 2: Preparation of (6-chloronaphthalen-2-yl)methylamine

[0556] Dissolve 6-chloro-2-naphthamide (640 mg, 3.11 mmol) in tetrahydrofuran (5 mL) and add tetrahydrofuran borane complex (1.34 g, 15.56 mmol) dropwise at room temperature. Heat to 60°C and stir for 18 hours. Quench with water under ice and concentrate directly to obtain the title compound (450 mg, yield: 75.4%).

[0557] MS m / z(ESI):192.1[M+H] + .

[0558] Step 3: Preparation of tert-butyl (2S,4R)-2-(((6-chloronaphthalen-2-yl)methyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate

[0559] (2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (542.9 mg, 2.35 mmol) was dissolved in dichloromethane (10 mL), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.06 g, 2.79 mmol) was added. N,N-diisopropylethylamine (750.6 mg, 5.8 mmol) and (6-chloronaphthalen-2-yl)methylamine (450 mg, 2.35 mmol) were then added. The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was poured into water (20 mL) and extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (770 mg, yield: 81.0%).

[0560] MS m / z(ESI):405.1[M+H] + .

[0561] Step 4: Preparation of (2S,4R)-N-((6-chloronaphthalen-2-yl)methyl)-4-hydroxypyrrolidine-2-carboxamide

[0562] Dissolve tert-butyl (2S,4R)-2-(((6-chloronaphthalen-2-yl)methyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (770 mg, 1.9 mmol) in dichloromethane (5 mL). Add 4M hydrogen chloride in 1,4-dioxane (2 mL) and react at room temperature for 2 hours. The reaction mixture was concentrated to obtain the title compound (560 mg, 96.6% yield).

[0563] MS m / z(ESI):305.2[M+H] + .

[0564] Step 5: Preparation of tert-butyl ((S)-1-((2S,4R)-2-(((6-chloronaphthalen-2-yl)methyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate

[0565] (2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (424.9 mg, 1.84 mmol) was dissolved in dichloromethane (10 mL). 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (837.8 mg, 2.2 mmol) was added, followed by N,N-diisopropylethylamine (563 mg, 4.36 mmol) and (2S,4R)-N-((6-chloronaphthalen-2-yl)methyl)-4-hydroxypyrrolidine-2-carboxamide (560 mg, 1.84 mmol). The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was poured into water (20 mL) and extracted twice with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (850 mg, yield: 89.3%).

[0566] MS m / z(ESI):518.3[M+H] + .

[0567] Step 6: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((6-chloronaphthalen-2-yl)methyl)-4-hydroxypyrrolidine-2-carboxamide

[0568] Tert-butyl ((S)-1-((2S,4R)-2-(((6-chloronaphthalen-2-yl)methyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (200 mg, 386.1 μmol) was dissolved in dichloromethane (5 mL). A 4M solution of hydrogen chloride in 1,4-dioxane (2 mL) was added and the mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated to obtain the title compound (150 mg, yield: 92.9%).

[0569] MS m / z(ESI):418.3[M+H] + .

[0570] Intermediate Preparation Example 30: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((S)-1-(6-fluoronaphthalen-2-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0571] Step 1: Preparation of (6-fluoronaphthalen-2-yl)methanol

[0572] Add 6-fluoro-2-naphthoic acid (1.3 g, 6.77 mmol) to a solution of lithium aluminum hydride (1.30 g, 33.8 mmol) in tetrahydrofuran and heat to 70°C for 4 hours. Add an appropriate amount of 10% aqueous sodium hydroxide solution to the reaction mixture to make it alkaline, dry over anhydrous sodium sulfate, filter, and concentrate in vacuo to obtain the title compound (1.04 g, yield: 86.3%).

[0573] MS m / z(ESI):177.1[M+H] + .

[0574] Step 2: Preparation of 6-fluoro-2-naphthaldehyde

[0575] (6-Fluoronaphthalen-2-yl)methanol (1.0 g, 5.68 mmol) was added to dichloromethane (5.00 mL) and tetrahydrofuran (5.00 mL). Dess-Martin periodinane (2.89 g, 6.81 mmol) was added with stirring. Under nitrogen, the mixture was stirred at 20°C for 12 hours. Sodium thiosulfate solution and saturated aqueous sodium bicarbonate solution were added to the reaction solution, and the mixture was stirred until clear. Ethyl acetate (30 mL) was then added and extracted three times. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain the title compound (720 mg, yield: 72.8%).

[0576] MS m / z(ESI):175.1[M+H] + .

[0577] Step 3: Preparation of (R)-N-((6-fluoronaphthalen-2-yl)methylene)-2-methylpropane-2-sulfenamide

[0578] The synthetic route in Intermediate Preparation Example 28 was used to replace the first step reaction raw material 4-bromo-2-fluorobenzaldehyde with 6-fluoro-2-naphthaldehyde to obtain the title compound (1.3 g, yield: 96.4%).

[0579] MS m / z(ESI):278.1[M+H] + .

[0580] Step 4: Preparation of (R)-N-((S)-1-(6-fluoronaphthalen-2-yl)ethyl)-2-methylpropane-2-sulfenamide

[0581] Using the synthetic route in Intermediate Preparation Example 28, the second-step reaction raw material (R)-N-(4-bromo-2-fluorobenzylidene)-2-methylpropane-2-sulfenamide was replaced with (R)-N-((6-fluoronaphthalen-2-yl)methylene)-2-methylpropane-2-sulfenamide to obtain the title compound (750 mg, yield: 59.1%).

[0582] MS m / z(ESI):294.1[M+H] + .

[0583] Step 5: Preparation of (S)-1-(6-fluoronaphthalen-2-yl)ethylamine

[0584] Using the synthetic route in Intermediate Preparation Example 28, the fifth step reaction raw material (R)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-2-methylpropane-2-sulfenamide was replaced with (R)-N-((S)-1-(6-fluoronaphthalen-2-yl)ethyl)-2-methylpropane-2-sulfenamide to obtain the title compound (500 mg, yield: 83.8%).

[0585] MS m / z(ESI):190.1[M+H] + .

[0586] Step 6: Preparation of tert-butyl (2S,4R)-2-(((S)-1-(6-fluoronaphthalen-2-yl)ethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate

[0587] Using the synthetic route in Intermediate Preparation Example 28, the sixth step reaction raw material (S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine was replaced with (S)-1-(6-fluoronaphthalene-2-yl)ethanamine to obtain the title compound (980 mg, yield: 92.2%).

[0588] MS m / z(ESI):403.1[M+H] + .

[0589] Step 7: Preparation of (2S,4R)-N-((S)-1-(6-fluoronaphthalen-2-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0590] Using the synthetic route in Intermediate Preparation Example 28, the raw material for the seventh step reaction, (2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester, was replaced with (2S,4R)-2-(((S)-1-(6-fluoronaphthalen-2-yl)ethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester to give the title compound (660 mg, yield: 97.6%).

[0591] MS m / z(ESI):303.2[M+H] + .

[0592] Step 8: Preparation of tert-butyl ((S)-1-((2S,4R)-2-(((S)-1-(6-fluoronaphthalen-2-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate

[0593] The synthetic route in Intermediate Preparation Example 28 was used to replace the raw material for the eighth step reaction (2S,4R)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide with (2S,4R)-N-((S)-1-(6-fluoronaphthalen-2-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide to obtain the title compound (990 mg, yield: 95.8%).

[0594] MS m / z(ESI):516.3[M+H] + .

[0595] Step 9: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((S)-1-(6-fluoronaphthalen-2-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0596] Using the synthetic route in Intermediate Preparation Example 28, the raw material for the ninth step reaction was replaced with tert-butyl ((S)-1-((2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate to give tert-butyl ((S)-1-((2S,4R)-2-(((S)-1-(6-fluoronaphthalen-2-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate to obtain the title compound (780 mg, yield: 97.7%).

[0597] MS m / z(ESI):416.1[M+H] + .

[0598] Intermediate Preparation Example 31: Preparation of (S)-ethyl 2-(piperidin-3-yloxy)acetate

[0599] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with (S)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester to obtain the title compound (260 mg, yield: 78.1%).

[0600] MS m / z(ESI):188.1[M+H] + .

[0601] Intermediate Preparation Example 32: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-hydroxypyrrolidine-2-carboxamide

[0602] Step 1: Preparation of tert-butyl (R)-(1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)carbamate

[0603] Dissolve tert-butyl (R)-(1-(4-bromophenyl)-2-hydroxyethyl)carbamate (1.2 g, 3.76 mmol) and (2-chlorophenyl)boronic acid (712.2 mg, 4.51 mmol) in 1,4-dioxane (10 mL) and water (2 mL). Add potassium carbonate (1.84 g, 13.19 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (138.8 mg, 187.86 μmol). Replace the atmosphere with nitrogen three times, heat to 90°C, and stir for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to obtain the title compound (1.2 g, yield: 91.8%).

[0604] MS m / z(ESI):348.1[M+H] + .

[0605] Step 2: Preparation of (R)-2-amino-2-(2'-chloro-[1,1'-biphenyl]-4-yl)ethan-1-ol

[0606] Add tert-butyl (R)-(1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)carbamate (1.2 g, 3.45 mmol) to 1,4-dioxane (5 mL) and a 4M solution of hydrogen chloride in 1,4-dioxane (5 mL). The mixture was reacted at 20°C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the title compound (790 mg, 92.4% yield).

[0607] MS m / z(ESI):248.1[M+H] + .

[0608] Step 3: Preparation of tert-butyl (2S,4R)-2-(((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate

[0609] Using the synthetic route in Intermediate Preparation Example 28, the sixth step reaction raw material (S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine was replaced with (R)-2-amino-2-(2'-chloro-[1,1'-biphenyl]-4-yl)ethan-1-ol to obtain the title compound (1.1 g, yield: 87.5%).

[0610] MS m / z(ESI):461.1[M+H] + .

[0611] Step 4: Preparation of (2S,4R)-N-((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-hydroxypyrrolidine-2-carboxamide

[0612] Using the synthetic route in Intermediate Preparation Example 28, the raw material for the seventh step reaction, (2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester, was replaced with (2S,4R)-2-(((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester to give the title compound (810 mg, yield: 94.1%).

[0613] MS m / z(ESI):361.1[M+H] + .

[0614] Step 5: Preparation of tert-butyl ((S)-1-((2S,4R)-2-(((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate

[0615] The synthetic route in Intermediate Preparation Example 28 was used to replace the raw material for the eighth step reaction (2S,4R)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide with (2S,4R)-N-((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-hydroxypyrrolidine-2-carboxamide to obtain the title compound (1.15 g, yield: 89.2%).

[0616] MS m / z(ESI):574.1[M+H] + .

[0617] Step 6: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-hydroxypyrrolidine-2-carboxamide

[0618] Using the synthetic route in Intermediate Preparation Example 28, the starting material of the ninth step reaction, ((S)-1-((2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamic acid tert-butyl ester was replaced with ((S)-1-((2S,4R)-2-(((R)-1-(2'-chloro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamic acid tert-butyl ester to give the title compound (910 mg, yield: 95.8%).

[0619] MS m / z(ESI):474.1[M+H] + .

[0620] Intermediate Preparation Example 33: Preparation of ethyl 2-(2-azaspiro[3.4]octan-6-yloxy)acetate

[0621] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 6-hydroxy-2-azaspiro[3.4]octane-2-carboxylic acid tert-butyl ester to obtain the title compound (112 mg, yield: 95.0%).

[0622] MS m / z(ESI):214.1[M+H] + .

[0623] Intermediate Preparation Example 34: Preparation of 6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole

[0624] Step 1: Preparation of 3-bromo-5-fluoro-4-iodo-2-methylaniline

[0625] 3-Bromo-5-fluoro-2-methylaniline (7.0 g, 34.5 mmol) was dissolved in dichloromethane (60 mL), followed by the addition of N-iodosuccinimide (7.6 g, 34.0 mmol). The mixture was reacted at 30°C for 16 hours. A saturated sodium thiosulfate solution (60 mL) was added, and the mixture was extracted twice with dichloromethane (60 mL). The organic phase was washed with saturated brine (40 mL), dried, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 9, volume ratio) to give the title compound (5.3 g, yield: 47.3%).

[0626] MS m / z(ESI):329.1[M+H] + .

[0627] Step 2: Preparation of 4-bromo-6-fluoro-5-iodo-1H-indazole

[0628] 3-Bromo-5-fluoro-4-iodo-2-methylaniline (5.3 g, 16.1 mmol) was dissolved in acetic acid (18 mL), and sodium nitrite (1.3 g, 18.8 mmol) was added. The mixture was stirred at 20°C for 7 hours. The reaction mixture was added to water (30 mL) and extracted twice with ethyl acetate (18 mL). The mixture was separated, dried, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 4, volume ratio) to obtain the title compound (1.71 g, yield: 31.1%).

[0629] MS m / z(ESI):341.1[M+H] + .

[0630] Step 3: Preparation of 4-bromo-6-fluoro-5-iodo-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0631] Dissolve 4-bromo-6-fluoro-5-iodo-1H-indazole (1.71 g, 5.0 mmol) in dichloromethane (25 mL), add p-toluenesulfonic acid hydrate (96.4 mg, 506.9 μmol), and then add 4-hydropyran (852 mg, 10.1 mmol). Stir at 20°C for 18 hours, dilute with dichloromethane (25 mL), and wash the organic phase with saturated aqueous sodium bicarbonate (15 mL). Dry the organic phase over anhydrous sodium sulfate and concentrate under reduced pressure. The residue is purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 7, volume ratio) to obtain the title compound (1.35 g, yield: 63.4%).

[0632] MS m / z(ESI):425.1[M+H] + .

[0633] Step 4: Preparation of 4-bromo-6-fluoro-5-methyl-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0634] 4-Bromo-6-fluoro-5-iodo-(tetrahydro-2H-pyran-2-yl)-1H-indazole (1.35 g, 3.2 mmol) was dissolved in 1,4-dioxane (5 mL). 2,4,6-Trimethyl-1,3,5,2,4,6-triborane trioxide (7.97 g, 31.7 mmol), a solution of potassium phosphate (2.02 g, 9.5 mmol) in water (0.5 mL), and 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (230.5 mg, 317.6 μmol) were added to the reaction mixture. After the addition, the atmosphere was purged with nitrogen three times and the mixture was reacted at 95°C for 12 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / petroleum ether = 2 / 1, volume ratio) to obtain the title compound (285 mg, yield: 28.65%).

[0635] MS m / z(ESI):313.1[M+H] + .

[0636] Step 5: Preparation of 6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole

[0637] 4-Bromo-6-fluoro-5-methyl-(tetrahydro-2H-pyran-2-yl)-1H-indazole (285 mg, 910.1 μmol) was dissolved in 1,4-dioxane (3 mL). Potassium acetate (422.5 mg, 4.3 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (63.4 mg, 86.2 μmol), and pinacol diboron (437.9 mg, 1.7 mmol) were added. The atmosphere was purged with nitrogen three times and the reaction was carried out at 110°C for 12 hours. The mixture was diluted with water (15 mL) and extracted twice with dichloromethane (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 5, volume ratio) to obtain the title compound (80 mg, yield: 25.76%).

[0638] MS m / z(ESI):361.2[M+H] + .

[0639] Intermediate Preparation Example 35: Preparation of ethyl 3-(2-azaspiro[3.3]heptane-6-yl)propanoate

[0640] Step 1: Preparation of tert-butyl 6-(methoxymethylene)-2-azaspiro[3.3]heptane-2-carboxylate

[0641] To a solution of (methylmethoxy)-triphenylphosphine chloride (1.77 g, 4.7 mmol) in tetrahydrofuran (10 mL) at -78°C was added lithium diisopropylamide (2 M, 2.32 mL). The resulting red solution was then allowed to react at -78°C for 0.5 h. A solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (495 mg, 2.34 mmol) in tetrahydrofuran (2 mL) was then added dropwise. After the addition was complete, the mixture was slowly heated to 25°C and stirred for 16 h. The reaction was quenched by addition of saturated aqueous ammonium chloride (10 mL), followed by extraction twice with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 9 / 1, volume ratio) to afford the title compound (140 mg, yield: 24.97%).

[0642] MS m / z(ESI):240.2[M+H] + .

[0643] Step 2: Preparation of tert-butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate

[0644] 6-(Methoxymethylene)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (140 mg, 585.0 μmol) was dissolved in dichloromethane (1 mL), water (2 mL) was added, and trifluoroacetic acid (0.1 mL) was added dropwise. The reaction was allowed to react at 25 ° C for 2 hours. The reaction was quenched by adding aqueous ammonium chloride (10 mL), then extracted twice with ethyl acetate (10 mL), and the organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 9 / 1, volume ratio) to give the title compound (99 mg, yield: 24.97%).

[0645] Step 3: Preparation of tert-butyl 6-(3-ethoxy-3-oxo-1-en-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate

[0646] Tert-butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate (99 mg, 439.4 μmol) was dissolved in dry dichloromethane (3 mL), and ethyl 2-(triphenylphosphinoylene)acetate (139.2 mg, 399.5 μmol) was added. The mixture was reacted overnight at 25°C. After concentration, the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 4, volume ratio) to obtain the title compound (85.5 mg, yield: 72.46%).

[0647] Step 4: Preparation of tert-butyl 6-(3-ethoxy-3-oxopropyl)-2-azaspiro[3.3]heptane-2-carboxylate

[0648] Dissolve tert-butyl 6-(3-ethoxy-3-oxo-1-en-1-yl)-2-azaspiro[3.3]hept-2-carboxylate (85.5 mg, 289.4 μmol) in ethanol (2 mL), add 10% palladium hydroxide (20 mg), and react at 25°C under a hydrogen atmosphere for 12 hours. Filter and concentrate to obtain the title compound (80.7 mg, crude product), which is used directly in the next step.

[0649] MS m / z(ESI):320.2[M+Na] + .

[0650] Step 5: Preparation of ethyl 3-(2-azaspiro[3.3]heptane-6-yl)propionate

[0651] Dissolve tert-butyl 6-(3-ethoxy-3-oxopropyl)-2-azaspiro[3.3]heptane-2-carboxylate (80.7 mg, 271.5 μmol) in a 4M solution of hydrogen chloride in 1,4-dioxane (1 mL) and react at 25°C for 2 hours. Concentrate to obtain the title compound (60 mg, crude product), which is used directly in the next step.

[0652] MS m / z(ESI):220.2[M+Na] + .

[0653] Intermediate Preparation Example 36: Preparation of methyl 2-azaspiro[3.3]heptane-6-carboxylate

[0654] Step 1: Preparation of 2-tert-butyl-6-methyl-2-azaspiro[3.3]heptane-2,6-dicarboxylate

[0655] 2-(tert-Butoxycarbonyl)-2-azaspiro[3.3]heptane-6-carboxylic acid (49 mg, 203.1 μmol) was dissolved in methanol (2.5 mL), and thionyl chloride (0.5 mL, 203.1 μmol) was added. The mixture was reacted at 25°C for 2 hours and concentrated to give the title compound (50 mg, crude product).

[0656] MS m / z(ESI):256.1[M+H] + .

[0657] Step 2: Preparation of methyl 2-azaspiro[3.3]heptane-6-carboxylate

[0658] 2-tert-Butyl-6-methyl-2-azaspiro[3.3]heptane-2,6-dicarboxylate (50 mg, 195.9 μmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.4 mL) was added, and the mixture was reacted at 25°C for 2 hours. The mixture was concentrated to give the title compound (60 mg, crude product).

[0659] MS m / z(ESI):156.1[M+H] + .

[0660] Intermediate Preparation Example 37: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((S)-1-(6-chloronaphthalen-2-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0661] The synthetic route in Intermediate Preparation Example 30 was adopted, and the first step reaction raw material 6-fluoro-2-naphthoic acid was replaced with 6-chloro-2-naphthoic acid to obtain the title compound (50 mg, crude product).

[0662] MS m / z(ESI):432.2[M+H] + .

[0663] Intermediate Preparation Example 38: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((S)-1-(naphthalen-2-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0664] The synthetic route in Intermediate Preparation Example 6 was used to replace the first step reaction raw material 2-(aminomethyl)naphthalene with (S)-1-(naphthalene-2-ethyl)-1-amine to obtain the title compound (360 mg, yield: 51.1%).

[0665] MS m / z(ESI):398.2[M+H] + .

[0666] Intermediate Preparation Example 39: Preparation of (R)-ethyl 2-(morpholin-2-ylmethoxy)acetate

[0667] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with (R)-2-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester to obtain the title compound (200 mg, yield: 63.0%).

[0668] MS m / z(ESI):204.1[M+H] + .

[0669] Intermediate Preparation Example 40: Preparation of 7-(tert-Butoxycarbonyl)-7-azaspiro[3.5]nonane-2-carboxylic acid

[0670] Tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (200 mg, 835.7 μmol) and 1-(isocyanatomethylsulfonyl)-4-methylbenzene (195.8 mg, 1.00 mmol) were dissolved in tert-butanol (4 mL), and potassium tert-butoxide (94.7 mg, 835.7 μmol) was added. The mixture was reacted at 25°C for 2 hours. The reaction solution was diluted with water (20 mL) and extracted three times with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was dissolved in methanol (4 mL), and a solution of sodium hydroxide (33.7 mg, 835.7 μmol) in water (1 mL) was added. The mixture was reacted at 70°C for 12 hours. The reaction solution was diluted with water (20 mL), adjusted to pH 3-4 with 1 M dilute hydrochloric acid, extracted three times with ethyl acetate (10 mL), and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (200 mg, crude product).

[0671] MS m / z(ESI):270.1[MH] - .

[0672] Intermediate Preparation Example 41: Preparation of (2S)-2-[6-(piperidin-4-yloxy)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]-3,3-dimethylbutanoate

[0673] Step 1: Preparation of methyl (2S)-2-(6-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-3,3-dimethylbutanoate

[0674] Methyl 5-bromo-2-(bromomethyl)benzoate (4.9 g, 15.91 mmol) and methyl L-tert-leucinate (2.77 g, 19.09 mmol) were dissolved in dimethyl sulfoxide (20 mL). N,N-diisopropylethylamine (8.22 g, 63.64 mmol) was added, and the atmosphere was replaced with nitrogen three times. The temperature was raised to 100°C and stirred for 24 hours. Water (50 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (4.4 g, yield: 81.3%).

[0675] MS m / z(ESI):340.1[M+H] + .

[0676] Step 2: Preparation of tert-butyl (S)-4-((2-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-3-oxoisoindol-5-yl)oxy)piperidine-1-carboxylate

[0677] Methyl (2S)-2-(6-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-3,3-dimethylbutanoate (400 mg, 1.18 mmol) and tert-butyl 4-hydroxypiperidine-1-carboxylate (1.18 g, 5.88 mmol) were added to toluene (10 mL), and tris(dibenzylideneacetone)dipalladium (108.05 mg, 0.118 mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (50.11 mg, 0.118 mmol) and cesium carbonate (1.54 g, 4.72 mmol) were added. The atmosphere was replaced with nitrogen three times and the reaction was stirred at 110°C for 24 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to give the title compound (170 mg, yield: 31.4%).

[0678] MS m / z(ESI):461.3[M+H] + .

[0679] Step 3: Preparation of (2S)-2-[6-(piperidin-4-yloxy)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]-3,3-dimethylbutanoate

[0680] (S)-tert-Butyl 4-((2-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-3-oxoisoindol-5-yl)oxy)piperidine-1-carboxylate (170 mg, 0.37 mmol) was added to a 4M solution of hydrogen chloride in ethyl acetate (10 mL) and reacted at 20°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the title compound (100 mg, yield: 78.7%).

[0681] MS m / z(ESI):361.2[M+H] + .

[0682] Intermediate Preparation Example 42: Preparation of 2-(2-((4-(8-tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropylmethyl)-2-azaspiro[3.5]nonan-7-yl)oxy)acetic acid

[0683] Step 1: Preparation of tert-butyl 3-(7-chloro-2-((1-((7-(2-ethoxy-2-oxoethoxy)-2-azaspiro[3.5]non-2-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0684] Tert-butyl 3-(7-chloro-8-fluoro-2-(1-((methylsulfonyl)oxy)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.0 g, 1.75 mmol) and ethyl 2-(2-azaspiro[3.5]nonan-7-oxy)acetate (720 mg, 2.73 mmol) were dissolved in N,N-dimethylacetamide (10 mL). Potassium iodide (290.2 mg, 1.75 mmol) and potassium carbonate (1.21 g, 8.74 mmol) were added, and the mixture was reacted at 60°C for 5 hours. The reaction solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (750 mg, yield: 61.0%).

[0685] MS m / z(ESI):703.3[M+H] + .

[0686] Step 2: Preparation of tert-butyl 3-(2-((1-((7-(2-ethoxy-2-oxoethoxy)-2-azaspiro[3.5]non-2-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0687] tert-Butyl 3-(7-chloro-2-((1-((7-(2-ethoxy-2-oxoethoxy)-2-azaspiro[3.5]non-2-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (630 mg, 895.85 μmol) and 2-[8-ethyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4,4,5,5- Tetramethyl-1,3,2-dioxaborolane (419.5 mg, 1.16 mmol) was dissolved in 1,4-dioxane (10 mL). A solution of potassium phosphate (570.5 mg, 2.69 mmol) in water (2 mL) and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (65.2 mg, 89.6 μmol) were added. After nitrogen substitution three times, the reaction was stirred at 100°C for 6 hours. The mixture was cooled to room temperature and diluted with ethyl acetate (20 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (600 mg, yield: 72.84%).

[0688] MS m / z(ESI):901.4[M+H] + .

[0689] Step 3: Preparation of 2-(2-((4-(8-tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropylmethyl)-2-azaspiro[3.5]nonan-7-yl)oxy)acetic acid

[0690] Tert-butyl 3-(2-((1-((7-(2-ethoxy-2-oxoethoxy)-2-azaspiro[3.5]non-2-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (480 mg, 532.7 μmol) was dissolved in tetrahydrofuran (9 mL), and a solution of lithium hydroxide hydrate (111.8 mg, 2.66 mmol) in water (1 mL) was added, and the mixture was reacted at 25°C for 12 hours. After the reaction solution was concentrated at low temperature, water (10 mL) was added, the pH was adjusted to 6-7 with 1 M aqueous hydrochloric acid solution, and the mixture was extracted three times with dichloromethane (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (459 mg, yield: 98.7%).

[0691] MS m / z(ESI):873.5[M+H] + .

[0692] Intermediate Preparation Example 43: Preparation of ethyl {[(3R)-tetrahydro-1H-pyrrol-3-yl]oxy}acetate

[0693] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with (3R)-3-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester to obtain the title compound (0.8 g, yield: 87.0%).

[0694] MS m / z(ESI):174.1[M+H] + .

[0695] Intermediate Preparation Example 44: Preparation of ethyl {[(3S)-tetrahydro-1H-pyrrol-3-yl]oxy}acetate

[0696] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with (3S)-3-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester to obtain the title compound (0.7 g, yield: 91.3%).

[0697] MS m / z(ESI):174.1[M+H] + .

[0698] Intermediate Preparation Example 45: Preparation of (2S,4R)-1-((S)-2-amino-2-cyclohexylacetyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0699] Step 1: Preparation of tert-butyl ((S)-1-cyclohexyl-2-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-2-oxoethyl)carbamate

[0700] (2S)-2-Cyclohexyl-2-({[(2-methylpropan-2-yl)oxy]carbonyl}amino)acetic acid (90.0 mg, 349.75 μmol) and (2S,4R)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (139.1 mg, 419.69 μmol) were dissolved in DMF (2 mL). N,N-Diisopropylethylamine (135.6 mg, 1.05 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (266.0 mg, 699.5 μmol) were added with cooling to 0°C, and the mixture was stirred at 25°C for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (168.0 mg, yield: 84.2%).

[0701] MS m / z(ESI):571.2[M+H] + .

[0702] Step 2: Preparation of (2S,4R)-1-((S)-2-amino-2-cyclohexylacetyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0703] Tert-butyl ((S)-1-cyclohexyl-2-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-2-oxoethyl)carbamate (168.0 mg, 294.35 μmol) was added to a 4 M solution of hydrogen chloride in ethyl acetate (10 mL) and reacted at 20°C for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain the title compound (140.0 mg, yield: 93.8%).

[0704] MS m / z(ESI):471.2[M+H] + .

[0705] Intermediate Preparation Example 46: Preparation of 2-((7-((1-(((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-7-azaspiro[3.5]nonan-2-yl)oxy)acetic acid

[0706] Step 1: Preparation of tert-butyl 3-(2-((1-((2-(2-ethoxy-2-oxoethoxy)-7-azaspiro[3.5]non-7-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0707] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxy-methoxy)naphthalen-1-yl)-8-fluoro-2-((1-((methylsulfonyl)oxy)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (800.0 mg, 1.04 mmol) and ethyl (7-azaspiro[3.5]nonan-2-yloxy)acetate (272.76 mg, 1.2 mmol) were dissolved in DMF (3 mL), potassium carbonate (289.9 mg, 2.1 mmol) and potassium iodide (71.9 mg, 433.3 μmol) were added, and the mixture was reacted at 50° C. for 4 hours. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (750 mg, yield: 80.1%).

[0708] MS m / z(ESI):901.4[M+H] + .

[0709] Step 2: Preparation of 2-((7-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-7-azaspiro[3.5]nonan-2-yl)oxy)acetic acid

[0710] Tert-butyl 3-(2-((1-((2-(2-ethoxy-2-oxoethoxy)-7-azaspiro[3.5]non-7-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (750.0 mg, 832.3 μmol) was dissolved in methanol (3 mL) and water (0.5 mL), and lithium hydroxide monohydrate (62.94 mg, 1.5 mmol) was added, and the mixture was stirred at 25°C for 2 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 6 with 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate (10 mL). The organic phase was collected and washed once with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give the title compound (700 mg, yield: 96.3%).

[0711] MS m / z(ESI):873.4[M+H] + .

[0712] Intermediate Preparation Example 47: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((R)-1-fluoro-[1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-hydroxypyrrolidine-2-carboxamide

[0713] Using the synthetic route in Intermediate Preparation Example 7, the first step reaction raw material N-[(1S)-1-(4-bromophenyl)ethyl]carbamic acid tert-butyl ester was replaced with {[(1R)-1-(4-bromophenyl)-2-hydroxyethyl]amino}carboxylic acid tert-butyl ester to obtain the title compound (0.8 g, yield: 95.9%).

[0714] MS m / z(ESI):458.2[M+H] + .

[0715] Intermediate Preparation Example 48: Preparation of ethyl (octahydrocyclopenta[1,2-c]pyrrol-5-yloxy)acetate

[0716] The synthetic route in Intermediate Preparation Example 1 was adopted, and the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 5-hydroxyhexahydrocyclopenta[C]pyrrole-2(1H)-carboxylic acid tert-butyl ester to obtain the title compound (0.4 g, yield: 52.6%).

[0717] MS m / z(ESI):214.1[M+H] + .

[0718] Intermediate Preparation Example 49: Preparation of ethyl (2-azaspiro[3.3]hept-6-yloxy)acetate

[0719] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester to obtain the title compound (0.4 g, yield: 50.8%).

[0720] MS m / z(ESI):200.1[M+H] + .

[0721] Intermediate Preparation Example 50: Preparation of ethyl (6-azaspiro[3.4]octan-2-yloxy)acetate

[0722] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 2-hydroxy-6-azaspiro[3.4]octane-6-carboxylic acid tert-butyl ester to obtain the title compound (550 mg, yield: 80.1%).

[0723] MS m / z(ESI):214.1[M+H] + .

[0724] Intermediate Preparation Example 51: Preparation of ethyl [(8-azabicyclo[3.2.1]oct-3-ylmethyl)oxy]acetate

[0725] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester to obtain the title compound (300 mg, yield: 95.4%).

[0726] MS m / z(ESI):228.1[M+H] + .

[0727] Intermediate Preparation Example 52: Preparation of ethyl (8-azabicyclo[3.2.1]oct-3-yloxy)acetate

[0728] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester to obtain the title compound (700 mg, yield: 91.2%).

[0729] MS m / z(ESI):214.1[M+H] + .

[0730] Intermediate Preparation Example 53: Preparation of ethyl 3-(7-azaspiro[3.5]nonan-2-yl)propanoate

[0731] Using the synthetic route in Intermediate Preparation Example 26, the first step reaction raw material 7-oxo-2-azaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester was replaced with 2-oxo-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester to obtain the title compound (700 mg, yield: 73.7%).

[0732] MS m / z(ESI):226.2[M+H] + .

[0733] Intermediate Preparation Example 54: Preparation of 3-(7-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-7-azaspiro[3.5]nonan-2-yl)propanoic acid

[0734] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]nonan-2-yloxy)ethyl acetate was replaced with 3-(7-azaspiro[3.5]nonan-2-yl)propanoic acid ethyl ester to obtain the title compound (110 mg, yield: 77.4%).

[0735] MS m / z(ESI):871.4[M+H] + .

[0736] Intermediate Preparation Example 55: Preparation of ethyl ({[(2S)-1,4-oxazepan-2-yl]methyl}oxy)acetate

[0737] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with (S)-2-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester to obtain the title compound (930 mg, yield: 79.9%).

[0738] MS m / z(ESI):204.1[M+H] + .

[0739] Intermediate Preparation Example 56: Preparation of 2-(((2S)-4-((1-((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)morpholin-2-yl)methoxyacetic acid

[0740] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]nonan-2-yloxy)ethyl acetate was replaced with ({[(2S)-1,4-oxazacyclohexan-2-yl]methyl}oxy)ethyl acetate to obtain the title compound (250 mg, yield: 89.4%).

[0741] MS m / z(ESI):849.4[M+H] + .

[0742] Intermediate Preparation Example 57: Preparation of ethyl {[(3R)-piperidin-3-yl]oxy}acetate

[0743] Using the synthetic route in Intermediate Preparation Example 1, the first step reaction raw material 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester was replaced with (R)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester to obtain the title compound (1.1 g, yield: 97.8%).

[0744] MS m / z(ESI):188.2[M+H] + .

[0745] Intermediate Preparation Example 58: Preparation of 2-(((3R)-1-((1-((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-3-yl)oxy)acetic acid

[0746] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]non-2-yloxy)ethyl acetate was replaced with {[(3R)-piperidin-3-yl]oxy}ethyl acetate to obtain the title compound (40 mg, yield: 48.1%).

[0747] MS m / z(ESI):833.4[M+H] + .

[0748] Intermediate Preparation Example 59: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((6-fluoronaphthalen-2-yl)methyl)-4-hydroxypyrrolidine-2-carboxamide

[0749] The synthetic route in Intermediate Preparation Example 29 was adopted, and the starting material in the first step, 6-chloro-2-naphthoic acid, was replaced with 6-fluoronaphthalene-2-carboxylic acid to obtain the title compound (80 mg, yield: 91.6%).

[0750] MS m / z(ESI):402.2[M+H] + .

[0751] Intermediate Preparation Example 60: Preparation of 5-chloronaphthalene-2-carboxylic acid

[0752] Dissolve 5-bromonaphthalene-2-carboxylic acid (700 mg, 2.788 mmol) in dimethyl sulfoxide (10 mL), add cuprous chloride (1.08 g, 10.9 mmol), and react at 140°C under microwave for 4 hours. Filter, wash the filter cake with dimethyl sulfoxide (10 mL), and collect the filtrate. Add the filtrate dropwise to water (50 mL) to precipitate a solid, filter, and dry the filter cake to obtain the title compound (500 mg, yield: 86.8%).

[0753] MS m / z(ESI):207.1[M+H] + .

[0754] Intermediate Preparation Example 61: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-N-((5-chloronaphthalen-2-yl)methyl)-4-hydroxypyrrolidine-2-carboxamide

[0755] The synthetic route in Intermediate Preparation Example 29 was adopted, and the first step reaction raw material 6-chloro-2-naphthoic acid was replaced with 5-chloronaphthalene-2-carboxylic acid to obtain the title compound (336 mg, yield: 95.7%).

[0756] MS m / z(ESI):418.2[M+H] + .

[0757] Intermediate Preparation Example 62: Preparation of (S)-2-(6-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0758] Step 1: Preparation of tert-butyl (S)-4-(2-(1-methoxy-3,3-dimethyl-1-oxobutane-2-yl)-3-oxoisoindolin-5-yl)piperazine-1-carboxylate

[0759] Methyl (S)-2-(6-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoate (142.5 mg, 418.9 μmol) and tert-butyl piperazine-1-carboxylate (234.0 mg, 1.26 mmol) were dissolved in 1,4-dioxane (5 mL). Tris(dibenzylideneacetone)dipalladium (38.4 mg, 41.89 μmol), 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (260.8 mg, 418.9 μmol), and cesium carbonate (545.9 mg, 1.68 mmol) were added. Nitrogen was then purged for one minute and the mixture was microwaved at 100°C for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 2, volume ratio) to obtain the title compound (114 mg, yield: 61.1%).

[0760] MS m / z(ESI):446.3[M+H] + .

[0761] Step 2: Preparation of (S)-2-(6-(4-(tert-butoxycarbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0762] Tert-butyl (S)-4-(2-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-3-oxoisoindolin-5-yl)piperazine-1-carboxylate (114 mg, 255.9 μmol) was dissolved in tetrahydrofuran (2 mL), and lithium hydroxide hydrate (45.2 mg, 1.1 mmol) was added. The mixture was reacted at 25°C for 12 hours. The reaction solution was concentrated at low temperature, and an appropriate amount of water was added. The pH was adjusted to 6-7 with 1 M aqueous hydrochloric acid. The mixture was extracted three times with dichloromethane (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the title compound (81 mg, yield: 88.1%).

[0763] MS m / z(ESI):432.3[M+H] + .

[0764] Intermediate Preparation Example 63: Preparation of (2S)-2-(6-((1-((((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0765] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]non-2-yloxy)ethyl acetate was replaced with (2S)-2-[6-(piperidin-4-yloxy)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]-3,3-dimethylbutanoic acid methyl ester to obtain the title compound (150 mg, yield: 59.6%).

[0766] MS m / z(ESI):1020.5[M+H] + .

[0767] Intermediate Preparation Example 64: Preparation of ethyl 2-(azetidin-3-ylmethoxy)acetate

[0768] Step 1: Preparation of tert-butyl 3-ethoxycarbonylmethoxymethylazetidine-1-carboxylate

[0769] Dissolve tert-butyl 3-hydroxymethylazetidine-1-carboxylate (1.94 g, 10.36 mmol) in tetrahydrofuran (15 mL) and add sodium hydride (539 mg, 13.47 mmol). The atmosphere is purged with nitrogen and stirred at 0°C for 20 minutes. Ethyl 2-bromoacetate (2.25 g, 13.47 mmol) is then added dropwise. The mixture is allowed to warm to room temperature and stirred for 12 hours. Saturated aqueous ammonium chloride is added to the reaction mixture to quench the reaction. The reaction mixture is concentrated and the residue is purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to obtain the title compound (1.39 g, yield: 49.0%).

[0770] MS m / z(ESI):274.1[M+H] + .

[0771] Step 2: Preparation of ethyl 2-(azetidin-3-ylmethoxy)acetate

[0772] Dissolve tert-butyl 3-ethoxycarbonylmethoxymethylazetidine-1-carboxylate (1.39 g, 5.07 mmol) in 4M hydrogen chloride in ethyl acetate (6 mL) and stir at room temperature for 12 hours. Concentrate the reaction mixture to obtain the title compound (1.06 g, 5.04 mmol, yield: 99.3%).

[0773] MS m / z(ESI):174.1[M+H] + .

[0774] Intermediate Preparation Example 65: Preparation of ethyl 2-(azetidin-3-yloxy)acetate

[0775] Using the synthetic route in Intermediate Preparation Example 64, the first step reaction raw material 3-hydroxymethylazetidine-1-carboxylic acid tert-butyl ester was replaced with 3-hydroxyazetidine-1-carboxylic acid tert-butyl ester to obtain the title compound (1.34 g, yield: 99.9%).

[0776] MS m / z(ESI):160.1[M+H] + .

[0777] Intermediate Preparation Example 66: Preparation of ethyl 2-(7-azaspiro[3.5]nonan-2-yl)acetate

[0778] Using the synthetic route in Intermediate Preparation Example 21, the first step reaction raw material, oxo-2-azaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester, was replaced with 2-oxo-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester to obtain the title compound (304 mg, yield: 98.1%).

[0779] MS m / z(ESI):212.1[M+H] + .

[0780] Intermediate Preparation Example 67: Preparation of ethyl 2-(3-azaspiro[5.5]undec-9-yl)acetate

[0781] Using the synthetic route in Intermediate Preparation Example 21, the first step reaction raw material, oxo-2-azaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester, was replaced with 9-oxo-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester to obtain the title compound (219 mg, yield: 98.3%).

[0782] MS m / z(ESI):240.1[M+H] + .

[0783] Intermediate Preparation Example 68: Preparation of ethyl 2-(2-azaspiro[3.3]heptane-6-yl)acetate

[0784] Using the synthetic route in Intermediate Preparation Example 21, the first step reaction raw material, oxo-2-azaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester, was replaced with 6-oxo-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester to obtain the title compound (221 mg, yield: 96.7%).

[0785] MS m / z(ESI):184.1[M+H] + .

[0786] Intermediate Preparation Example 69: Preparation of (S)-3,3-dimethyl-2-(1-oxo-5-(piperidin-4-yloxy)isoindolin-2-yl)butanoic acid methyl ester

[0787] Step 1: Preparation of methyl 2-(5-bromo-1-oxo-1,3-dihydroisoindol-2-yl)-3,3-dimethylbutanoate

[0788] Methyl 4-bromo-2-bromomethylbenzoate (1.94 g, 6.30 mmol) and methyl L-tert-leucinate hydrochloride (1.72 g, 9.45 mmol) were dissolved in dimethyl sulfoxide (20 mL). N,N-diisopropylethylamine (3.26 g, 25.20 mmol) was added dropwise. The atmosphere was purged with nitrogen and the reaction was stirred at 100°C for 24 hours. The reaction solution was cooled to room temperature and diluted with ethyl acetate (80 mL). The mixture was washed once with saturated brine (20 mL). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 7 / 1, volume ratio) to obtain the title compound (1.63 g, yield: 76.2%).

[0789] MS m / z(ESI):340.1[M+H] + .

[0790] Step 2: Preparation of tert-butyl (S)-4-((2-(1-methoxy-3,3-dimethyl-1-oxobutane-2-yl)-1-oxoisoindolin-5-yl)oxy)piperidine-1-carboxylate

[0791] Methyl 2-(5-bromo-1-oxo-1,3-dihydroisoindolin-2-yl)-3,3-dimethylbutanoate (1.49 g, 4.38 mmol), tert-butyl 4-hydroxypiperidine-1-carboxylate (1.06 g, 5.26 mmol), tris(dibenzylideneacetone)dipalladium (402 mg, 438.40 μmol), 5-di-tert-butylphosphine-1',3',5'-triphenyl-1'H-[1,4']dipyrazole (444 mg, 876.81 μmol) and cesium carbonate (2.14 g, 6.58 mmol) were added to toluene (20 mL), stirred evenly, replaced with nitrogen three times, and reacted at 100 ° C for 4 hours. The reaction solution was concentrated, diluted and dissolved with ethyl acetate (40 mL), and washed once with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, volume ratio) to give the title compound (243 mg, yield: 12.0%).

[0792] MS m / z(ESI):461.1[M+H] + .

[0793] Step 3: Preparation of (S)-3,3-dimethyl-2-(1-oxo-5-(piperidin-4-yloxy)isoindolin-2-yl)butanoic acid methyl ester

[0794] Dissolve (S)-tert-Butyl 4-((2-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-5-yl)oxy)piperidine-1-carboxylate (243 mg, 526.64 μmol) in 4 M hydrogen chloride in ethyl acetate (1.5 mL) and allow to react at room temperature for 12 hours. The reaction mixture was concentrated to provide the title compound (189 mg, 99.4% yield).

[0795] MS m / z(ESI):361.1[M+H] + .

[0796] Intermediate Preparation Example 70: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)butyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0797] Step 1: Preparation of tert-butyl (S)-4-(2-(1-methoxy-3,3-dimethyl-1-oxobutane-2-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate

[0798] Methyl 2-(5-bromo-1-oxo-1,3-dihydroisoindolin-2-yl)-3,3-dimethylbutanoate (495 mg, 1.45 mmol), tert-butyl piperazine-1-carboxylate (325 mg, 1.75 mmol), tris(dibenzylideneacetone)dipalladium (133 mg, 145.5 μmol), 5-di-tert-butylphosphine-1',3',5'-triphenyl-1'H-[1,4']dipyrazole (147 mg, 291.0 μmol), and cesium carbonate (711 mg, 2.18 mmol) were added to toluene (30 mL), stirred, and the atmosphere was replaced with nitrogen three times. The reaction mixture was stirred at 100°C for 12 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, volume ratio) to obtain the title compound (500 mg, yield: 77.1%).

[0799] MS m / z(ESI):446.2[M+H] + .

[0800] Step 2: Preparation of (S)-2-(5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0801] Dissolve tert-butyl (S)-4-(2-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (146 mg, 326.56 μmol) in methanol (10 mL). Add lithium hydroxide monohydrate (69 mg, 1.63 mmol) and water (3 mL), stir well, and react at 40°C for 16 hours. After the reaction mixture cools to room temperature, add 1M dilute hydrochloric acid (2 mL) dropwise to adjust the pH to 4-5. Concentrate the reaction mixture, dilute with ethyl acetate (50 mL), and wash once with saturated brine (15 mL). Dry the organic phase over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain the title compound (141 mg, yield: 99.8%).

[0802] MS m / z(ESI):432.1[M+H] + .

[0803] Step 3: Preparation of tert-butyl 4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutane-2-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate

[0804] (S)-2-(5-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid (141 mg, 325.82 μmol) was dissolved in N,N-dimethylacetamide (4 mL), and N,N-diisopropylethylamine (170 mg, 1.32 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyl Urea hexafluorophosphate (164 mg, 429.29 μmol) was then added, followed by the addition of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutyryl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide (158 mg, 429.29 μmol). The atmosphere was purged with nitrogen three times and the reaction was allowed to proceed at room temperature for 12 hours. The reaction solution was diluted with ethyl acetate (20 mL) and washed once with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 15 / 1, volume ratio) to obtain the title compound (103 mg, yield: 42.4%).

[0805] MS m / z(ESI):745.1[M+H] + .

[0806] Step 4: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)butyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0807] Tert-butyl 4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (103 mg, 138.21 μmol) was dissolved in 4 M hydrogen chloride in ethyl acetate (1 mL). The reaction was allowed to react at room temperature for 12 hours. The reaction solution was concentrated to give the title compound (94 mg, yield: 99.6%).

[0808] MS m / z(ESI):645.1[M+H] + .

[0809] Intermediate Preparation Example 71: Preparation of tert-butyl 7-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((methylsulfonyl)oxy)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate

[0810] Step 1: Preparation of tert-butyl 7-(2,7-dichloro-8-fluoro-pyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate

[0811] 2,4,7-Trichloro-8-fluoro-pyrido[4,3-d]pyrimidine (485 mg, 1.92 mmol) was dissolved in dichloromethane (15 mL), and N,N-diisopropylethylamine (745 mg, 5.76 mmol) was added. 3-Oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid tert-butyl ester (417 mg, 1.83 mmol) was added to the reaction system at 0°C, and the mixture was reacted at 0°C for 2 hours. Saturated brine (20 mL) was added to the reaction solution, and the mixture was extracted three times with dichloromethane (45 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / ethyl acetate = 10 / 1, volume ratio) to obtain the title compound (837 mg, yield: 97.9%).

[0812] MS m / z(ESI):444.1[M+H] + .

[0813] Step 2: Preparation of tert-butyl 7-[7-chloro-8-fluoro-2-[[1-(hydroxymethyl)cyclopropyl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate

[0814] 7-(2,7-Dichloro-8-fluoro-pyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid tert-butyl ester (837 mg, 1.88 mmol) and [1-(hydroxymethyl)cyclopropyl]methanol (577 mg, 5.65 mmol) were dissolved in N,N-dimethylacetamide (15 mL), and triethylamine (191 mg, 1.89 mmol) and cesium carbonate (1.84 g, 5.65 mmol) were added. The atmosphere was replaced with nitrogen three times and the reaction was carried out at room temperature for 12 hours. The reaction solution was diluted with ethyl acetate (35 mL) and washed twice with saturated brine (15 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / ethyl acetate = 3 / 1, volume ratio) to give the title compound (949 mg, yield: 98.9%).

[0815] MS m / z(ESI):510.1[M+H] + .

[0816] Step 3: Preparation of tert-butyl 7-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate

[0817] tert-Butyl 7-[7-chloro-8-fluoro-2-[[1-(hydroxymethyl)cyclopropyl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate (934 mg, 1.83 mmol), 2-[8-ethyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4,4,5,5-tetramethyl-1,3,2-dioxabicyclo[3.3.1]nonane-9-carboxylate (934 mg, 1.83 mmol), Borane (792 mg, 2.20 mmol), potassium phosphate (1.17 g, 5.51 mmol), and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (133 mg, 182.62 μmol) were dissolved in 1,4-dioxane (20 mL). Water (4 mL) was added and the mixture was stirred until uniform. The atmosphere was replaced with nitrogen three times and the reaction temperature was 100°C for 6 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1, volume ratio) to obtain the title compound (826 m, yield: 63.9%).

[0818] MS m / z(ESI):708.1[M+H] + .

[0819] Step 4: Preparation of tert-butyl 7-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((methylsulfonyl)oxy)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate

[0820] Tert-butyl 7-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate (826 mg, 1.17 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (591 mg, 5.84 mmol) was added to the system. After stirring, methanesulfonyl chloride (267 mg, 2.33 mmol) was added dropwise to the system. The atmosphere was replaced with nitrogen three times and the reaction was carried out at room temperature for 24 hours. The reaction solution was diluted with dichloromethane (50 mL) and washed twice with saturated brine (25 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / ethyl acetate = 4 / 1, volume ratio) to give the title compound (199 mg, yield: 21.6%).

[0821] MS m / z(ESI):786.1[M+H] + .

[0822] Intermediate Preparation Example 72: Preparation of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-chlorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide

[0823] The synthetic route in Intermediate Preparation Example 7 was adopted, and the starting material in the first step (2-fluorophenyl)boric acid was replaced with (2-chlorophenyl)boric acid to obtain the title compound (152 mg, yield: 86.7%).

[0824] MS m / z(ESI):458.1[M+H] + .

[0825] Intermediate Preparation Example 73: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(1-methyl-1H-pyrazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0826] The synthetic route in Intermediate Preparation Example 7 was used to replace the first step reaction raw material (2-fluorophenyl)boronic acid with 1-methyl-1H-pyrazole-5-boronic acid pinacol ester to obtain the title compound (1.18 g, yield: 94.8%).

[0827] MS m / z(ESI):428.1[M+H] + .

[0828] Intermediate Preparation Example 74: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(1-ethyl-1H-pyrazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0829] Using the synthetic route in Intermediate Preparation Example 7, the first step reaction raw material (2-fluorophenyl)boronic acid was replaced with 1-ethyl-1H-pyrazole-5-boronic acid pinacol ester to obtain the title compound (1.51 g, yield: 99.7%).

[0830] MS m / z(ESI):442.1[M+H] + .

[0831] Intermediate Preparation Example 75: Preparation of (2S)-2-(6-((1-((((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0832] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]nonan-2-yloxy)ethyl acetate was replaced with (S)-3,3-dimethyl-2-(1-oxo-5-(piperidin-4-yloxy)isoindolin-2-yl)butanoic acid methyl ester to obtain the title compound (200 mg, yield: 49.6%).

[0833] MS m / z(ESI):1020.5[M+H] + .

[0834] Intermediate Preparation Example 76: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-formylcyclopropyl)methoxy]pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0835] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy]pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (5.0 g, 7.23 mmol) was dissolved in dichloromethane (50 mL), and pyridinium chlorochromate (711 mg, 10.85 mmol) was added, followed by reaction at room temperature for 16 hours. The reaction solution was concentrated and directly purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, volume ratio) to obtain the title compound (4.7 g, yield: 94.2%).

[0836] MS m / z(ESI):690.2[M+H] + .

[0837] Intermediate Preparation Example 77: Preparation of (2S,4R)-1-((S)-2-azido-3,3-dimethylbutanoyl)-N-(S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0838] Step 1: Preparation of trifluoromethanesulfonyl azide

[0839] Sodium azide (1.12 g, 17.2 mmol) was dissolved in water (5 mL), followed by the addition of dichloromethane (10 mL). Trifluoromethanesulfonic anhydride (0.97 g, 3.44 mmol) was added dropwise at 0°C, and the reaction was stirred at 0°C for 2 hours. The liquids were separated, and the aqueous phase was extracted twice with dichloromethane (5 mL). The organic phase was washed with sodium bicarbonate solution (10 mL). The liquids were separated to obtain a dichloromethane solution (20 mL) of the title compound, which was used directly in the next step.

[0840] MS m / z(ESI):274.1[M+H] + .

[0841] Step 2: Preparation of (2S,4R)-1-((S)-2-azido-3,3-dimethylbutanoyl)-N-(S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0842] (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (0.5 g, 1.13 mmol) was dissolved in methanol (10 mL) and water (10 mL). Potassium carbonate (0.55 g, 3.97 mmol) and copper sulfate pentahydrate (27.5 mg, 0.11 mmol) were added, followed by a dichloromethane solution (20 mL) of trifluoromethanesulfonyl azide. The reaction was stirred at room temperature for 12 hours. The mixture was extracted three times with dichloromethane (15 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (0.24 g, yield: 45.4%).

[0843] MS m / z(ESI):468.2[M+H] + .

[0844] Intermediate Preparation Example 78: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(S)-piperidin-2-yl)acetylamino)butyryl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0845] Step 1: Preparation of tert-butyl (S)-2-(2-(((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperidine-1-carboxylate

[0846] (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (130 mg, 295 μmol) was dissolved in N,N-dimethylacetamide (2 mL), and N,N-diisopropylethylamine (114 mg, 0.88 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (168 mg, 442.5 μmol) were added. Then, (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid (71.8 mg, 295 μmol) was added and the mixture was reacted at room temperature for 2 hours. The reaction solution was added dropwise to water (15 mL) to precipitate a solid, which was filtered and the filter cake was dried to obtain the title compound (160 mg, yield: 81.2%).

[0847] MS m / z(ESI):667.4[M+H] + .

[0848] Step 2: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(S)-piperidin-2-yl)acetylamino)butyryl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0849] (S)-tert-Butyl 2-(2-(((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (160 mg, 239.9 μmol) was dissolved in 4 M hydrogen chloride in ethyl acetate (1 mL). The reaction was allowed to proceed at room temperature for 2 hours. The reaction solution was concentrated, and the residue was diluted with ethyl acetate (10 mL). The organic phase was washed with sodium bicarbonate solution (10 mL). The layers were separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give the title compound (110 mg, yield: 80.9%).

[0850] MS m / z(ESI):567.3[M+H] + .

[0851] Intermediate Preparation Example 79: Preparation of ethyl 3-(3-azaspiro[5.5]undec-9-yl)propanoate

[0852] Using the synthetic route in Intermediate Preparation Example 35, the first step raw material, tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate, was replaced with tert-butyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate to obtain the title compound (400 mg, yield: 49.6%).

[0853] MS m / z(ESI):254.2[M+H] + .

[0854] Intermediate Preparation Example 80: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((R)-2-hydroxy-1-(naphthalen-2-yl)ethyl)pyrrolidine-2-carboxamide

[0855] Using the synthetic route in Intermediate Preparation Example 6, the first step reaction raw material 2-(aminomethyl)naphthalene was replaced with (2R)-2-amino-2-(naphthalen-2-yl)ethane-1-ol to obtain the title compound (340 mg, yield: 90.6%).

[0856] MS m / z(ESI):414.2[M+H] + .

[0857] Intermediate Preparation Example 81: Preparation of 2-((3-((1-(((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl)oxy)acetic acid

[0858] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]non-2-yloxy)ethyl acetate was replaced with 2-((3-azaspiro[5.5]undec-9-yl)oxy)ethyl acetate to obtain the title compound (79 mg, yield: 77.4%).

[0859] MS m / z(ESI):901.4[M+H] + .

[0860] Intermediate Preparation Example 82: Preparation of 2-((2-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-2-azaspiro[3.5]nonan-7-yl)oxy)acetic acid

[0861] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]non-2-yloxy)ethyl acetate was replaced with 2-((2-azaspiro[3.5]non-7-yl)oxy)ethyl acetate to obtain the title compound (40 mg, yield: 60.2%).

[0862] MS m / z(ESI):873.4[M+H] + .

[0863] Intermediate Preparation Example 83: Preparation of 2-(((3S)-1-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-3-yl)oxy)acetic acid

[0864] Using the synthetic route in Intermediate Preparation Example 46, the first step reaction raw material (7-azaspiro[3.5]non-2-yloxy)ethyl acetate was replaced with (S)-2-(piperidin-3-yloxy)ethyl acetate to obtain the title compound (378 mg, yield: 88.4%).

[0865] MS m / z(ESI):833.4[M+H] + .

[0866] Intermediate Preparation Example 84: Preparation of 2-((3-((1-(((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl)oxy)acetic acid

[0867] Step 1: Preparation of tert-butyl 3-(2-((1-((9-(2-ethoxy-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0868] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxy-methoxy)naphthalen-1-yl)-8-fluoro-2-((1-((methylsulfonyl)oxy)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (200.0 mg, 217.06 μmol) and ethyl 2-((3-azaspiro[5.5]undec-9-yl)oxy)acetate (66.47 mg, 260.47 μmol) were dissolved in DMF (3 mL), potassium carbonate (120.0 mg, 868.24 μmol) and potassium iodide (36.0 mg, 216.7 μmol) were added, and the mixture was reacted at 50° C. for 4 hours. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (220 mg, yield: 93.8%).

[0869] MS m / z(ESI):1081.6[M+H] + .

[0870] Step 2: Preparation of 2-((3-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl)oxy)acetic acid

[0871] Tert-butyl 3-(2-((1-((9-(2-ethoxy-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (220.0 mg, 203.59 μmol) was dissolved in methanol (3 mL) and water (0.5 mL), lithium hydroxide monohydrate (62.94 mg, 1.5 mmol) was added, and the mixture was stirred at 25°C for 2 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 6 with 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate (10 mL). The organic phase was collected and washed once with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give the title compound (162 mg, yield: 75.6%).

[0872] MS m / z(ESI):1053.6[M+H] + .

[0873] Intermediate Preparation Example 85: Preparation of 2-((2-((1-(((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-2-azaspiro[3.5]nonan-7-yl)oxy)acetic acid

[0874] Using the synthetic route in Intermediate Preparation Example 84, the first step reaction raw material 2-((3-azaspiro[5.5]undec-9-yl)oxy)ethyl acetate was replaced with 2-((2-azaspiro[3.5]non-7-yl)oxy)ethyl acetate to obtain the title compound (94 mg, yield: 69.5%).

[0875] MS m / z(ESI):1025.5[M+H] + .

[0876] Intermediate Preparation Example 86: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(2-((R)-piperidin-2-yl)acetylamino)butyryl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0877] Using the synthetic route in Intermediate Preparation Example 78, the first step reaction raw material (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid was replaced with (R)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid to obtain the title compound (106 mg, yield: 94.7%).

[0878] MS m / z(ESI):567.3[M+H] + .

[0879] Intermediate Preparation Example 87: Preparation of 3-(3-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl)propanoic acid

[0880] Using the synthetic route in Intermediate Preparation Example 84, the first step reaction raw material 2-((3-azaspiro[5.5]undec-9-yl)oxy)ethyl acetate was replaced with 3-(3-azaspiro[5.5]undec-9-yl)propionic acid ethyl ester to obtain the title compound (562 mg, yield: 76.4%).

[0881] MS m / z(ESI):1051.6[M+H] + .

[0882] Intermediate Preparation Example 88: Preparation of (2S,4R)-1-((S)-2-(4-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0883] Methyl 5-bromo-2-(bromomethyl)benzoate (250 mg, 0.817 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (360.5 mg, 0.817 mmol) were dissolved in DMSO (20 mL), and N,N-diisopropylethylamine (422.3 mg, 3.27 mmol) was added. The atmosphere was replaced with nitrogen three times, and the temperature was raised to 100°C and stirred for 24 hours. Water (50 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (300 mg, yield: 57.8%).

[0884] MS m / z(ESI):636.2[M+H] + .

[0885] Intermediate Preparation Example 89: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-4-(((S)-piperidin-3-yl)oxy)isoindolin-2-yl)butanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0886] Step 1: Preparation of tert-butyl (S)-3-((2-((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-4-yl)oxy)piperidine-1-carboxylate

[0887] (2S,4R)-1-((S)-2-(4-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (165 mg, 0.26 mmol) and (S)-tert-butyl 3-hydroxypiperidine-1-carboxylate (261.4 mg, 1.3 mmol) were added to toluene (5 mL), and tris(dibenzylideneacetone)dipalladium (23.8 mg, 0.026 mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (11.04 mg, 0.026 mmol) and cesium carbonate (338.85 mg, 1.04 mmol) were added. The atmosphere was replaced with nitrogen three times and the reaction was stirred at 110°C for 24 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, volume ratio) to give the title compound (50 mg, yield: 25.4%).

[0888] MS m / z(ESI):757.4[M+H] + .

[0889] Step 2: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-4-(((S)-piperidin-3-yl)oxy)isoindolin-2-yl)butyryl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0890] (S)-tert-Butyl 3-((2-((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-4-yl)oxy)piperidine-1-carboxylate (50 mg, 0.066 mmol) was added to a 4 M solution of hydrogen chloride in ethyl acetate (2 mL) and reacted at 20°C for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain the title compound (40 mg, yield: 92.2%).

[0891] MS m / z(ESI):657.3[M+H] + .

[0892] Intermediate Preparation Example 90: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-4-(piperazin-1-yl)isoindolin-2-yl)butanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0893] Using the synthetic route in Intermediate Preparation Example 89, the first step reaction raw material (S)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester was replaced with 1-tert-butyloxycarbonylpiperazine to obtain the title compound (50 mg, yield: 88.5%).

[0894] MS m / z(ESI):642.3[M+H] + .

[0895] Intermediate Preparation Example 91: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-formylcyclobutyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0896] Step 1: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-(hydroxymethyl(cyclobutyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0897] Tert-butyl 3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (198 mg, 462 μmol) and 1,1-cyclobutane dimethanol (102 mg, 878 μmol) were dissolved in N,N-dimethylacetamide (2 mL). Cesium carbonate (301 mg, 925 μmol) and triethylamine (47 mg, 462 μmol) were added, stirred, and the atmosphere was purged with nitrogen three times. The reaction mixture was allowed to react at 25°C for 15 hours. The reaction solution was diluted with ethyl acetate (10 mL) and washed twice with saturated brine (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified on a silica gel preparative plate (eluent: dichloromethane / methanol = 15 / 1, volume ratio) to obtain the title compound (161 mg, yield: 68.7%).

[0898] MS m / z(ESI):508.2[M+H] + .

[0899] Step 2: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-formylcyclobutyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0900] Tert-butyl 3-(7-chloro-8-fluoro-2-((1-(hydroxymethyl(cyclobutyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (161 mg, 318 μmol) was dissolved in dichloromethane (6 mL), and pyridinium chlorochromate (103 mg, 477 μmol) was added. The mixture was reacted at 25°C for 16 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 15 / 1, volume ratio) to give the title compound (113 mg, yield: 70.3%).

[0901] MS m / z(ESI):506.3[M+H] + .

[0902] Intermediate Preparation Example 92: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(piperidin-4-yloxy)acetylamino)butyryl)-N-(S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0903] Using the synthetic route in Intermediate Preparation Example 78, the first step reaction raw material (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid was replaced with 1-tert-butoxycarbonyl-4-piperidinyloxyacetic acid to obtain the title compound (25 mg, yield: 97.5%).

[0904] MS m / z(ESI):583.3[M+H] + .

[0905] Intermediate Preparation Example 93: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(4-(piperidin-4-yl)-1H-1,2,3-triazol-1-yl)butanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0906] Step 1: Preparation of tert-butyl 4-(1-((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate

[0907] 1-tert-Butyloxycarbonyl-4-ethynylpiperidine (23 mg, 108 μmol) and (2S,4R)-1-((S)-2-azido-3,3-dimethylbutanoyl)-N-(S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (50 mg, 108 μmol) were dissolved in dimethyl sulfoxide (1 mL). Water (125 μL) was added dropwise and stirred to dissolve. Sodium ascorbate (32 mg, 162 μmol) and copper sulfate pentahydrate (54 mg, 215 μmol) were added to the system and reacted at 25°C for 2 hours. The reaction solution was diluted with ethyl acetate (10 mL), washed twice with saturated brine (6 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was separated and purified on a silica gel preparation plate (eluent: dichloromethane / methanol = 12 / 1, volume ratio) to give the title compound (71 mg, yield: 96.8%).

[0908] MS m / z(ESI):677.4[M+H] + .

[0909] Step 2: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(4-(piperidin-4-yl)-1H-1,2,3-triazol-1-yl)butanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0910] Tert-butyl 4-(1-((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate (71 mg, 104 μmol) was dissolved in 4 M hydrogen chloride in ethyl acetate (0.5 mL) and reacted at 25°C for 12 hours. The reaction mixture was concentrated to obtain the title compound (60 mg, yield: 99.7%).

[0911] MS m / z(ESI):577.4[M+H] + .

[0912] Intermediate Preparation Example 94: Preparation of (S)-N-((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)piperidine-2-carboxamide

[0913] Using the synthetic route in Intermediate Preparation Example 78, the first step reaction raw material (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid was replaced with (S)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid to obtain the title compound (200 mg, yield: 94.9%).

[0914] MS m / z(ESI):553.3[M+H] + .

[0915] Intermediate Preparation Example 95: Preparation of (R)-N-((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)piperidine-2-carboxamide

[0916] Using the synthetic route in Intermediate Preparation Example 78, the first step reaction raw material (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid was replaced with (R)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid to obtain the title compound (180 mg, yield: 97.3%).

[0917] MS m / z(ESI):553.3[M+H] + .

[0918] Intermediate Preparation Example 96: Preparation of (2S,4R)-1-((S)-2-(2-((2-azaspiro[3.5]nonan-7-yl)oxy)acetylamino)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0919] Using the synthetic route in Intermediate Preparation Example 78, the first step reaction raw material (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid was replaced with 2-((2-(tert-butoxycarbonyl)-2-azaspiro[3.5]non-7-yl)oxy)acetic acid to obtain the title compound (180 mg, yield: 97.3%).

[0920] MS m / z(ESI):623.3[M+H] + .

[0921] Intermediate Preparation Example 97: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((S)-1-(2',6'-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0922] The synthetic route in Intermediate Preparation Example 7 was used to replace the first step reaction raw material (2-fluorophenyl)boric acid with (2,6-difluorophenyl)boric acid to obtain the title compound (125 mg, yield: 95.1%).

[0923] MS m / z(ESI):460.2[M+H] + .

[0924] Intermediate Preparation Example 98: Preparation of (2S,4R)-N-((S)-1-(2',6'-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-1-((S)-3,3-dimethyl-2-(2-(piperidin-4-yloxy)acetylamino)butyryl)-4-hydroxypyrrolidine-2-carboxamide

[0925] Using the synthetic route in Intermediate Preparation Example 78, the first step reaction raw material (S)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid was replaced with 1-tert-butoxycarbonyl-4-piperidinyloxyacetic acid, and (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide was replaced with (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((S)-1-(2',6'-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide to obtain the title compound (53 mg, yield: 68.7%).

[0926] MS m / z(ESI):601.3[M+H] + .

[0927] Intermediate Preparation Example 99: Preparation of (2S,4R)-1-((S)-2-(4-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0928] Using the synthetic route in Intermediate Preparation Example 88, the first step reaction raw material (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutyryl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide was replaced with (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutyryl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide to obtain the title compound (150 mg, yield: 57.8%).

[0929] MS m / z(ESI):639.2[M+H] + .

[0930] Intermediate Preparation Example 100: Preparation of (2S,4R)-1-((S)-2-(4-(7-azaspiro[3.5]nonan-2-yl)oxy)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0931] The synthetic route in Intermediate Preparation Example 89 was used to replace the first step reaction raw material (2S,4R)-1-((S)-2-(4-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide with (2S,4R)-1-((S)-2-(4- bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide, (S)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester was replaced by 2-hydroxy-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester to give the title compound (90 mg, yield: 66.3%).

[0932] MS m / z(ESI):700.4[M+H] + .

[0933] Intermediate Preparation Example 101: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-4-(piperidin-4-yloxy)isoindolin-2-yl)butyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0934] The synthetic route in Intermediate Preparation Example 89 was used to replace the first step reaction raw material (2S,4R)-1-((S)-2-(4-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide with (2S,4R)-1-((S)-2-(4-bromo-1- oxoisoindolin-2-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide, (S)-tert-butyl 3-hydroxypiperidine-1-carboxylate (S)-tert-butyl 3-hydroxypiperidine-1-carboxylate was replaced with tert-butyl 4-hydroxypiperidine-1-carboxylate to give the title compound (40 mg, yield: 98.2%).

[0935] MS m / z(ESI):660.4[M+H] + .

[0936] Intermediate Preparation Example 102: Preparation of (S)-2-(4-(((R)-1-(1-((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0937] Step 1: Preparation of tert-butyl (R)-3-((2-(S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-4-yl)oxy)piperidine-1-carboxylate

[0938] Methyl (2S)-2-(4-bromo-1-oxoisoindolin-2-yl)-3,3-dimethylbutyrate (400 mg, 1.2 mmol), tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate (483.0 mg, 2.3 mmol), tris(dibenzylideneacetone)dipalladium (108.8 mg, 116.4 μmol), 5-di-tert-butylphosphino-1',3',5'-triphenyl-1'H-[1,4']dipyrazole (118. mg, 232.8 μmol), and cesium carbonate (758.2 mg, 2.33 mmol) were dissolved in toluene (5 mL) and the atmosphere was replaced with nitrogen three times. The reaction was carried out at 100°C for 4 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 15 / 1, volume ratio) to give the title compound (180 mg, yield: 33.6%).

[0939] MS m / z(ESI):461.3[M+H] + .

[0940] Step 2: Preparation of methyl (S)-3,3-dimethyl-2-(1-oxo-4-((R)-piperidin-3-yl)oxy)isoindolin-2-yl)butyrate

[0941] Dissolve tert-butyl (R)-3-((2-(S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-4-yl)oxy)piperidine-1-carboxylate (150 mg, 309.4 μmol) in dichloromethane (1 mL). Add 4M hydrogen chloride in 1,4-dioxane (1 mL) and react at 25°C for 1 hour. The reaction mixture was concentrated to obtain the title compound (120 mg, 97.7% yield).

[0942] MS m / z(ESI):361.2[M+H] + .

[0943] Step 3: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)-8-fluoro-2-((R)-3-((S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-4-yl)oxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0944] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-formylcyclopropyl)methoxy]pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 115.98 μmol) and methyl (S)-3,3-dimethyl-2-(1-oxo-4-((R)-piperidin-3-yl)oxy)isoindolin-2-yl)butyrate (120 mg, 232 μmol) were dissolved in tetrahydrofuran (4 mL), acetic acid (0.05 mL) was added, and the mixture was reacted at room temperature for 2 hours. Then, sodium cyanoborohydride (14.6 mg, 232 μmol) was added, and the mixture was reacted at 25°C for 15 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 15 / 1, volume ratio) to give the title compound (50 mg, yield 41.68%).

[0945] MS m / z(ESI):1034.5[M+H] + .

[0946] Step 4: Preparation of (S)-2-(4-(((R)-1-(1-((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)-3,3-dimethylbutanoic acid

[0947] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)-8-fluoro-2-((R)-3-((S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-oxoisoindolin-4-yl)oxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 45.9 μmol) was dissolved in tetrahydrofuran (1.0 mL) and water (1.0 mL), and lithium hydroxide monohydrate (9.6 mg, 229.6 μmol) was added, and the mixture was stirred at 25°C for 12 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 6 with 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate (10 mL). The organic phase was collected, washed once with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated to give the title compound (42 mg, yield: 89.6%).

[0948] MS m / z(ESI):1020.5[M+H] + .

[0949] Intermediate Preparation Example 103: Preparation of (2S,4R)-1-((S)-3,3-dimethyl-2-(1-oxo-4-(piperidin-4-oxy)isoindolin-2-yl)butanoyl)-N-((S)-1-(2-fluoro-[1,1-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[0950] Using the synthetic route in Intermediate Preparation Example 89, the first step reaction raw material (S)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester was replaced with 4-hydroxypiperidine-1-carboxylic acid tert-butyl ester to obtain the title compound (100 mg, yield: 78.3%).

[0951] MS m / z(ESI):657.3[M+H] + .

[0952] Synthesis Example:

[0953] Example 1: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 1)

[0954] Step 1: Preparation of tert-butyl 3-(7-chloro-2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0955] Tert-butyl 3-(7-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (400.0 mg, 699.3 μmol) and ethyl 2-(piperidin-4-ylmethoxy)acetate (168.7 mg, 839.2 μmol) were dissolved in DMF (6 mL), potassium carbonate (289.9 mg, 2.1 mmol) and potassium iodide (116.1 mg, 699.3 μmol) were added, and the mixture was reacted at 50°C for 4 hours. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (300 mg, yield: 75.0%).

[0956] MS m / z(ESI):677.3[M+H] + .

[0957] Step 2: Preparation of tert-butyl 3-(2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0958] Tert-butyl 3-(7-chloro-2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (240.0 mg, 354.5 μmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- A mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was dissolved with 2,4-dioxane (5 mL), 1,4-dioxane (1,4-dioxane), 1,1'-naphthalenyl), 1,1'-biphenyl-2-yl)triisopropylsilane (272.5 mg, 531.7 μmol). Potassium phosphate (225.7 mg, 1.06 mmol) and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (25.8 mg, 35.45 μmol) were added. The atmosphere was purged with nitrogen three times, and the mixture was heated to 100°C with stirring for 3.5 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 1, volume ratio) to obtain the title compound (150.0 mg, yield: 41.2%).

[0959] MS m / z(ESI):1027.5[M+H] + .

[0960] Step 3: Preparation of 2-((1-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro))-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetic acid

[0961] Tert-butyl 3-(2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (150.0 mg, 146.0 μmol) was dissolved in methanol (3 mL) and water (0.7 mL), and lithium hydroxide monohydrate (30.63 mg, 730.0 μmol) was added, and the mixture was stirred at 25°C for 2 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 6 with 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate (10 mL). The organic phase was collected and washed once with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give the title compound (140 mg, yield: 95.9%).

[0962] MS m / z(ESI):999.5[M+H] + .

[0963] Step 4: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-((4-((2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)))))ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0964] 2-((1-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro))-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetic acid (140.0 mg, 140.10 μmol) and (2S,4R)-1-[(2S)-2-amino]-[[(2S)-3-(methoxymethoxy)-8-(triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy]methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy]acetic acid (140.0 mg, 140.10 μmol) were added. [3,3-dimethylbutyryl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide (80.87 mg, 168.12 μmol) was dissolved in DMF (2 mL), and N,N-diisopropylethylamine (72.43 mg, 560.4 μmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (79.9 mg, 210.15 μmol) were added with cooling to 0°C. The mixture was stirred at 25°C for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (160 mg, yield: 80.1%).

[0965] MS m / z(ESI):1425.7[M+H] + .

[0966] Step 5: Preparation of tert-butyl 3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-((2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0967] 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-((4-((2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)))))ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutane-2-yl) To the reaction mixture was added tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (60 mg, 42.08 μmol): tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (60 mg, 42.08 μmol): 1,2-diamino-2-oxoethoxy-1,2-dimethyl ...

[0968] MS m / z(ESI):1269.6[M+H] + .

[0969] Step 6: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0970] 3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-((2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutane- To the reaction mixture, tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (45.0 mg, 35.45 μmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (200 μL) was added, and the mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated, and the residue was diluted with ethyl acetate (10 mL). The pH was adjusted to 8-9 with sodium bicarbonate solution. The layers were separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by high-performance liquid chromatography to obtain the title compound (14 mg, yield: 35.1%).

[0971] MS m / z(ESI):1125.5[M+H] + .

[0972] 1 H-NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.98(s,1H),8.45(d,J=7.2Hz,1H),7.97(dd,J=9.2,6.0Hz,1 H),7.50-7.25(m,6H),7.17(d,J=2.4Hz,1H),4.88-4.78(m,1H),4.59-4.18(m,7H),3.91-3.78(m,4H) ,2.98(d,J=10.8Hz,3H),2.72-2.62(m,1H),2.45(s,4H),2.41-2.20(m,5H),1.98-1.90(m,5H),1.81 -1.43(m,9H),1.36(d,J=6.8Hz,3H),1.31-1.11(m,4H),1.00-0.81(m,9H),0.64(s,2H),0.42(s,2H).

[0973] Example 2: Preparation of (2S,4R)-1-(S)-2-(1-(3,8-diazabicyclo[3.2.1]octyl-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 2)

[0974] Using the synthetic route in Example 1, the first step reaction raw material 2-(piperidin-4-ylmethoxy)ethyl acetate was replaced with 2-(piperidin-4-oxy)ethyl acetate to obtain the title compound (6 mg, yield: 15.1%).

[0975] MS m / z(ESI):1111.5[M+H] + .

[0976] 1 H-NMR (400MHz, DMSO-d6) δ9.03(s,1H),8.99(s,1H),8.46(d,J=4.0Hz,1H),7.97(dd,J=4.0,8.0Hz,1 H),7.48-7.31(m,6H),7.17(d,J=4.0Hz,1H),4.90-4.86(m,1H),4.54-4.18(m,6H),3.99-3.92(m,3H) ,3.21(d,J=8.4Hz,3H),2.88-2.66(m,1H),2.49-2.33(m,4H),2.30-2.21(m,4H),1.98-1.90(m,6H), 1.82-1.45(m,9H),1.36(d,J=10.0Hz,3H),1.26-1.05(m,4H),0.94(s,9H),0.64(s,2H),0.40(s,2H).

[0977] Example 3: Preparation of (2S,4R)-1-(S)-(2-(1-((1-((4-(3,8-diazabicyclo[3.2.1]octyl-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrole-2-carboxamide (Compound 9)

[0978] Step 1: Preparation of tert-butyl 3-(2-((1-((4-((2-ethoxy-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0979] Tert-butyl 3-(7-chloro-2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (200.0 mg, 301.6 μmol) and 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl 1,3,2-Dioxaborolane (162.8 mg, 452 μmol) was dissolved in 1,4-dioxane (5 mL) and water (0.5 mL). Potassium phosphate (190.8 mg, 0.9 mmol) and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (21.99 mg, 30.2 μmol) were added. The atmosphere was purged with nitrogen three times, and the mixture was heated to 100°C with stirring for 6 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 1, volume ratio) to obtain the title compound (130.0 mg, yield: 50.0%).

[0980] MS m / z(ESI):861.4[M+H] + .

[0981] Step 2: Preparation of 2-((1-(1-((((4-(8-(tert-butyloxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetic acid

[0982] Dissolve tert-butyl 3-(2-((1-((4-((2-ethoxy-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (130.0 mg, 151.1 μmol) in methanol (3 mL). Lithium hydroxide monohydrate (31.7 mg, 755.8 μmol) was added to a mixture of 4-[ ...

[0983] MS m / z(ESI):833.4[M+H] + .

[0984] Step 3: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoro-2-((1-(4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0985] 2-((1-(1-((((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetic acid (38 mg, 43.43 μmol), (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide (32 mg, 65 μmol) were added. mol) and diisopropylethylamine (23 mg, 173 μmol) were dissolved in DMF (1.5 mL), cooled to 0°C, and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (25 mg, 65 μmol) was added. The atmosphere was replaced with nitrogen, and the mixture was stirred at room temperature for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 11 / 1, volume ratio) to obtain the title compound (17 mg, yield: 29.6%).

[0986] MS m / z(ESI):1259.6[M+H] + .

[0987] Step 4: Preparation of (2S,4R)-1-(S)-(2-(1-((1-((4-(3,8-diazabicyclo[3.2.1]octyl-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrole-2-carboxamide

[0988] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoro-2-((1-(4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (17 mg, 13 μmol) was dissolved in dichloromethane (1.5 mL), the temperature was cooled to 0°C, trifluoroacetic acid (0.15 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. Aqueous ammonia was added to the reaction solution to adjust the system pH to 8-9, and the reaction solution was concentrated to obtain an oily crude product. The product was purified by high performance liquid chromatography to obtain the title compound (1.4 mg, yield: 9.3%).

[0989] MS m / z(ESI):1115.5[M+H] + .

[0990] 1 H-NMR (400MHz, DMSO-d6) δ9.08(s,1H),8.98(s,1H),8.45(d,J=7.2Hz,1H),7.76(dd,J=9.2,6.0Hz,1H),7.43(d,J=8.0Hz,2H),7.37-7.31 (m,5H),7.02(d,J=2.4Hz,1H),5.14(s,1H),4.88(t,J=7.2Hz,1H),4.52(d,J=9.6Hz,1H),4.46-4.39(m,3H),4.31-4.26(m,2H),3.93(d,J= 12.0Hz,1H),3.63-3.52(m,5H),2.77-2.71(m,1H),2.29(d,J=2.4Hz,3H),2.09(s,6H),1.84-1.77(m,3H),1.67-1.61(m,4H),1.46(d,J=7 .2Hz,2H),1.36(d,J=6.4Hz,4H),1.15(s,1H),1.05(t,J=7.2Hz,1H),0.92-0.80(m,12H),0.72(t,J=7.2Hz,4H),0.64(s,2H),0.40(s,2H).

[0991] Example 4: Preparation of (2S,4R)-1-((2S)-2-(2-((7-((4-(3,8-diazabicyclo[3.2.1]octyl-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl-7-azaspiro[3.5]nonan-2-yl]oxy)acetylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 20)

[0992] Using the synthetic route in Example 1, the first step reaction raw material 2-(piperidin-4-ylmethoxy)ethyl acetate was replaced with (7-azaspiro[3.5]nonan-2-yloxy)ethyl acetate to obtain the title compound (25 mg, yield: 33.3%).

[0993] MS m / z(ESI):1151.5[M+H] + .

[0994] 1 H-NMR (400MHz, DMSO-d6) δ9.02 (s, 1H), 8.98 (s, 1H), 8.45 (d, J = 7.2Hz, 1H), 8.22 (s, 1H), 7. 97(dd,J=9.2,6.4Hz,1H),7.46-7.42(m,2H),7.39-7.30(m,4H),7.17(d,J=2.4Hz,1H),4.8 8(t,J=7.2Hz,1H),4.54-4.40(m,3H),4.26(d,J=12.0Hz,4H),4.02(t,J=7.2Hz,1H),3.93( s,1H),3.80(d,J=2.4Hz,2H),3.65(d,J=12.4Hz,1H),3.60-3.53(m,7H),2.45(s,3H),2.26 (d,J=6.0Hz,3H),2.12-2.04(m,3H),1.75(d,J=8.8Hz,1H),1.68-1.65(m,4H),1.60-1.55( m,2H),1.50-1.43(m,6H),1.37-1.20(m,6H),0.92-0.83(m,9H),0.62(s,2H),0.39(s,2H).

[0995] Example 5: Preparation of (2S,4R)-1-((2S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7)-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide (Compound 36)

[0996] Step 1: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-(4-(2-((S)-1-(2S,4R)-4-hydroxy-2-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0997] 2-((1-((1-(((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro))-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetic acid (70 mg, 0.071 mmol) was dissolved in N,N-dimethylformamide (4 mL) and 2-(7-azo)-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetic acid (70 mg, 0.071 mmol) was added. To the mixture was added (40.5 mg, 0.11 mmol) of N,N-diisopropylethylamine (36.73 mg, 284.20 mmol) and (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide (437.72 mg, 1.43 mmol), followed by stirring at this temperature for 30 minutes and then returning the mixture to room temperature for 3 hours. The reaction mixture was poured into water (20 mL), resulting in the precipitation of a yellow solid product. The filter cake was filtered to obtain the title compound (82 mg, 85.4% yield).

[0998] MS m / z(ESI):1350.7[M+H] + .

[0999] Step 2: Preparation of tert-butyl 3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(2-((S)))-1-((2S,4R)-4-hydroxy-2-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1000] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-(4-(2-((S)-1-(2S,4R)-4-hydroxy-2-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (82 mg, 0.062 mmol) was dissolved in DMF (4 mL), cesium fluoride (92.2 mg, 0.62 mmol) was added, and the mixture was reacted at room temperature for 2 hours. The reaction solution was poured into water (10 mL) to precipitate a yellow solid product, which was filtered and retained by filtration to obtain the title compound (46 mg, yield: 63.4%).

[1001] MS m / z(ESI):1194.5[M+H] + .

[1002] Step 3: Preparation of (2S,4R)-1-((2S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7)-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide

[1003] Tert-butyl 3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(2-((S)))-1-((2R,4S)-4-hydroxy-2-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (46 mg, 0.039 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (0.3 mL) was added, and the reaction was carried out at room temperature for 2 hours. The residue was concentrated and the crude product was purified by high performance liquid chromatography to give the title compound (7 mg, yield: 14.8%).

[1004] MS m / z(ESI):1050.5[M+H] + .

[1005] 1 H-NMR (400MHz, CD3OD) δ8.93 (d, J=4.0Hz, 1H), 7.82-7.75 (m, 5H), 7.47-7.38 (m, 3H), 7.36-7.28 (m, 2H ),7.22(dd,J=8.0,4.0Hz,1H),4.72-4.33(m,12H),4.03(dd,J=20.0,8.0Hz,2H),3.84(dd,J=16.0,8. 0Hz,2H),3.68(d,J=6.4Hz,4H),3.55-3.47(m,2H),3.02(s,2H),2.60(s,2H),2.28-2.16(m,2H),2.12 -1.96(m,4H),1.88-1.71(m,6H),1.31(d,J=12.4Hz,2H),1.07-0.98(m,9H),0.74(s,2H),0.54(s,2H).

[1006] Example 6: Preparation of (2S,4R)-1-(S)-2-(1-(3,8-diazabicyclo[3.2.1]octyl-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (Compound 35)

[1007] The synthetic route in Example 5 was used to replace the first step reaction raw material (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide with (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutyryl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide to give the title compound (3 mg, yield: 21.7%).

[1008] MS m / z(ESI):1108.5[M+H] + .

[1009] 1 H-NMR(400MHz,DMSO-d6)δ9.03(s,1H),8.45(d,J=7.6Hz,1H),7.99-7.95(m,1H),7.53-7.49(m,4 H),7.44-7.35(m,3H),7.35-7.27(m,3H),4.56-4.43(m,3H),4.34-4.23(m,4H),3.94-3.88(m,3H ),3.57-3.46(m,5H),2.80-2.65(m,4H),2.35-2.32(m,2H),2.12-2.03(m,4H),1.88-1.78(m,3H) ,1.72-1.68(m,4H),1.40-1.37(m,5H),1.26-1.21(m,4H),0.93(s,9H),0.64(s,2H),0.41(s,2H).

[1010] Example 7: Preparation of (2S,4R)-1-((S)-2-(3-(4-((1-(((3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperazin-1-yl)propionamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(S)-((4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 33)

[1011] Using the synthetic route in Example 1, the first step reaction raw material 2-(piperidin-4-ylmethoxy)ethyl acetate was replaced with 3-(piperazin-1-yl)propionic acid ethyl ester to obtain the title compound (8 mg, yield: 11.3%).

[1012] MS m / z(ESI):1110.5[M+H] +.

[1013] 1 H-NMR (400MHz, DMSO-d6) δ9.03(s,1H),8.99(s,1H),8.41(t,J=12.0Hz,2H),8.34(s,2H),7.97(dd,J=4.0 ,8.0Hz,1H),7.48-7.36(m,6H),7.17(d,J=4.0Hz,1H),4.90-4.87(m,2H),4.51-4.39(m,3H),4.33-4.25( m,4H),3.94(s,1H),3.66-3.41(m,8H),2.69-2.61(m,2H),2.45-2.40(m,4H),2.36-2.25(m,6H),2.04-1. 99(m,3H),1.81-1.74(m,2H),1.67(s,4H),1.37(d,J=4.0Hz,3H),0.94(s,9H),0.63(s,2H),0.39(s,2H).

[1014] Example 8: Preparation of (2S,4R)-1-(S)-(2-(1-((1-((4-(3,8-diazabicyclo[3.2.1]octyl-3-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrole-2-carboxamide (Compound 50)

[1015] Using the synthetic route in Example 3, the first step reaction raw material 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was replaced with (2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)boronic acid to give the title compound (37 mg, yield: 49.2%).

[1016] MS m / z(ESI):1093.5[M+H] + .

[1017] 1H-NMR (400MHz, DMSO-d6) δ9.07 (s, 1H), 8.99 (s, 1H), 8.47 (d, J = 8.0Hz, 1H), 7.92 (s, 2H), 7.46-7.30 (m, 5H), 7.1 7(t,J=8.0Hz,1H),5.15(s,1H),4.90-4.86(m,1H),4.53(d,J=12.0Hz,1H),4.46-4.39(m,3H),4.27(s,3H),3.99 -3.88(m,3H),3.59-3.51(m,8H),2.73-2.67(m,2H),2.45(s,3H),2.33-2.30(m,2H),2.09-2.04(m,3H),1.81-1 .72(m,3H),1.62-1.58(m,4H),1.38-1.33(m,2H),1.35(d,J=4.0Hz,3H),0.92(s,9H),0.64(s,2H),0.40(s,2H).

[1018] Example 9: Preparation of (2S,4R)-1-((2S)-2-(2-((1-((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-chloro-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoroquinazolin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 60)

[1019] Using the synthetic route in Example 3, the first step reaction raw material 3-(7-chloro-2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester was replaced with 3-(7-bromo-6-chloro-2-((1-((4-(2-ethoxy-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester to give the title compound (15 mg, yield: 15.2%).

[1020] MS m / z(ESI):1148.5[M+H] + .

[1021] 1H-NMR (400MHz, DMSO-d6) δ9.97(s,1H),8.99(s,1H),8.47(d,J=8.0Hz,1H),7.90(s,1H),7.79-7.75(m,1H),7.46-7.30( m,6H),6.92(d,J=4.0Hz,1H),5.15(s,1H),4.90-4.86(m,1H),4.53(d,J=8.0Hz,1H),4.44(t,J=8.0Hz,1H),4.29-4.23( m,5H),3.96-3.88(m,2H),3.57-3.45(m,5H),2.72-2.67(m,2H),2.45(s,3H),2.33-2.03(m,7H),1.85-1.75(m,3H),1.7 0-1.65(m,4H),1.47(d,J=8.0Hz,3H),1.36(d,J=8.0Hz,3H),0.92(s,9H),0.75-0.66(m,3H),0.63(s,2H),0.38(s,2H).

[1022] Example 10: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoroquinazolin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 106)

[1023] Using the synthetic route in Example 3, the first step reaction raw material 3-(7-chloro-2-((1-((4-((2-ethoxy-2-oxoethoxy)methyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester was replaced with 3-(7-bromo-2-((1-((4-(2-ethoxy-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester to give the title compound (4 mg, yield: 7.3%).

[1024] MS m / z(ESI):1114.5[M+H] + .

[1025] 1H-NMR (400MHz, DMSO-d6) δ9.97 (s, 1H), 8.99 (s, 1H), 8.47 (d, J = 8.0Hz, 1H), 7.81-7.74 (m, 1H), 7.44-7.29 (m, 6H), 7.22-7 .10(m,2H),6.92(d,J=4.0Hz,1H),5.15(s,1H),4.90-4.86(m,1H),4.50(d,J=8.0Hz,1H),4.44(t,J=8.0Hz,1H),4.27-4. 23(m,5H),3.98-3.88(m,2H),3.57-3.43(m,5H),2.78-2.66(m,2H),2.45(s,3H),2.33-2.03(m,7H),1.85-1.75(m,3H),1 .70-1.65(m,4H),1.47(d,J=8.0Hz,3H),1.36(d,J=8.0Hz,3H),0.92(s,9H),0.73-0.66(m,3H),0.63(s,2H),0.39(s,2H).

[1026] Example 11: Preparation of (2S,4R)-1-((S)-2-(4-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 136)

[1027] Step 1: Preparation of tert-butyl 3-(7-chloro-8-fluoro-2-((1-((1-((S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1028] Tert-butyl 3-(7-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (400.0 mg, 699.3 μmol) and (S)-methyl 3,3-dimethyl-2-(4-((piperidin-4-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoate (326 mg, 1.05 mmol) were dissolved in DMF (5 mL), potassium carbonate (289.9 mg, 2.1 mmol) and potassium iodide (116.1 mg, 699.3 μmol) were added, and the mixture was reacted at 55°C for 4 hours. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (300 mg, yield: 54.5%).

[1029] MS m / z(ESI):786.3[M+H] + .

[1030] Step 2: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(1-((4-((1-(S)-1-methoxy-3,3-dimethyl-1-oxobutane-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1031] tert-Butyl 3-(7-chloro-8-fluoro-2-((1-((1-((S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (300 mg, 382 μmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl A mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was dissolved with 1,4-dioxane (5 mL), potassium phosphate (243 mg, 1.15 mmol) and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (27.8 mg, 38.2 μmol). The atmosphere was purged with nitrogen three times, and the mixture was heated to 100°C with stirring for 3.5 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 3 / 1, volume ratio) to obtain the title compound (220 mg, yield: 50.7%).

[1032] MS m / z(ESI):1136.5[M+H] + .

[1033] Step 3: Preparation of (2S)-2-(4-((1-(((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy))-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-3,3-dimethylbutanoic acid

[1034] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(1-((4-((1-(S)-1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (220 mg, 194 μmol) was dissolved in methanol (4 mL) and water (0.8 mL), and lithium hydroxide monohydrate (40.6 mg, 968 μmol) was added, and the mixture was stirred at 25°C for 2 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 6 with 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate (10 mL). The organic phase was collected and washed once with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give the title compound (188 mg, yield: 86.6%).

[1035] MS m / z(ESI):1122.6[M+H] + .

[1036] Step 4: Preparation of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-((4-((1-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1037] 2-((1-((1-(((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro))-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)methoxy)acetic acid (188.0 mg, 168 μmol) and ( 2S,4R)-4-Hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (55.6 mg, 168 μmol) was dissolved in DMF (2 mL), and N,N-diisopropylethylamine (86.8 mg, 672 μmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (95.8 mg, 252 μmol) were added at 0°C. The mixture was stirred at 25°C for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (130 mg, yield: 54.2%).

[1038] MS m / z(ESI):1435.7[M+H] + .

[1039] Step 5: Preparation of tert-butyl 3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(((S)-1-((2S,4R)-4-hydroxy-2-((((S))-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1040] 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-((1-((4-((1-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl) Tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 69.7 μmol) was dissolved in DMF (1 mL) and cesium fluoride (53.0 mg, 348 μmol) was added. The mixture was stirred at 25°C under nitrogen for 2 hours. Water (10 mL) was added to the reaction mixture, causing a white solid to precipitate. The filter cake was collected by filtration and dried to give the title compound (48 mg, 53.9% yield).

[1041] MS m / z(ESI):1279.6[M+H] + .

[1042] Step 6: Preparation of (2S,4R)-1-((S)-2-(4-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[1043] 3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(((S)-1-((2S,4R)-4-hydroxy-2-((((S))-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutane-2- To the mixture of tert-butyl (48 mg, 37.5 μmol) (48 mg, 37.5 μmol) and (2 mL) dichloromethane (2 mL), trifluoroacetic acid (200 μL) was added, and the mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated, and the residue was diluted with ethyl acetate (10 mL). The pH was adjusted to 8-9 with sodium bicarbonate solution. The layers were separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by high-performance liquid chromatography to obtain the title compound (8 mg, yield: 18.7%).

[1044] MS m / z(ESI):1135.5[M+H] + .

[1045] 1 H-NMR(400MHz,DMSO-d6)δ9.03(s,1H),8.99(s,1H),8.54(d,J=8.0Hz,1H),8.32-8.27(m,2H),8.22(s,1H) ,7.96(d,J=8.0Hz,1H),7.50-7.30(m,5H),7.17(d,J=4.0Hz,1H),5.48(s,1H),4.94-4.90(m,1H),4.53-4. 41(m,4H),4.29-4.25(m,3H),3.94(s,1H),3.67-3.51(m,9H),2.75-2.67(m,3H),2.46-2.25(m,4H),2.06( d,J=8.0Hz,2H),1.80-1.74(m,3H),1.67(s,2H),1.53-1.34(m,5H),0.98(s,9H),0.63(s,2H),0.40(s,2H).

[1046] Example 12: Preparation of (2S,4R)-1-((S)-2-(4-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-ylmethyl)-1H-1,2,3-triazol-1-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 137)

[1047] Using the synthetic route in Example 11, the first step reaction raw material (S)-3,3-dimethyl-2-(4-((piperidin-4-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoic acid methyl ester was replaced with (S)-3,3-dimethyl-2-(4-(piperidin-4-ylmethyl)-1H-1,2,3-triazol-1-yl)butanoic acid methyl ester to obtain the title compound (3 mg, yield: 11.2%).

[1048] MS m / z(ESI):1119.5[M+H] + .

[1049] 1 H-NMR(400MHz,DMSO-d6)δ9.04(s,1H),8.99(s,1H),8.51(d,J=8.0Hz,1H),8.31-8.26(m,2H),8.19(s,1H) ,7.96(d,J=8.0Hz,1H),7.49-7.31(m,5H),7.17(d,J=4.0Hz,1H),5.43(s,1H),4.94-4.91(m,1H),4.53-4. 41(m,4H),4.29-4.25(m,3H),3.94(s,1H),3.65-3.56(m,9H),2.75-2.63(m,3H),2.46-2.24(m,4H),2.06( d,J=8.0Hz,2H),1.79-1.74(m,3H),1.71(s,2H),1.53-1.34(m,5H),0.95(s,9H),0.63(s,2H),0.40(s,2H).

[1050] Example 13: Preparation of (2S,4R)-1-((2S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(4-chlorophenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (Compound 34)

[1051] The synthetic route in Example 5 was used to replace the first step reaction raw material (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(naphthalen-2-ylmethyl)pyrrolidine-2-carboxamide with (2S,4R)-1-((2S)-2-amino-3,3-dimethylbutyryl)-N-((S)-1-(4-chlorophenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide to give the title compound (5 mg, yield: 28.7%).

[1052] MS m / z(ESI):1048.5[M+H] + .

[1053] 1 H-NMR (400MHz, CD3OD) δ9.02 (s, 1H), 7.86 (dd, J = 4.0, 8.0Hz, 1H), 7.38-7.19 (m, 9H), 4.70-4.35 (m, 10H), 4.07-3.96 (m, 3H), 3.84-3.70 (m, 7H) ,3.52(dd,J=8.0,12.0Hz,3H),1.90(m,12H),1.51(d,J=8.0Hz,1H),1.4 4(d,J=8.0Hz,3H),1.29(s,1H),1.01(s,9H),0.79(s,2H),0.60(s,2H).

[1054] Example 14: Preparation of (2S,4R)-1-((2S)-2-(2-(2-((1-((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl-2-azaspiro[3.5]nonan-7-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 31)

[1055] Using the synthetic route in Example 1, the first step reaction raw material 2-(piperidin-4-ylmethoxy)ethyl acetate was replaced with 2-(2-azaspiro(3.5)non-7-yl)ethyl acetate to obtain the title compound (25 mg, yield: 26.8%).

[1056] MS m / z(ESI):1135.5[M+H] + .

[1057] 1 H-NMR(400MHz,CD3OD)δ9.05(s,1H),8.99(s,1H),8.88-8.83(m,1H),8.53(s,1H),7.89-7 .84(m,1H),7.44-7.30(m,5H),7.21(d,J=2.4Hz,1H),4.60(s,2H),4.58-4.53(m,2H),4.42 (d,J=12.0Hz,2H),4.29(d,J=12.0Hz,1H),3.87(d,J=12.0Hz,2H),3.73(d,J =8.0Hz,7H),3.35(s,1H),3.19(s,2H),2.48-2.44(m,3H),2.23-2.10(m,4H) ,2.03(s,3H),1.92(t,J=4.0Hz,4H),1.80(d,J=12.0Hz,3H),1.68(s,4H),1. 52(dd,J=8.0,12.4Hz,6H),1.28(s,1H),1.00(s,9H),0.81(d,J=16.0Hz,4H).

[1058] Example 15: Preparation of (2S,4R)-1-((2S)-2-(2-((9-((1-(((4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-9-azabicyclo[3.3.1]nonan-3-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 25)

[1059] Using the synthetic route in Example 1, the first step reaction raw material 2-(piperidin-4-ylmethoxy)ethyl acetate was replaced with 2-(9-azabicyclo(3.3.1)nonan-3-yloxy)ethyl acetate to obtain the title compound (41 mg, yield: 35.8%).

[1060] MS m / z(ESI):1151.5[M+H] + .

[1061] 1 H-NMR (400MHz, CD3OD) δ9.05(s,1H),8.90(s,1H),8.59(d,J=8.0Hz,1H),7.88(d,J=4.0Hz,1H),7.53(d,J=8.0Hz,1H),7.42(d,J=8.0Hz,4H),7.35 (d,J=8.0Hz,2H),7.20(d,J=4.0Hz,1H),4.99(d,J=8.0Hz,2H),4.84-4.6 3(m,3H),4.59-4.50(m,3H),4.46(d,J=12.0Hz,1H),4.29(s,2H),4.17-4. 11(m,1H),4.06-3.88(m,4H),3.87-3.71(m,3H),3.61-3.38(m,4H),2.96 -2.80(m,2H),2.47(d,J=4.0Hz,2H),2.15(dd,J=2.4,8.0Hz,8H),1.97(d d,J=8.0,12.0Hz,3H),1.75(s,1H),1.57(dd,J=4.0,8.0Hz,2H),1.51-1. 48(m,2H),1.31(d,J=16.0Hz,2H),1.04(s,9H),0.79(s,2H),0.60(s,2H).

[1062] Example 16: Preparation of (2S,4R)-1-((S)-2-(3-(1-(((4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)propionamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 7)

[1063] Using the synthetic route in Example 1, the first step reaction raw material 2-(piperidin-4-ylmethoxy)ethyl acetate was replaced with 3-(piperidin-4-yl)ethyl propionate to obtain the title compound (15 mg, yield: 38.9%).

[1064] MS m / z(ESI):1109.5[M+H] + .

[1065] 1 H-NMR (400MHz, CD3OD) δ9.06 (s, 1H), 8.87 (s, 1H), 8.50 (s, 1H), 7.87 (d, J = 4.0Hz, 1H), 7.46-7.39 (m, 4H ),7.34(d,J=8.0Hz,2H),7.21(d,J=4.0Hz,1H),5.03-4.98(m,1H),4.68-4.32(m,8H),3.91-3.67(m,8H) ,3.34(d,J=12.0Hz,2H),3.13(s,2H),2.84(s,2H),2.49-2.44(m,3H),2.30(s,2H),2.20(dd,J=8.0,12 .0Hz,1H),2.05-1.79(m,7H),1.53(dd,J=8.0,12.0Hz,6H),1.31(d,J=16.0Hz,2H),1.04-0.77(m,13H).

[1066] Example 17: Preparation of (2S,4R)-1-((S)-2-(2-((3-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl-9-oxy)acetamido)-3,3-dimethylbutanoyl-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 40)

[1067] Step 1: Preparation of tert-butyl 3-(7-chloro-2-((1-((9-(2-ethoxy-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1068] Tert-butyl 3-(7-chloro-8-fluoro-2-((1-(((methylsulfonyl)oxy)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (270 mg, 472 μmol) and ethyl (7-azaspiro[3.5]nonan-2-yloxy)acetate (241.1 mg, 943.9 μmol) were dissolved in DMF (10 mL), potassium carbonate (289.9 mg, 2.1 mmol) and potassium iodide (116.1 mg, 699.3 μmol) were added, and the mixture was reacted at 50°C for 4 hours. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (230 mg, yield: 60.6%).

[1069] MS m / z(ESI):731.1[M+H] + .

[1070] Step 2: Preparation of tert-butyl 3-(2-((1-((9-(2-ethoxy-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1071] Tert-butyl 3-(7-chloro-2-((1-((9-(2-ethoxy-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (190.0 mg, 259.8 μmol) and 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetrakis were added. Methyl-1,3,2-dioxaborolane (187.2 mg, 519.6 μmol) was dissolved in 1,4-dioxane (5 mL) and water (0.5 mL). Potassium phosphate (165.4 mg, 779.4 μmol) and [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (18.9 mg, 25.98 μmol) were added. The atmosphere was purged with nitrogen three times, and the mixture was heated to 100°C with stirring for 4 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 1, volume ratio) to obtain the title compound (130.0 mg, yield: 53.8%).

[1072] MS m / z(ESI):929.5[M+H] + .

[1073] Step 3: Preparation of 2-((3-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl)oxy)acetic acid

[1074] Tert-butyl 3-(2-((1-((9-(2-ethoxy-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (130.0 mg, 139.9 μmol) was dissolved in methanol (3 mL) and water (1 mL), and lithium hydroxide monohydrate (29.36 mg, 699.6 μmol) was added, and the mixture was stirred at 25°C for 2 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 6 with 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate (10 mL). The organic phase was collected and washed once with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give the title compound (110 mg, yield: 87.3%).

[1075] MS m / z(ESI):901.1[M+H] + .

[1076] Step 4: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((9-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((((2S)-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)-3-azaspiro[5.5]undec-3-yl)methyl)cyclopropyl)methoxy]pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1077] 2-((3-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl)oxy)acetic acid (110.0 mg, 122.1 μmol) and (2S,4R)-1-[(2S)-2-amino Dissolve 4-hydroxy-N-[(1S)-1-[4-(4-methylthiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide (70.47 mg, 146.5 μmol) in DMF (2 mL), cool to 0°C, add N,N-diisopropylethylamine (72.43 mg, 560.4 μmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (79.9 mg, 210.15 μmol), and stir at 25°C for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to give the title compound (120 mg, yield: 74.0%).

[1078] MS m / z(ESI):1327.7[M+H] + .

[1079] Step 5: Preparation of (2S,4R)-1-((S)-2-(2-((3-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-3-azaspiro[5.5]undec-9-yl-9-oxy)acetamido)-3,3-dimethylbutanoyl-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[1080] 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((9-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((((2S)-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)-3-azaspiro[5-yl]- Tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (35 mg, 26.36 μmol) (35 mg, 26.36 μmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was allowed to react at room temperature for 2 hours. The mixture was concentrated, and the crude product was purified by HPLC to obtain the title compound (4 mg, yield: 12.8%).

[1081] MS m / z(ESI):1183.6[M+H] + .

[1082] 1 H-NMR (400MHz, CD3OD) δ9.09 (s, 1H), 8.87 (s, 1H), 7.70-7.66 (m, 1H), 7.53-7.16 (m, 6H), 7.04 (d, J = 2.4Hz ,1H),5.02-4.97(m,2H),4.77-4.49(m,6H),4.45(s,2H),4.07-3.93(m,2H),3.84(d,J=10.8Hz,1H),3.79- 3.61(m,7H),3.49-3.46(m,2H),3.24-2.99(m,4H),2.47(d,J=2.0Hz,3H),2.22-2.17(m,2H),1.94-1.91(m ,2H),1.90-1.84(m,4H),1.85-1.45(m,14H),1.33-1.28(m,4H),1.02(d,J=5.2Hz,7H),0.95–0.74(m,6H).

[1083] Example 18: Preparation of (2S,4R)-1-((S)-2-(2-((2-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-2-azaspiro[3.5]nonan-7-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 41)

[1084] Using the synthetic route in Example 17, the first step reaction raw material (7-azaspiro[3.5]nonan-2-yloxy)ethyl acetate was replaced with 2-((2-azaspiro[3.5]nonan-7-yl)oxy)ethyl acetate to obtain the title compound (4 mg, yield: 35.6%).

[1085] MS m / z(ESI):1155.5[M+H] + .

[1086] 1 H-NMR(400MHz,CD3OD)δ9.09(s,1H),8.87(s,1H),8.52(s,1H),7.68(dd,J=6.0,8.8Hz,1H),7.48- 7.36(m,3H),7.34-7.18(m,2H),7.05(d,J=2.8Hz,1H),4.99(d,J=7.2Hz,3H),4.67-4.57(m,10H), 4.44-4.35(m,2H),4.01-3.69(m,7H),3.66(s,6H),3.21(s,2H),2.47(s,3H),2.26-2.13(m,2H),2 .09-1.75(m,8H),1.57-1.48(m,4H),1.33-1.28(m,3H),1.01(d,J=3.6Hz,9H),0.84-0.77(m,5H).

[1087] Example 19: Preparation of (2S,4R)-1-((S)-2-(2-((2-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-2-azaspiro[3.5]nonan-7-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 42)

[1088] Using the synthetic route in Example 17, the first step reaction raw material (7-azaspiro[3.5]nonan-2-yloxy)ethyl acetate was replaced with 2-((2-azaspiro[3.5]nonan-7-yl)methoxy)ethyl acetate to obtain the title compound (3 mg, yield: 14.7%).

[1089] MS m / z(ESI):1169.5[M+H] + .

[1090] 1 H-NMR (400MHz, CD3OD) δ9.08(s,1H),8.87(s,1H),7.69-7.65(m,1H),7.53-7. 17(m,6H),7.04(d,J=2.4Hz,1H),5.03-4.97(m,2H),4.71-4.29(m,8H),4.10- 3.46(m,12H),3.35-3.32(m,2H),3.13(s,2H),2.47(s,3H),2.26-1.71(m,13H ),1.68-1.42(m,6H),1.33-1.28(m,3H),1.21-0.94(m,9H),0.91-0.77(m,6H).

[1091] Example 20: Preparation of (2S,4R)-1-((S)-2-(2-((2-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-2-azaspiro[3.3]hept-6-yl)methoxy)acetylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 49)

[1092] Using the synthetic route in Example 17, the first step reaction raw material (7-azaspiro[3.5]non-2-yloxy)ethyl acetate was replaced with 2-((2-azaspiro[3.3]hept-6-yl)methoxy)ethyl acetate to obtain the title compound (7 mg, yield: 26.7%).

[1093] MS m / z(ESI):1141.5[M+H] + .

[1094] 1 H-NMR(400MHz,CD3OD)δ9.08(s,1H),8.87(s,1H),7.69-7.65(m,1H),7.45-7.20(m,6H),7.05(d, J=2.4Hz,1H),5.00-4.95(m,2H),4.69-4.50(m,4H),4.47-4.30(m,3H),4.23-3.77(m,8H),3.48(d ,J=5.6Hz,2H),3.25-3.11(m,2H),2.54-2.33(m,7H),2.27-2.08(m,4H),1.90(d,J=2.8Hz,2H),1 .85-1.77(m,4H),1.57-1.47(m,4H),1.33-1.28(m,2H),1.00(d,J=4.0Hz,9H),0.81-0.78(m,6H).

[1095] Example 21: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (Compound 58)

[1096] Step 1: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(2-(((S)-1-((2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1097] 2-((1-(1-((((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetic acid (40 mg, 48.02 μmol), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (33.3 mg, 72.03 μmol) were added.

[0014] 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (25 mg, 65 μmol) and N,N-diisopropylethylamine (23 mg, 173 μmol) were dissolved in DMF (3 mL). The temperature was lowered to 0°C, and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (25 mg, 65 μmol) was added. The atmosphere was replaced with nitrogen three times, and the mixture was stirred at room temperature for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (44 mg, yield: 71.7%).

[1098] MS m / z(ESI):1277.6[M+H] + .

[1099] Step 2: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[1100] Tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(2-(((S)-1-((2S,4R)-2-(((S)-1-(2-fluoro-4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (44 mg, 34.44 μmol) was dissolved in dichloromethane (3 mL), the temperature was cooled to 0°C, trifluoroacetic acid (1 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. Aqueous ammonia was added to the reaction solution to adjust the pH of the system to 8-9. The reaction solution was concentrated to obtain an oily crude product, which was purified by HPLC to obtain the title compound (9 mg, yield: 26.7%).

[1101] MS m / z(ESI):1133.2[M+H] + .

[1102] 1 H-NMR(400MHz,CD3OD)δ9.07(s,1H),8.90(s,1H),7.69-7.65(m,1H),7.48-7.14(m ,5H),7.04(s,1H),5.20-5.17(m,1H),4.72-4.28(m,9H),4.13-3.96(m,2H),3.85- 3.72(m,5H),3.58-3.44(m,2H),3.13-2.99(m,2H),2.86-2.66(m,3H),2.48(d,J=3 .6Hz,4H),2.30-1.76(m,11H),1.60-1.29(m,5H),1.02(m,9H),0.82-0.64(m,6H).

[1103] Example 22: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (Compound 61)

[1104] Step 1: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxy-methoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(2-((S)-1-(2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1105] 2-((1-(1-((((4-(8-(tert-Butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethyloxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methylpiperidin-4-yl)oxy)acetic acid (50 mg, 60.01 μmol), (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (31.8 mg, 72.1 μmol) and N N-Diisopropylethylamine (23.3 mg, 180 μmol) was dissolved in DMF (3 mL), cooled to 0°C, and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (34.2 mg, 90.1 μmol) was added. The atmosphere was replaced with nitrogen three times, and the mixture was stirred at room temperature for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (50 mg, yield: 66.3%).

[1106] MS m / z(ESI):1256.6[M+H] + .

[1107] Step 2: Preparation of (2S,4R)-1-((S)-2-(2-((1-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)piperidin-4-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide

[1108] tert-Butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxy-methoxy)naphthalen-1-yl)-8-fluoro-2-((1-((4-(2-((S)-1-(2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)methyl)cyclopropyl)methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 39.8 μmol) was dissolved in dichloromethane (3 mL), the temperature was cooled to 0°C, trifluoroacetic acid (1 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. Aqueous ammonia was added to the reaction solution to adjust the pH of the system to 8-9. The reaction solution was concentrated to obtain an oily crude product, which was purified by HPLC to obtain the title compound (6 mg, yield: 13.5%).

[1109] MS m / z(ESI):1112.5[M+H] + .

[1110] 1H-NMR (400MHz, CD3OD) δ9.06 (s, 1H), 7.69-7.65 (m, 1H), 7.61-7.10 (m, 10H), 7.05 (d, J = 2.4Hz, 1H),5.04-4.96(m,2H),4.71-4.51(m,4H),4.48-4.40(m,2H),4.08-3.79(m,2H),3.87-3.67(m, 6H),3.59-3.48(m,2H),3.13-3.05(m,2H),2.87-2.32(m,6H),2.24-2.17(m,2H),2.10-1.68(m ,9H),1.58-1.49(m,3H),1.33-1.28(m,2H),1.07-0.98(m,8H),0.81-0.78(m,4H),0.61(s,2H).

[1111] Example 23: Preparation of (2S,4R)-1-((S)-2-(2-((7-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-7-azaspiro[3.5]nonan-2-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (Compound 63)

[1112] Step 1: Preparation of tert-butyl 3-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((1-((2-(2-(((S)-1-((2S,4R)-2-(((S)-1-(2'-fluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)-7-azaspiro[3.5]nonan-7-yl)methyl)cyclopropyl)methoxy)pyridone[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[1113] 2-((7-((1-(((4-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)cyclopropyl)methyl)-7-azaspiro[3.5]nonan-2-yl)oxy)acetic acid (40 mg, 45.82 μmol), (2S,4R)-1-[(2S)-2-amino-3, 3-Dimethylbutyryl]-N-[(1S)-1-[4-(2-fluorophenyl)phenyl]ethyl]-4-hydroxypyrrolidine-2-carboxamide (24.3 mg, 54.9 μmol) and N,N-diisopropylethylamine (23 mg, 173 μmol) were dissolved in DMF (3 mL). The temperature was cooled to 0°C, and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (25 mg, 65 μmol) was added. The atmosphere was replaced with nitrogen three times, and the mixture was stirred at room temperature for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1, volume ratio) to obtain the title compound (25 mg, yield: 42.1%).

[1114] MS m / z(ESI):1296.6[M+H] + .

[1115] Step 2 Preparation of (2S,4R)-1-((S)-2-(2-((7-((1-(((4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrim...

Claims

1. A compound or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of formula (I): in: is a single bond or a double bond; When X 1 With X 2 between When it is a single bond, X 1 Selected from C(R 7 )2 and C(O); and X 2 Selected from N and CR 7 ; When X 1 With X 2 between When it is a double bond, X 1 Selected from CR 8 and N; and X 2 is C; When X 3 With X 4 between When it is a single bond, X 3 and X 4 Each independently selected from C(R 7 )2 and O; When X 3 With X 4 between When it is a double bond, X 3 and X 4 Each independently selected from CR 8 and N; Ring A is C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups; Ring B is a 3-12 membered nitrogen-containing heterocyclic group; L is selected from C 1-3 Alkylene and -C 1-2 Alkylene-OC 1-2 Alkylene-; L 1 Selected from O, S and NR 9 ; L 2 is a covalent bond, or is selected from C 1-6 Alkylene and halogenated C 1-6 alkylene; L 3 is a covalent bond, or is selected from C 1-6 Alkylene and halogenated C 1-6 alkylene; L 4 is a covalent bond, or is selected from O, NR 10 、C 1-6 Alkylene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -C 1-6 Alkylene-NR 10 -、-C 1-6 Alkylene-OC 1-6 Alkylene-, C 3-6 Cycloalkyl and 3-10 membered heterocyclic group, wherein the cycloalkyl and heterocyclic group are each optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups; L 5 Selected from -C(=O)-NR 11 -、-C 1-6 Alkylene-C(=O)-NR 11 -、-NR 11 -C(=O)-, -C 1-6 Alkylene-NR 11 -C(=O)- and 5-10 membered heteroaryl, said heteroaryl being optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups; Each R 1 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 1-6 alkyl halide; R 2 Selected from C 6-10 Aryl and 5-10 membered heteroaryl, each of which is optionally substituted by one or more R 12 replace; R 3 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 3-6 Cycloalkyl; R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-6 Alkylene -OH and C 3-6 Cycloalkyl; R 5 selected from halogen, phenyl and 5-6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted by one or more selected from halogen, hydroxy, cyano, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups; Each R 6 independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 haloalkyl; or R 5 and adjacent R 6 and the carbon atoms to which they are connected together form a benzene ring, which is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups; Each R 7 independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 haloalkyl; or two R on the same carbon atom 7 The carbon atoms they are connected to form carbonyl groups, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group; Each R 8 independently selected from hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl and -OC 3-6 Cycloalkyl; R 9 Selected from hydrogen and C 1-6 alkyl; R 10 Selected from hydrogen and C 1-6 alkyl; R 11 Selected from hydrogen and C 1-6 alkyl; When present, each R 12 Each independently selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl or heteroaryl are each optionally substituted by one or more selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Substitution of haloalkyl groups; m is selected from 0, 1, 2, 3 and 4; n is selected from 0, 1, 2, 3 and 4.

2. The compound of claim 1 or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of Formula (IA), (IB), (IC) or (ID): Among them, ring A, ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 , L 1 , L 2 , L 3 , L 4 , L 5 and n as defined in claim 1.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein each R 8 are independently selected from hydrogen and halogen.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein R 2 is optionally replaced by 1-3 R 12 substituted naphthyl, benzothiazolyl and benzopyrazolyl, and R 12 Each is independently selected from F, Cl, Br, I, methyl, ethyl, isopropyl, ethynyl, amino and hydroxyl, preferably, R 2 Selected from 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein L 1 It is -O-.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein L 2 C 1-3 Alkylene, L 3 C 1-3 Alkylene, Ring A is C 3-6 Cycloalkyl; preferably L 2 -CH2-, L 3 is -CH2-, and ring A is cyclopropyl or cyclobutyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein Ring B is selected from a 3-8 membered nitrogen-containing monoheterocyclic group, a 5-12 membered nitrogen-containing bridged heterocyclic group, a 6-12 membered nitrogen-containing heterocyclic group and a 7-12 membered nitrogen-containing spiro heterocyclic group; preferably, Ring B is selected from a 4-6 membered nitrogen-containing monoheterocyclic group, a 7-9 membered nitrogen-containing bridged heterocyclic group, a 6-8 membered nitrogen-containing heterocyclic group and a 7-11 membered nitrogen-containing spiro heterocyclic group.

8. The compound of claim 7 or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein ring B is selected from 9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein L 4 is a covalent bond, or is selected from C 1-6 Alkylene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O- and -C 1-6 Alkylene-OC 1-6 Alkylene-; preferably, L 4 is a covalent bond, or is selected from -CH2-, -CH2-CH2-, -O-CH2-, -CH2-O- and -CH2-O-CH2-.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein L 5 is selected from -C(=O)-NH- and 5-10 membered heteroaryl; preferably, L 5 Selected from -C(=O)-NH-, 11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein R 3 C 1-6 Alkyl or C 3-6 Cycloalkyl, R 4 For hydrogen, -C 1-6 Alkylene -OH or C 1-6 Alkyl, R 5 is fluorine, chlorine, phenyl optionally substituted by one or two halogens, or a 5-membered heteroaryl optionally substituted by one or two methyl or ethyl groups, R 6 is hydrogen, fluorine, chlorine or methoxy, n is 0 or 1; or R 5 and adjacent R 6 and the carbon atoms to which they are attached together form a benzene ring optionally substituted by one or two halogens; preferably, R 3 is tert-butyl or cyclohexyl, R 4 is hydrogen, -CH2OH or methyl, R 5 is chlorine, phenyl optionally substituted by fluorine or chlorine, or thiazolyl or pyrazolyl optionally substituted by methyl or ethyl, each R 6 are independently selected from hydrogen, fluorine, chlorine and methoxy, n is 0 or 1; or R 5 and adjacent R 6 and the carbon atoms to which they are attached together form a benzene ring optionally substituted by fluorine or chlorine.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, wherein the fragment Selected from Preferably selected from 13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the compound is selected from:

14. A pharmaceutical composition comprising a prophylactically and / or therapeutically effective amount of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, and one or more pharmaceutically acceptable carriers.

15. Use of the compound according to any one of claims 1 to 13 or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for preventing and / or treating KRAS G12D-mediated related diseases (preferably tumors or cancers).

16. A method for preparing the compound of claim 2, comprising the steps shown in the following scheme: Route 1 in Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 and n is as defined in any one of claims 1 to 13; L 5 -C(=O)-NR 11 -; LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group; PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl; The method of route 1 comprises the following steps: 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3; 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5; 3) Compound IB-5 is reacted with 3b The reagent of the group is reacted to obtain compound IB-6; 4) reacting compound IB-6 with compound IB-7 to obtain compound IB-8; 5) coupling reaction of compound IB-8 with compound IB-9 to obtain compound IB-10; 6) subjecting compound IB-10 to a hydrolysis reaction to obtain compound IB-11; 7) reacting compound IB-11 with compound IB-12 to obtain compound IB-13; and 8) subjecting compound IB-13 to a deprotection reaction to obtain compound IB; or, Route 2 in Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 , L 1 , L 2 , L 3 , L 4 , L 5 and n is as defined in any one of claims 1 to 13; LG b LG 1b LG 2b LG 3b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group; PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl; The method of route 2 comprises the following steps: 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3; 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5; 3) coupling reaction of compound IB-5 with compound IB-9 to obtain compound IB-6a; 4) Compound IB-6a is reacted with 3b The reaction is carried out with a reagent of the group to obtain compound IB-7a; 5) reacting compound IB-7a with compound IB-8a to obtain compound IB-13; and 6) subjecting compound IB-13 to a deprotection reaction to obtain compound IB; or, Route 3 in Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 , L 5 and n is as defined in any one of claims 1 to 13; LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group; PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl; The method of route 3 comprises the following steps: 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3; 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5; 3) coupling reaction of compound IB-5 with compound IB-9 to obtain compound IB-6a; 4) Compound IB-6a is reacted with 3b The reaction is carried out with a reagent of the group to obtain compound IB-7a; 5) reacting compound IB-7a with compound IB-8b to obtain compound IB-9b; 6) subjecting compound IB-9b to a hydrolysis reaction to obtain compound IB-10b; 7) reacting compound IB-10b with compound IB-11b to obtain compound IB-13; and 8) subjecting compound IB-13 to a deprotection reaction to obtain compound IB; or, Route 4 in Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 and n is as defined in any one of claims 1 to 13; L 5 -C(=O)-NR 11 -; LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group; PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl; The method of route 4 comprises the following steps: 1) reacting compound IC-1 with compound IC-2 to obtain compound IC-3; 2) reacting compound IC-3 with compound IC-4 to obtain compound IC-5; 3) Compound IC-5 is reacted with -LG 3b The reagent of the group is reacted to obtain compound IC-6; 4) reacting compound IC-6 with compound IC-7 to obtain compound IC-8; 5) coupling reaction of compound IC-8 with compound IC-9 to obtain compound IC-10; 6) subjecting compound IC-10 to a hydrolysis reaction to obtain compound IC-11; 7) reacting compound IC-11 with compound IC-12 to obtain compound IC-13; and 8) subjecting compound IC-13 to a deprotection reaction to obtain compound IC; or, Route 5 in Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 、R 11 , L 1 , L 2 , L 3 , L 4 and n is as defined in any one of claims 1 to 13; L 5 -C(=O)-NR 11 -; LG b LG 1b LG 2b LG 3b LG 4b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group; PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl; The method of route 5 comprises the following steps: 1) reacting compound IB-1 with compound ID-2 to obtain compound ID-3; 2) reacting compound ID-3 with compound ID-4 to obtain compound ID-5; 3) coupling reaction of compound ID-5 with compound IB-9 to obtain compound ID-6; 4) Compound ID-6 is reacted with 3b The reaction was carried out with a reagent of the group to obtain compound ID-7; 5) reacting compound ID-7 with compound IB-7 to obtain compound ID-8; 6) subjecting compound ID-8 to a hydrolysis reaction to obtain compound ID-9; 7) reacting compound ID-9 with compound IB-12 to obtain compound ID-10; and 8) Compound ID-10 was subjected to a deprotection reaction to obtain Compound ID. or, Route 6 in Ring A, Ring B, R 2 、R 3 、R 4 、R 5 、R 6 、R 8 , L 1 , L 2 , L 3 , L 4 , L 5 and n is as defined above; LG b LG 1b LG 2b and LG 5b each independently represents a leaving group, such as a halogen, a triflate, a methylthio, a methylsulfinyl, a methylsulfonyl, a boronic acid, a borate ester, a methoxy group, or an ethoxy group; PG 1b represents a protecting group, for example, benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methyl or benzyl; The method of route 6 comprises the following steps: 1) reacting compound IB-1 with compound IB-2 to obtain compound IB-3; 2) reacting compound IB-3 with compound IB-4 to obtain compound IB-5; 3) coupling reaction of compound IB-5 with compound IB-9 to obtain compound IB-6a; 4) subjecting compound IB-6a to an oxidation reaction to obtain compound IB-7c; 5) reacting compound IB-7c with compound IB-8a to obtain compound IB-13; and 6) Compound IB-13 is subjected to a deprotection reaction to obtain Compound IB.